前往化源商城

524924-76-3 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: IP6K1-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.

1. Reagent, 3 uL of 1.3 mM ATP and 130 uM IP6 mixture in assay buffer was dispensed to a white, 1536-well assay plate.
2. Compound, 23 nL of compounds of the top two doses (57.5 uM and 19.1 uM final concentration) of the libraries were dispensed into the mixture using the Kalypsis pintool.
3. Reagent, 1 uL of 2.4 uM IP6K1 was dispensed to the assay plates.
4. Incubation, 2 hr incubation at room temperature.
5. Reagent, 2 uL of ADP-Glo reagent was added to the wells.
6. Incubation, 1 hr incubation at room temperature.
7. Reagent, 4 uL or ADP-Glo substate was added to the wells.
8. Incubation, 45 min incubation at room temperature.
9. Detection, luminescence signal was detected using the ViewLux microplate imager (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Majority of the compounds were tested at 58uM and 11uM. Percent inhibition at 58uM (Max_Response) was obtained and used for compound ranking.
2. For all inactive compounds, with Max_Response >= -25.00, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds (Max_Response < -25.00, more than 25% inhibition) a score range was given between 25 and 100. The activity score is based on the absolute value of the Max_Response.
PhenotypeAnalysis CommentActivity_ScoreMax_ResponseActivity at 0.029 uMActivity at 0.115 uMActivity at 0.144 uMActivity at 0.230 uMActivity at 0.575 uMActivity at 1.257 uMActivity at 2.059 uMActivity at 2.870 uMActivity at 3.790 uMActivity at 5.750 uMActivity at 7.911 uMActivity at 11.54 uMActivity at 17.22 uMActivity at 25.95 uMActivity at 38.35 uMActivity at 57.50 uMActivity at 85.10 uMActivity at 115.2 uMActivity at 153.0 uMActivity at 245.0 uMActivity at 288.0 uMCompound QC
Inactive0-0.963.5361-0.96QC'd by Chemdiv
Inactive0-0.9559-3.6852-0.9559QC'd by Chemdiv
Inactive0-0.9553-5.7534-0.9553QC'd by Chemdiv
Inactive0-0.9545-5.6084-0.9545QC'd by ChemRoutes
Inactive0-0.953-2.3216-0.953QC'd by Sytravon
Inactive0-0.94922.2186-0.9492QC'd by Edelris
Inactive0-0.9486-1.2758-0.9486QC'd by Chemdiv
Inactive0-0.94674.4666-0.9467QC'd by ChemRoutes
Inactive0-0.9436-8.9932-0.9436QC'd by Chemdiv
Inactive0-0.9422-1.7826-0.9422QC'd by Analyticon
Inactive0-0.9415.2115-0.941QC'd by Chemdiv
Inactive0-0.93984.3972-0.9398QC'd by Sytravon
Inactive0-0.93624.3836-0.9362QC'd by Chemdiv
Inactive0-0.92992.8643-0.9299QC'd by Sytravon
Inactive0-0.92934.8772-0.9293QC'd by Chemdiv
Inactive0-0.9286-10.0521-0.9286QC'd by Chemdiv
Inactive0-0.9253-2.1742-0.9253QC'd by Sytravon
Inactive0-0.92040.4163-0.9204QC'd by Edelris
Inactive0-0.9193-0.0183-0.9193QC'd by Analyticon
Inactive0-0.9182-0.8109-0.9182QC'd by Analyticon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:disintegrin and metalloproteinase domain-containing protein 17 preproprotein [Homo sapiens]
External ID: ADAM17_INH_QFRET_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that inhibit ADAM17. This assay employs a fluorophore and quencher pair. F =EDANS fluorophore, Q = DABCYL quencher. When intact, EDANS emission at 460nm is quenched by DABCYL via fluorescence resonance energy transfer. Upon cleavage of the scissile bond (A~V) by ADAM protease, the distance between fluorophore and quencher increases resulting in fluorescence increase at 460nm. Compounds are tested in singlicate at a final nominal concentration of 6.95 micromolar.

Protocol Summary:

Prior to the start of the assay, 2.5 microliters 2X ADAM17 enzyme (20 nM in Assay Buffer: 50 mM HEPES, 0.01% Brij, pH 7.5) are dispensed into 1536 microtiter plates. Compounds are added to plate (final concentration TBD) and incubated for 30 minutes at 25 degrees Celsius. The assay is started by dispensing 2.5 microliter of2X DM2 substrate (20 uM in Assay Buffer) to all wells. Plates are centrifuged and after 3 hours of incubation at 25 degrees Celsius, fluorescence is measured (excitation = 359nm, emission = 460nm).

The % inhibition for each well was then calculated as follows:

%_Inhibition = ( RFU_Test_Compound - MedianRFU_Low_Control ) / ( MedianRFU_High_Control - MedianRFU_Low_Control ) * 100

Where:

Test_Compound is defined as wells containing test compound.
High_Control is defined as wells treated with 1 micromolar Marimastat
Low_Control is defined as wells containing DMSO.


Interval Cutoff:
A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Four values were calculated: (1) the average percent inhibition of all high controls tested plus three times the standard deviation of the high controls, (2) the average percent inhibition of all low controls tested minus three times the standard deviation of the low controls, (3) the average percent inhibition of all compounds tested between (1) and (2), and (4) three times their standard deviation. The sum of two of these values, (3) and (4), was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition/activity than the cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The activity score range for active compounds is 100-8, for inactive 8-0.

List of Reagents:

ADAM17 enzyme (R&D Systems, part # 930-ADB)
EDANS-DABCYL DM2 peptide substrate (Supplied by Assay Provider)
0.5M HEPES solution, pH7.5 (Teknova, part #101319-900)
Brij-35 (Sigma-Aldrich, part # P1254)
1536 well plate (Corning, part # 7261)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. In this case the results of each separate campaign were assigned "Active/Inactive" status based upon that campaign's specific compound activity cutoff value. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 6.95 uM
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
1.23
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A4437
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-8.32134.95490.64234-4.834640 0 0 0 0 0 1-4.4443-2.77887.36895.36932.33973.33831.6715-4.4443QC'd by Sytravon0
Inhibitor2.391969.704984Complete curve; high efficacy-5.62130.90.993-69.49290.212-1.10 0 0 0 0 0 0-66.6604-0.25131.2197-5.3806-9.9311-37.162-53.3921-66.6604QC'd by Sytravon0
Inhibitor9.522176.407442Partial curve; high efficacy-5.02131.1110.9951-75.90940.498-2.10 0 0 0 0 0 0-66.59123.4283-1.6815-1.5622-0.1199-13.7121-41.7015-66.5912QC'd by Sytravon0
Inactive0-4.52131.75290.9212-24.98775.540 0 0 0 0 0 0-17.48977.36232.46169.84163.36053.96510.8896-17.4897QC'd by Sytravon0
Inhibitor1.5092115.26487Complete curve; high efficacy-5.82131.46410.9934-109.85685.4073-1.10 0 0 0 0 0 0-110.2979-0.81499.86343.518-7.3368-73.6123-100.848-110.2979QC'd by Sytravon0
Inhibitor1.6933117.978187Complete curve; high efficacy-5.77134.50450.9912-112.735.2481-1.10 0 0 0 0 0 0-115.265815.93722.4103-1.24092.2518-88.9575-109.7932-115.2658QC'd by Sytravon0
Inhibitor4.772481.295643Partial curve; high efficacy-5.321310.9946-78.60572.6899-2.10 0 0 0 0 0 0-71.671-0.64476.43020.1885-3.4582-24.3313-55.7062-71.671QC'd by Sytravon0
Inhibitor7.563794.395183Complete curve; high efficacy-5.12134.95490.9967-94.6258-0.2307-1.10 0 0 0 0 0 0-93.87483.4317-2.5012-1.7201-2.44552.6182-85.3984-93.8748QC'd by Sytravon0
Inhibitor2.683765.029784Complete curve; high efficacy-5.57134.0950.989-65.3833-0.3537-1.10 0 0 0 0 0 0-70.4739-2.312-0.8042-1.22813.0628-22.6396-60.696-70.4739QC'd by Sytravon0
Inhibitor7.563757.206142Partial curve; partial efficacy-5.12131.62590.9942-54.13193.0742-2.20 0 0 0 0 0 0-52.30876.2072.82521.47620.0987-3.9796-35.0702-52.3087QC'd by Sytravon0
Inhibitor1.198874.619785Complete curve; high efficacy-5.92131.13410.9933-70.92043.6993-1.10 0 0 0 0 0 0-71.49064.2219-0.18864.5237-17.1469-46.9199-63.4145-71.4906QC'd by Sytravon0
Inhibitor2.1317118.451686Complete curve; high efficacy-5.67132.72020.993-110.08868.3631-1.10 0 0 0 0 0 0-116.12727.57825.10285.881412.5352-56.6231-102.2879-116.1272QC'd by Sytravon0
Inhibitor2.1317122.703187Complete curve; high efficacy-5.67132.40640.9787-115.72726.9759-1.10 0 0 0 0 0 0-122.07513.858917.443-6.083311.7009-62.2871-106.7609-122.0751QC'd by Sytravon0
Inhibitor6.7412121.082984Complete curve; high efficacy-5.17134.0950.9954-126.4671-5.3842-1.10 0 0 0 0 0 0-126.975-0.8069-3.4445-2.4548-11.8834-10.2564-113.7668-126.975QC'd by Sytravon0
Inhibitor4.772486.82744Partial curve; high efficacy-5.321310.9941-85.3831.444-2.10 0 0 0 0 0 0-78.6992-2.43161.8612-0.004-1.8987-28.5107-58.6303-78.6992QC'd by Sytravon0
Inhibitor7.5637125.15484Complete curve; high efficacy-5.12133.92950.9979-122.58722.5668-1.10 0 0 0 0 0 0-123.07953.09863.12671.8871-2.10935.2605-101.0355-123.0795QC'd by Sytravon0
Inhibitor0.6741119.919989Complete curve; high efficacy-6.17131.37230.9986-109.745410.1745-1.10 0 0 0 0 0 0-110.8548.84597.74156.7576-35.5397-88.9969-106.7803-110.854QC'd by Sytravon0
Inhibitor6.7412115.981384Complete curve; high efficacy-5.17132.30310.9963-113.59672.3846-1.10 0 0 0 0 0 0-113.37-1.2322-1.59845.85995.7708-6.0722-86.9448-113.37QC'd by Sytravon0
Inhibitor1.5092114.050988Complete curve; high efficacy-5.82131.96730.9946-113.91580.1351-1.10 0 0 0 0 0 0-113.0117-0.8223-4.0553-2.3728-1.6822-81.3904-111.2484-113.0117QC'd by Sytravon0
Inhibitor8.486660.792742Partial curve; partial efficacy-5.07132.40640.9868-57.96392.8287-2.20 0 0 0 0 0 0-56.54736.87814.87661.3348-2.20081.3516-39.1581-56.5473QC'd by Sytravon0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1100
Protocol: DT40-hTDP1 cells without 20 nM Camptothecin (add 20 microL of DMSO in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inactive04-3.0662-2.41261.9741-4.0617-0.6298-3.0662QC'd by "Chem Div"
Inactive04.95490.7346-0.808-4.30840 0 0 0 0-0.431-4.3080.8987-1.5892-1.522-0.431QC'd by "Chem Div"
Inactive04.95490.6448-12.51274.558540 0 0 0 0-9.75096.55851.6006-0.810411.697-9.7509QC'd by "Chem Div"
Inhibitor18.356499.037841Partial curve; high efficacy-4.73622.84730.9985-99.5803-0.5425-2.10 0 0 0 0-92.8278-1.5772-1.93651.8258-13.1847-92.8278QC'd by "Chem Div"
Inhibitor29.092942.181510Single point of activity-4.53624.95490.9879-50.8391-8.6577-30 0 0 0 0-46.8496-7.6387-8.6142-11.6103-6.66-46.8496QC'd by "Chem Div"
Inhibitor18.3564123.871841Partial curve; high efficacy-4.73621.62590.9975-121.45782.414-2.10 0 0 0 0-98.82245.0098-1.1767-0.5372-27.2941-98.8224QC'd by "Chem Div"
Inhibitor14.581109.907342Partial curve; high efficacy-4.83621.82650.9637-106.40863.4987-2.10 0 0 0 0-94.670912.0352-9.70946.0901-28.9742-94.6709QC'd by "Chem Div"
Inactive00.30.9096-34.0578-3.769740 0 0 0 0-28.0098-7.7697-15.2699-21.1534-19.3019-28.0098QC'd by "Chem Div"
Inhibitor29.092990.897810Single point of activity-4.53624.44950.9936-90.33680.561-30 0 0 0 0-79.96355.0637-2.1732-1.69030.5114-79.9635QC'd by "Chem Div"
Inactive00.30.426615.2787-6.721340 0 0 0 010.4803-5.72138.5589-5.30466.71910.4803QC'd by "Chem Div"
Inactive01.96730.6089-9.50825.296840 0 0 0 0-7.95747.2968-1.890310.39461.3036-7.9574QC'd by "Chem Div"
Inhibitor16.360145.504710Single point of activity-4.78624.95490.9618-49.1256-3.6209-30 0 0 0 0-48.9315-7.5358-6.3332.7698-6.0371-48.9315QC'd by "Chem Div"
Inactive0-5.28620.80.9747-26.74278.437240 0 0 0 0-20.71279.43722.29650.248-14.6534-20.7127QC'd by "Chem Div"
Inactive04.95490.9526-10.392812.159440 0 0 0 0-10.30087.659413.806714.3816-9.7278-10.3008QC'd by "Chem Div"
Inactive02.25260.9456-15.0824-3.824740 0 0 0 0-14.7061-2.8247-5.6912-3.1226-9.4063-14.7061QC'd by "Chem Div"
Inhibitor12.995378.844742Partial curve; high efficacy-4.88621.55790.9935-82.5518-3.7072-2.10 0 0 0 0-72.8175-6.4603-0.3489-8.7793-32.8366-72.8175QC'd by "Chem Div"
Inhibitor18.356449.742410Single point of activity-4.73622.84730.9797-46.14163.6008-30 0 0 0 0-42.7679-0.89924.9836.9739-2.5062-42.7679QC'd by "Chem Div"
Inactive04.95490.8308-9.79910.472540 0 0 0 0-5.08718.47258.256110.070916.081-5.0871QC'd by "Chem Div"
Inactive01.88510.9722-5.76856.220540 0 0 0 0-5.0636.2205-1.5445-7.1037-5.5678-5.063QC'd by "Chem Div"
Inactive00.30.842-31.92493.17440 0 0 0 0-26.7418-0.826-13.6909-13.1344-14.0869-26.7418QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2D6395
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (quinidine) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-7.260.70.983122040 0 0 0 0 0 0 018.72430.75090.74030.16150.22082.57129.062412.490518.7243QC'd by Labotest0
Inactive00043.08132.90954.18193.06831.54751.9993-1.48293.82823.0813QC'd by Labotest0
Inhibitor10.96462.697110Partial curve; high efficacy; poor fit-4.964.95490.998-66.9977-4.3007-2.31 0 0 0 0 0 0 0-65.7875-42.8846-3.6636-4.8429-3.3836-3.8623-4.4736-41.4229-65.7875QC'd by Microsource0
Inhibitor38.901833.850110Partial curve; partial efficacy; poor fit-4.414.95490.924-33.35010.5-2.40 0 0 0 0 0 0 0-29.0418-1.55510.52060.875-1.2476-0.5605-1.80927.4199-29.0418QC'd by SIGMA0
Inhibitor1.737781.229885Complete curve; high efficacy-5.761.96730.9976-79.95641.2734-1.10 0 0 0 0 0 0 0-78.3324.47950.76060.0181-0.701-3.7995-49.0322-80.0522-78.332QC'd by Tocris0
Inhibitor34.671337.231710Partial curve; partial efficacy; poor fit-4.462.35310.9195-37.23170-2.40 0 0 0 0 0 0 0-28.52643.96925.0423-3.0201-3.1048-1.1738-0.8348-2.4447-28.5264QC'd by Microsource0
Inhibitor15.487171.27341Partial curve; high efficacy-4.811.44870.9928-70.41130.8617-2.10 0 0 0 0 0 0 0-61.76430.28531.9381-1.2811-0.34364.6186-4.2001-27.4432-61.7643QC'd by GVK0
Inhibitor0.218891.972890Complete curve; high efficacy-6.660.80.9894-90.01021.9626-1.10 0 0 0 0 0 0 0-83.87692.77070.8657-14.6874-27.4321-55.0254-79.0233-92.6031-83.8769QC'd by Prestwick Chemical; Inc.0
Inhibitor34.671345.828810Single point of activity-4.462.35310.9938-45.82880-30 0 0 0 0 0 0 0-35.0976-0.4182-0.112-0.91482.1786-0.5211-0.77-3.3082-35.0976QC'd by Vitas0
Inhibitor13.8029116.598142Partial curve; high efficacy-4.860.70.9704-115.4741.1242-2.10 0 0 0 0 0 0 0-87.4803-1.2071.2781-1.1552-1.0641-0.761-34.877-47.6739-87.4803QC'd by Vitas0
Inhibitor19.497171.169541Partial curve; high efficacy-4.712.33320.9649-71.6292-0.4597-2.10 0 0 0 0 0 0 0-66.007-7.5073.5896-6.58233.21022.04942.4442-17.4355-66.007QC'd by Enzo0
Inactive0004-0.33970.68341.1935-3.1601-7.1353-6.692-3.5353-4.6055-0.3397QC'd by Microsource0
Inhibitor38.901899.707710Single point of activity-4.412.90230.9979-103.2475-3.5398-30 0 0 0 0 0 0 0-78.9754-2.6538-1.9475-2.4198-3.036-5.7354-4.4174-6.1242-78.9754QC'd by Labotest0
Inactive00040.55794.29663.86970.9141.57842.77632.2827-0.27460.5579QC'd by Microsource0
Inactive0004-2.28934.50485.93892.79056.12561.13645.75735.7586-2.2893QC'd by Tocris0
Inhibitor12.301842.282721Partial curve; partial efficacy-4.912.33320.9667-45.1528-2.8702-2.20 0 0 0 0 0 0 0-43.5551-8.1379-5.4062-0.92150.1464-0.2747-3.1761-22.7908-43.5551QC'd by Labotest0
Inactive00042.7074-0.37290.3242.07662.64641.1615-0.70884.47812.7074QC'd by Prestwick0
Inactive0004-1.99643.70481.65273.62083.19225.03624.9342-1.7586-1.9964QC'd by Microsource0
Inactive0-6.360.80.89615-7.047740 0 0 0 0 0 0 04.9227-4.8515-7.6164-8.7898-3.26990.29170.34185.50584.9227QC'd by VitasInactive00
Inhibitor3.4671109.162545Partial curve; high efficacy-5.460.90.9982-103.53135.6312-2.10 0 0 0 0 0 0 0-96.39795.98693.1773.47834.7559-9.3266-39.4946-74.1667-96.3979QC'd by Enzo0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1101
Protocol: DT40-hTDP1 cells with 20 nM Camptothecin (add 20 microL of 1 mM CPT stock in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inhibitor20.5962118.89141Partial curve; high efficacy-4.68622.30310.9994-116.16692.7241-2.10 0 0 0 0-99.94512.72414.25720.7717-13.7373-99.9451QC'd by "Asinex Ltd."
Inactive00.80.9749-16.17712.005740 0 0 0 0-13.14662.00571.2486-2.8352-5.7162-13.1466QC'd by "Asinex Ltd."
Inactive04.95490.6148-11.8012.205940 0 0 0 0-9.7999-4.79413.64526.73633.1419-9.7999QC'd by "Asinex Ltd."
Inactive0-5.03622.33320.9795-28.8852-5.272340 0 0 0 0-28.1997-7.2723-3.3531-4.7215-17.5124-28.1997QC'd by "Asinex Ltd."
Inhibitor5.173594.688584Complete curve; high efficacy-5.28622.90230.9917-96.1842-1.4957-1.10 0 0 0 0-96.0073-7.53084.5779-6.8491-81.1577-96.0073QC'd by "Asinex Ltd."
Inhibitor18.356494.01210Single point of activity-4.73623.62720.9999-96.5346-2.5226-30 0 0 0 0-93.107-2.9055-1.9361-2.363-9.7613-93.107QC'd by "Asinex Ltd."
Inactive04.95490.8434-31.3086-2.25540 0 0 0 0-27.0497-0.755-10.5210.92280.8125-27.0497QC'd by "Asinex Ltd."
Inactive04.44950.7303-25.728-7.249240 0 0 0 0-25.3982-8.7492-13.51280.9177-19.0413-25.3982QC'd by "Asinex Ltd."
Inhibitor20.5962100.541141Partial curve; high efficacy-4.68622.09370.998-104.3872-3.8461-2.10 0 0 0 0-88.9539-4.1551-2.0443-7.1093-18.8654-88.9539QC'd by "Asinex Ltd."
Inhibitor29.092991.413310Single point of activity-4.53624.95490.9947-88.35973.0536-30 0 0 0 0-79.845-1.16852.65594.53855.7131-79.845QC'd by "Asinex Ltd."
Inactive04.95490.786-1.849912.995440 0 0 0 116.19477.995418.22950.5262-1.875716.1947QC'd by "Asinex Ltd."
Inactive04.95490.9259-4.54544.383940 0 0 0 0-3.72395.38394.7472.6664.8335-3.7239QC'd by "Asinex Ltd."
Inactive0-6.23624.95490.9762-1.408619.454340 0 0 0 01.208619.454317.7088-3.3481-2.37561.2086QC'd by "Asinex Ltd."
Inactive04.95490.4363-4.5616-11.561640 0 0 0 0-4.5336-11.5616-1.6565-10.5162-2.2482-4.5336QC'd by "Asinex Ltd."
Inactive00.70.98896.5184-6.981640 0 0 0 02.8921-7.4816-5.7762-3.9537-1.52422.8921QC'd by "Asinex Ltd."
Inactive04.95490.5926-22.1394-0.155940 0 0 0 0-20.8088-4.1559-8.30412.2914-0.0696-20.8088QC'd by "Asinex Ltd."
Inhibitor29.092964.218610Single point of activity-4.53624.95490.9684-70.1227-5.9041-30 0 0 0 0-64.396-9.2052-0.418-11.9994-2.9068-64.396QC'd by "Asinex Ltd."
Inactive01.210.9644-26.92634.843740 0 0 0 0-17.96476.84374.96630.5719-1.9517-17.9647QC'd by "Asinex Ltd."
Inactive04.95490.9261-29.9871.936440 0 0 0 0-26.99980.4364-0.7582-0.45327.9656-26.9998QC'd by "Asinex Ltd."
Inactive04.0950.45761.780312.60740 0 0 0 06.613211.107-4.99860.1865.25796.6132QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2C9536
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix supplemented with 0.4% Bovine Serum Albumin was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (sulfaphenazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at 37C for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inhibitor21.317485.520741Partial curve; high efficacy-4.67133.19250.957-74.520711-2.10 0 0 0 0 0 0-71.26736.65818.66165.03429.029624.68310.5948-71.2673QC'd by Microsource0
Inactive00040.31867.0625.1975.69257.23591.2670.52010.3186QC'd by Microsource0
Inhibitor7.563793.544743Partial curve; high efficacy-5.12131.92820.9984-89.27954.2653-2.10 0 0 0 0 0 0-87.52897.16565.07882.79792.1575-3.7741-60.4613-87.5289QC'd by Tocris0
Inhibitor26.83748.635610Single point of activity-4.57132.24810.9788-42.84845.7872-30 0 0 0 0 0 0-35.46775.96295.47962.709210.27554.6543-0.1967-35.4677QC'd by NCI0
Inhibitor8.4866130.766843Partial curve; high efficacy-5.071310.9992-119.896710.8701-2.10 0 0 0 0 0 0-102.475811.946611.24277.15545.0781-16.0537-65.0649-102.4758QC'd by BIOMOL0
Inhibitor5.354799.189644Partial curve; high efficacy-5.27130.90.9888-96.57122.6185-2.10 0 0 0 0 0 0-87.001-0.2592-1.6376.8143-4.5159-32.2161-61.4841-87.001QC'd by BIOMOL0
Inactive0-4.67132.33320.6923-15.1448-0.540 0 0 0 0 0 0-13.8707-3.7401-1.27785.1005-4.69041.916-3.5213-13.8707QC'd by InterBioScreen0
Inhibitor25.401256.202240Partial curve; partial efficacy-4.59514.50450.9727-57.7888-1.5865-2.20 0 0 0 0 0 0 0-57.6748-1.4876-4.4957-6.22962.86763.1906-3.7494-18.0858-57.6748QC'd by LightBiologicalsInhibitor40.258241.12110Single point of activity-4.39512.95230.943-42.7254
Inhibitor7.563797.471243Partial curve; high efficacy-5.12131.92820.9955-91.45176.0195-2.10 0 0 0 0 0 0-89.13426.42811.19024.98681.8065-2.3315-62.2028-89.1342QC'd by Tocris0
Inhibitor21.317476.663841Partial curve; partial efficacy-4.67131.24750.9713-70.16386.5-2.20 0 0 0 0 0 0-53.059711.862810.1962-0.30794.2931.9517-17.9254-53.0597QC'd by SigmaAldrich0
Inhibitor26.837101.665640Partial curve; high efficacy-4.57131.59360.9916-96.27045.3952-2.10 0 0 0 0 0 0-73.31095.62388.78586.24482.4666-0.9326-13.5438-73.3109QC'd by Tocris0
Inhibitor3.790887.146544Partial curve; high efficacy-5.42130.80.9942-85.19521.9512-2.10 0 0 0 0 0 0-78.88451.4625-1.87161.6032-10.9203-35.4628-58.552-78.8845QC'd by Tocris0
Inhibitor37.9083129.914810Single point of activity-4.42134.95490.9896-129.29750.6173-30 0 0 0 0 0 0-114.6255-1.4437-2.5082-0.90198.8381-4.54583.1106-114.6255QC'd by SigmaAldrich0
Inhibitor26.837109.062140Partial curve; high efficacy-4.57131.34370.9459-109.3538-0.2917-2.10 0 0 0 0 0 0-82.84382.53255.07320.78280.5149-19.3744-20.4297-82.8438QC'd by Bosche0
Inactive0-4.412.90230.8395-17.3952-0.540 0 0 0 0 0 0 0-13.246-3.84691.9539-0.2562-2.65371.4770.7446-0.9487-13.246QC'd by ACC0
Inactive0-8.363.1320.36283-4.516440 0 0 0 0 0 0 02.109-4.1803-1.83775.2557-1.05048.3001-3.10856.7452.109QC'd by Pharmaron0
Inactive00040.5041-8.57852.70450.1138-10.58420.93582.08840.5041QC'd by Toronto Research0
Inhibitor44.493235.276510Single point of activity-4.35173.67720.8478-34.72730.5492-30 0 0 0 0 0 0 0-32.3137-1.4989-3.7044-1.139-0.492412.1946-1.1884-3.139-32.3137QC'd by RTI0
Inactive00046.63087.63316.0247.39860.22633.18743.42856.6308QC'd by Tocris0
Inactive00045.326112.576410.112211.536311.2627.1953.95915.3261QC'd by NCGCChem0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Broad Institute 靶标:N/A
External ID: Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition - 7011-01_Antagonist_SinglePoint_HTS_Activity
Protocol: Protocol

Day 0:
Cell Culture
HEK 293 cells are plated in DMEM culture media (containing 10% Fetal Bovine Serum (FBS) and 1X penn/strep/glutamine) at a density of 5x106 cells/T175 flask and grown for 3 days at 37 degrees C in 5% CO2 incubator.

Day 3:
Transient Transfection
Cells are transiently transfected in DMEM transfection media (containing 1X penn/strep/glutamine without serum) using polyethyleneimine (PEI).
1)Mix 2.9ug/flask of cDNA encoding the wild-type Bursicon Receptor with 14.6ng/flask of cDNA encoding a CRE-luciferase reporter gene with a PEST/HCL sequence in 2mL of transfection media
2)Add 61uL/flask of PEI of 1mg/mL in 1.5mL of transfection media
3)Mix the 2mL cDNA solution with 1.5mL of PEI solution and incubate at RT for 20 mins
4)Aspirated the culture media from the cells in T175 flask
5)Add 25 mL of transfection media and 3.5mL of transfection mixture to T175 falsk.
6)Mix the media with transfection mixture well and transfect for 2 days at 37 degrees C in 5% CO2 incubator

Day 5:
Cell Plating
1)Typsinize the Cells with 5mL of 0.05% Trypsin and incubate at 37oC for 5 min.
2)Add 5mL of DMEM assay media (containing DMEM without phenol red, 10% NuSerum and 1x Pen/Strep/Glutamine) to inactive trypsin
3)Collect cells by centrifugation at 1000rpm for 5 min
4)Suspend the cells in DMEM assay media to a cell density of 4x105 cells/mL
5)Plate the cells to 1536-well Aurora Mako plate with 2000 cells/well/5uL using ViaFill
6)Incubate the cells at 37 degrees C in 5% CO2 incubator on GS system for overnight

Day 6:
Compound Treatment, Agonist Stimulation and Detection
Assay Setup
1)Thaw aliquoted Bursicon conditioned media and diluted with DMEM assay media at a 1/20 dilution. Filter the solution through a 0.22uM filter
2)Add DMEM condition media, the diluted Bursicon conditioned media and SteadyGlo to the bottles and setup BioRAPTR

Run automation protocol on GS system
1)Take the assay plate with transfected cells from the incubator
2)Transfer 5nL/well of 10mM compound to assay plate
3)Incubate 30 mins in incubator
4)Add 1uL/well of DMEM assay media to PosCon wells and diluted Bursicon solution to the other wells using BioRAPTR (Beckman) based on the plate map
5)Incubate the assay plate for 4 h in incubator
6)Take the plate out from the incubator and equilibrate the assay plate at RT for 10 mins
7)Add 1uL/well of SteadyGlo to assay plate using BioRAPTR, incubate at RT for 10 mins
8)Read the plate on ViewLux (PerkinElmer) for Luminescence.

Culture Media
DMEM high glucose, no glutamine (Invitrogen, 11960)
Pen/Strep/Glutamine (Invitrogen 10378-016)
Fetal Bovine Serum (Atlanta Biological, S10350)

Transfection Media
DMEM high glucose, no glutamine (Invitrogen, 11960)
Pen/Strep/Glutamine (Invitrogen 10378-016)

Assay Media
DMEM no phenol red (Invitrogen, 21063-029)
Pen/Strep/Glutamine (Invitrogen 10378-016)
NuSerum (BD biosciences, 24883)

0.05% Trypsin-EDTA (Invitrogen, 25300-062)
Aurora 1536-well Mako plate (Aurora/Brooks, 00028778)
Comment:
REPRODUCIBILITY_COSINE_TRANSFORMPCT_ACTIVE_REPLICATESREPLICATE_A_ACTIVITY_SCORE_9.99uM_(%)
00-208.81
0.99840-216.092
00-162.651
00-162.095
00-158.917
00-156.183
00-151.809
00-151.967
0.99950-161.183
00-147.708
0.99890-146.736
00-141.126
0.99690-165.263
0.99960-146.86
10-137.448
0.9870-136.764
0.9990-135.905
00-134.44
0.99980-139.162
0.99710-155.151
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:apical membrane antigen 1, AMA1 [Plasmodium falciparum 3D7]
External ID: AMA1100
Protocol: Two microliters of his-tagged AMA1 3D7 allele protein (final concentration 25 nM) was dispensed into a 1,536-well assay plate. Small molecules and positive control peptides were pin-transferred (23 nL or 46 nL) via Kalypsys pin-tool equipped with a 1,536-pin array, resulting in final compound and peptide concentration ranges of 91.5 nM - 57.2 muM, and 15.6 nM - 2.00 muM, respectively. Unlabeled RON2 peptide or R1 peptide (VFAEFLPLFSKFGSRMHILK) that specifically binds the 3D7 AMA1 was used as a positive control that inhibited the binding of RON2L to AMA1. After 15 minutes incubation, 1 uL of biotinylated RON2 peptide (final concentration 25 nM) or buffer were dispensed and the assay plate was incubated for an additional 30 minutes at room temperature and protected from light. This was followed by an addition of 1 uL mixture of donor and acceptor beads (10 ug/mL final concentrations for each). The plates were incubated for 30 min at room temperature and read using the EnVision(R) plate reader (PerkinElmer). Maximum inhibition response was normalized to the positive control signal while no inhibition response was normalized to the DMSO treated wells.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003270000 uMActivity at 0.0009544551 uMActivity at 0.00288 uMActivity at 0.00366 uMActivity at 0.00867 uMActivity at 0.021 uMActivity at 0.030 uMActivity at 0.050 uMActivity at 0.094 uMActivity at 0.198 uMActivity at 0.251 uMActivity at 0.464 uMActivity at 0.897 uMActivity at 1.696 uMActivity at 2.322 uMActivity at 4.534 uMActivity at 7.297 uMActivity at 11.61 uMActivity at 22.22 uMActivity at 49.68 uMActivity at 58.24 uMActivity at 116.2 uMActivity at 202.9 uMActivity at 287.0 uMCompound QC
Inactive0-5.454.95490.9995-21.6945-3.795440 0 0 0-21.4769-3.9962-5.4459-21.8288-21.4769QC'd by "Asinex Ltd."
Inactive03.57221241441 0 0 116.162738.571416.397623.929916.1627QC'd by "Asinex Ltd."
Inactive04.95490.8166-5.76510.864640 0 0 0-4.399-0.9461-7.3042-5.8485-4.399QC'd by "Asinex Ltd."
Inactive04.95490.4375.5140 0 0 04.60782.7228.14.16484.6078QC'd by "Asinex Ltd."
Inactive04-3.7445-0.2668-0.8024-2.3835-3.7445QC'd by "Asinex Ltd."
Inactive04.95490.7866-8.1438-1.854640 0 0 1-2.6156-3.3559-0.2955-6.7865-2.6156QC'd by "Asinex Ltd."
Inactive04.95490.9338-11.3197-1.936540 0 0 1-0.7525-3.0486-1.1971-8.1831-0.7525QC'd by "Asinex Ltd."
Inactive04.95490.78796.5-5.148440 0 0 02.9562-3.4579.07547.04232.9562QC'd by "Asinex Ltd."
Inactive04.95490.9133-3.96244.540 0 0 0-2.24453.6677-4.3032-4.9687-2.2445QC'd by "Asinex Ltd."
Inactive01.98870.9998-5.10661440 0 0 16.300713.72557.3637-3.83886.3007QC'd by "Asinex Ltd."
Inactive045.076811.17933.835814.49345.0768QC'd by "Asinex Ltd."
Inactive03.57220.8282-1.91986.540 0 0 0-1.59984.47328.83694.5255-1.5998QC'd by "Asinex Ltd."
Inactive04.95490.8325-2.30529.540 0 0 00.96937.6964-3.308-4.00440.9693QC'd by "Asinex Ltd."
Activator3.981137.72840Single point of activity-5.44.50450.999943.7284630 0 0 121.21646.17468.793743.587221.2164QC'd by "Asinex Ltd."
Inactive04.50450.8329-4.23445.540 0 0 0-1.8623.02116.35366.4558-1.862QC'd by "Asinex Ltd."
Inactive040-1.8127-2.8808-4.73930QC'd by "Asinex Ltd."
Inactive02.40640.9078-20.539-5.663440 0 0 0-15.4491-7.6231-3.8862-5.9113-15.4491QC'd by "Asinex Ltd."
Inactive04.95490.9986-16.7525-3.633141 0 0 0-16.460427.6578-3.4443-12.258-16.4604QC'd by "Asinex Ltd."
Inactive04.95490.9998-10.7679-2.829841 0 0 1-2.411376.2714-2.7748-8.9733-2.4113QC'd by "Asinex Ltd."
Inactive04.95490.9657-4.3794740 0 0 0-4.94775.0336-5.3161-3.2761-4.9477QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:abhydrolase domain-containing protein 4 isoform 1 [Mus musculus]
External ID: ABHD4_INH_FP_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this biochemical assay is to identify compounds that act as inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4). In this assay, ABHD4 protein is incubated with test compounds and fluorophosphonate-rhodamine (FP-Rh) activity-based probe. The reaction is excited with linear polarized light and the intensity of the emitted light is measured as the polarization value (mP). As designed, test compounds that act as ABHD4 inhibitors will prevent ABHD4-probe interactions, thereby increasing the proportion of free (unbound) fluorescent probe in the well, leading to low fluorescence polarization. Compounds are tested in singlicate at a nominal test concentration of 8.92 micromolar.

Protocol Summary:

Prior to the start of the assay, 4 microliters of assay buffer (50 mM HEPES pH 7.0, 150 mM NaCl and 0.01% Pluronic F-127) were dispensed into column 2 only. Next, 4 microliters of assay buffer containing 46.9 ug/mL of ABHD4 mutant protein (S159A) were dispensed into columns 1 and 3 of 1536 microtiter plates and 4 microliters of assay buffer containing 46.9 ug/mL of ABHD4 wild type protein were dispensed into columns 4 thru 48. Then, 45 nL of test compound in DMSO or DMSO alone (0.89% final concentration) were added to the appropriate wells and incubated for 45 minutes at 25 degrees Celsius.

The assay was started by dispensing 1.0 microliter of 188 nM FP-Rh in assay buffer to all wells. Plates were centrifuged and after 60 minutes of incubation at 25 degrees Celsius, fluorescence polarization was read on a Viewlux microplate reader (PerkinElmer, Turku, Finland) using a BODIPY TMR FP filter set and a BODIPY dichroic mirror (excitation = 525nm, emission = 598nm) for 30 seconds for each polarization plane (parallel and perpendicular).

Prior to further calculations, the following formula was used to calculate fluorescence polarization (FP):

FP = ( Raw1 - Raw2 ) / ( Raw1 + Raw2 )

Where:

Raw1 is defined as the S channel.
Raw2 is defined as the P channel.

The percent inhibition for each compound was calculated as follows:

100 *( ( Test_Compound - Median_Low_Control ) / ( Median_High_Control - Median_Low_Control ) )

Where:

Test_Compound is defined as wells containing ABHD4 wild type protein in the presence of test compound and FP-Rh.
High_Control is defined as wells containing ABHD4 mutant protein, DMSO and FP-Rh.
Low_Control is defined as the median of the wells containing test compounds.

PubChem Activity Outcome and Score:


A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated: (1) the average percent inhibition of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition than the cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The activity score range for active compounds is 100-6, for inactive 6-0.

List of Reagents:

mABHD4 wild type protein (supplied by Assay Provider)
mABHD4 (S159A) mutant protein (supplied by Assay Provider).
FP-Rh probe (supplied by Assay Provider)
HEPES (Sigma, part 83264)
NaCl (Sigma, part S6546)
Pluronic F-127 (Invitrogen, part P6866)
1536-well plates (Corning, part 7261)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 8.92 uM
10.42
10.41
10.41
10.41
10.41
10.41
10.41
10.41
10.4
10.4
10.4
10.4
10.4
10.4
10.4
10.39
10.39
10.39
10.39
10.38
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Broad Institute 靶标:E-Selectin
External ID: 2152-01_Activator_SinglePoint_HTS_Activity
Protocol: . Coat plates with 0.1% Gelatin in PBS (20ul per well) for 20 minutes at room temp.
Day 0
. Plate 3,000 HUVEC cells/well in 384 well plates, 50l per well, in EGM-2 medium, incubate at 37 degrees Celsius
Day 2
. Pin 100nl of compound, DMSO
. Add 10 ul Positive Control (TNFalpha at 0.3ng/ml)
. Incubate 16h
Day 3
. Aspirate media using plate washer
. Add 70 ul wash buffer using Thermo Multidrop Combi or plate washer (assay provider uses combi)
. Aspirate wash buffer with plate washer
. Add 20 ul blocking antibody (IgG) with combi
. Incubate at room temp for 15 minutes
. Aspirate
. Add 20 ul Biotin conjugated anti-e-selectin antibody with combi
. Incubate 30 minutes at room temp (or 15 minutes at 37 degrees Celsius)
. Aspirate
. Add 70 ul wash buffer using combi or plate washer (assay provider uses combi)
. Aspirate
. Add 20 ul streptavidin-PE using combi or plate washer (assay provider uses combi)
. Incubate 30 minutes at room temp (or 15 minutes at 37 degrees Celsius)
. Aspirate
. Add 70 ul of PBS (not wash buffer)
. Aspirate
. Add 20ul Hoechst/4% PF/PBS mix (fix cells and stain nuclei)
. Incubate 15 minutes at room temp
. Aspirate (PF is a hazardous waste and is collected in a seperate hazardous waste container)
. Add 70ul PBS
. Aspirate
. Add 70 ul PBS
Plates are sealed with foil seal and stored overnight at 4 degrees Celsius prior to imaging

Plates are imaged on an automated microscope (ImageXpress Micro, Molecular Devices Inc.) at 2x magnification using appropriate filter sets for Hoechst and PE fluorescence.

Cell counts and % of cells positive for PE fluorescence are quantified by using a modified Cell Scoring application module in the image analysis software (MetaXpress, Molecular Devices Inc.)
Comment: PRESENCE OF CONTROLS: Neutral control wells (NC) and positive control wells (PC) were included on every plate.

EXPECTED OUTCOME: Active compounds result in increasing readout signal.

NORMALIZATION:
The raw signals of the plate wells were normalized using the 'Stimulators Minus Neutral Controls' method in Genedata Assay Analyzer (v10.0.2):
The median raw signal of the intraplate neutral control wells was set to a normalized activity value of 0.
The median raw signal of the intraplate positive control wells was set to a normalized activity value of 100.
Experimental wells values were scaled to this range.

PATTERN CORRECTION: No plate pattern correction algorithm from Genedata Condoseo (v.10.0.2) was applied.

PUBCHEM_ACTIVITY_SCORE:
This was set as equal to the mean of the normalized sample replicate activities, rounded to the nearest integer .
Compounds decreasing cell viability by more than 20 per cent were eliminated. The minimum PUBCHEM_ACTIVITY_SCORE of E-selectin positive cells required for a compound to be called a hit (the activity threshold, or AT) was set at 10.

PERCENTAGE OF ACTIVE REPLICATES:
For each sample, the percentage of replicates (PCT_ACTIVE_REP) which had activity scores >= AT was determined.
The minimum percentage of replicates required for a compound to be called a hit (PAR_T) was set at 60.

PUBCHEM_ACTIVITY_OUTCOME:
Samples passing BOTH threshold criteria were assigned an outcome of 2 (active):
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP >= PAR_T

Samples passing NEITHER threshold criteria were assigned an outcome of 1 (inactive):
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP < PAR_T

Samples passing AT only were assigned an outcome of 1 (inactive) :
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP < PAR_T

Samples passing PAR_T only were assigned an outcome of 1 (inactive) :
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP >= PAR_T
REPRODUCIBILITY_COSINE_TRANSFORMPCT_ACTIVE_REPLICATESREPLICATE_A_ACTIVITY_SCORE_7.58uM_(%)REPLICATE_B_ACTIVITY_SCORE_7.58uM_(%)
0.6130-0.1850.023
0.99880-0.16-0.145
0.22400.231-0.145
0.719800.0211.166
0.769200.0170.188
0.92620-0.091-0.038
0.955800.4780.903
0.84730-0.338-0.077
0.41360-0.4150.156
0.00680-0.1020.101
0.85060-0.315-0.074
0.6150-0.1971.591
0.62950-0.1661.582
0.90320-0.114-0.04
0.918701.1570.461
0.3570-0.2470.552
0.68970-0.0421.739
0.682600.467-0.016
0.993100.030.024
0.70170-0.0060.811
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MCC011
Protocol: A high-throughput screen was conducted in 1536-well white flat bottom plates (Corning) on a Kalypsys robotic system. Cell lines WAGA, MKL-1, MKL-2, MCC-13, MCC-26, UISO, HaCaT, HEK293T, CRL7250, and NIH-3T3 were screened against 2 small molecule annotated drug libraries NPC and MIPE in dose response (8 and 11 pt. respectively) measuring cell viability after 72 hours of incubation. Briefly, cell lines were dissociated with trypsin or accutase (MKL-1 and MKL-2 only), passed through a 40 micron cell-strainer, and then plated with a Multidrop Combi Reagent Dispenser (ThermoFisher) into 1,536 well plates and plated down at a starting density ranging from 50 cells/ uL (HEK293T), 80 cells/ uL (NIH-3T3), 100 cells /uL (MKL-1, MKL-2, MCC-13, MCC-26, HaCaT, CRL7250, and UISO), 250 cells/ uL (WAGA) in a final volume of 5 uL of media (MCC cells: RPMI 1640, Control cells: DMEM) supplemented with 10% FBS and 1X Pen/Strep. A 1,536 pintool (Kalypsys) was used to transfer 23 nL of compound in DMSO to the 1,536-well assay plates. After 72 hr incubation at 37 degree celsius, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a BiorapTR. Plates were incubated at room temperature for 10 min, transferred to a ViewLux (PerkinElmer) and the luminescence was recorded using an exposure time of 2 seconds. Relative luminescence units (RLUs) were normalized to in-plate controls (no cells as a positive (cytotoxicity) control, DMSO as negative control) and the normalized data was processed using NCATS in-house software.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000059000 uMActivity at 0.0000296505 uMActivity at 0.0000627629 uMActivity at 0.0001361338 uMActivity at 0.0003144137 uMActivity at 0.0006678285 uMActivity at 0.00124 uMActivity at 0.00266 uMActivity at 0.00558 uMActivity at 0.00707 uMActivity at 0.017 uMActivity at 0.031 uMActivity at 0.069 uMActivity at 0.181 uMActivity at 0.368 uMActivity at 0.597 uMActivity at 1.656 uMActivity at 1.863 uMActivity at 4.836 uMActivity at 9.224 uMActivity at 16.10 uMActivity at 45.96 uMActivity at 92.69 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uM
Inhibitor37.2212127.575310Single point of activity-4.42924.95490.9931-128.5776-1.0023-30 0 0 0 0 0 0 0 0 0 0-97.40730-4.332400
Inactive0.01329.42330-7.87920.70.50130.57671040 0 0 0 0 0 0 0 0 0 01.93587.145312.24143.02923.39297.25620.5823-2.85275.4621-1.3525-0.54921.9358
Inactive0.05933.8540-7.22920.40.62832.5-1.35440 0 0 0 0 0 0 0 1 0 17.57680.82459.716.2951-2.79521.778223.810718.618626.701-8.723728.99317.5768
Inhibitor37.221243.146710Single point of activity-4.42924.95490.9703-43.14670-30 0 0 0 0 0 0 0 0 0 0-32.62230000
Inactive00004-2.32246.8981-3.111413.08049.03891.9974.8517-1.51738.13746.73713.5409-2.3224
Inhibitor37.221295.834310Single point of activity-4.42924.95490.9646-96.6556-0.8213-30 0 0 0 0 0 0 0 0 0 0-73.22402.0597-7.5145-4.9351
Inactive00004-5.924613.9115-2.239922.3817-3.690217.64660.983-10.40496.39419.0991-4.1342-5.9246
Inhibitor26.350682.76740Partial curve; partial efficacy-4.57924.0950.8717-86.5714-3.8044-2.20 0 0 0 0 0 0 0 0 0 0-78.842-5.93801.3974-28.1211
Inactive000040.022410.248810.425-3.06316.088911.75171.77591.22993.8630.57482.4410.0224
Inactive3.31737.88330-5.47924.95490.5098-2.8833540 0 0 0 0 0 0 0 0 0 0-5.73613.93155.0136.2883-1.901311.20266.12033.29585.5784-2.02860.5573-5.7361
Inactive37.221215.87970-4.42924.95490.5221-17.3797-1.540 0 0 0 0 0 0 0 0 0 0-13.2331-1.0197-4.23261.5878-1.3704
Inactive0.06627.93390-7.17920.90.59320.56618.540 0 0 0 0 0 0 0 0 0 01.56674.512510.965311.77192.24175.45342.31084.412-1.6116-0.46240.62181.5667
Inactive0.132125.77010-6.87924.95490.559-15.700910.069240 0 0 0 0 0 0 0 0 0 0-20.7968-1.38432.39852.132723.511324.9349-16.09082.2208-21.3286-30.7571-5.6999-20.7968
Inactive000040-2.3996-4.4114-2.0746-4.8678
Inactive0.66194.58310-6.17922.72020.3338-1.08313.540 0 0 0 0 0 0 0 0 0 14.56861.8671-0.85384.05730.46459.58014.53941.4181-0.6516-1.3193-0.67644.5686
Inactive000040-0.800500.13270.7944
Inactive0000414.25472.5411.436-2.13565.219813.942315.81650.97664.85062.1093-0.697614.2547
Inactive000040-49.4569-14.24420-2.3916
Inactive0.833321.05840-6.07921.37230.9479-17.0584440 0 0 0 0 0 0 0 0 0 1-3.30275.89232.6361.32297.05843.94520.8401-3.7291-9.8453-18.382-14.8977-3.3027
Inactive000040.99194.0284.60455.0511-2.99924.45879.54511.8796-2.51456.0782-1.32220.9919
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CIB1-p1-p2
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 3 uL; Protein or buffer (4/3x)
2; Compound; 46 nL; Control inhibitor / compound library
3; Time; 15 min; Room temperature incubation
4; Reagent; 1 uL; Fluorescent labeled peptide (4x)
5; Time; 1000 rpm; Centrifuge
6; Time; 15 min; Room temperature incubation
7; Detection; Ex 480/ Em 540; ViewLux Fluorescence Read

NOTES (numbers refer to sequence above)
1; Protein Mixture: C1B1-GST (final concentrations of 1 uM). Buffer composition: 5 mM HEPES pH 7.4, 125 mM NaCl, 5 mM CaCl2, 0.01% Tween20.
2; Control Inhibitor: unlabeled peptide (final concentration range 17.4 nM to 572 uM). Compound Library final concentration range 18.3 nM to 114 uM.
3; Room temperature incubation.
4; Fluorescent Labeled Peptide: FITC-aIIb (final concentration of 100 nM). Sequence of alphaIIb peptide: Acetyl-LVLAMWKVGFFKRNRK-FITC (purity is 95.83%).
5; Centrifuge 1000 rpm (164 g) for 15 seconds.
6; Room temperature incubation.
7; ViewLux Fluorescent Polization Read: excitation = 480(20) / emission = 540(25) S and P; FITC Dichroic mirror.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0002019424 uMActivity at 0.0004510146 uMActivity at 0.0009668607 uMActivity at 0.00168 uMActivity at 0.00290 uMActivity at 0.00509 uMActivity at 0.00877 uMActivity at 0.025 uMActivity at 0.041 uMActivity at 0.083 uMActivity at 0.136 uMActivity at 0.247 uMActivity at 0.490 uMActivity at 1.070 uMActivity at 2.238 uMActivity at 4.221 uMActivity at 6.448 uMActivity at 12.37 uMActivity at 30.23 uMActivity at 57.68 uMActivity at 114.0 uMActivity at 227.8 uMActivity at 383.5 uMActivity at 573.0 uMCompound QC
Inactive00043.79243.150.9632.38293.40883.72213.7924QC'd by MedChem Express
Inactive00041.27893.51021.5281.92384.63466.41821.2789QC'd by Selleck
Inactive00040.0037-4.4248-0.615-1.2841-0.0588-4.05140.0037QC'd by Selleck
Inactive0004-3.0131-5.3427-2.388-5.1553-1.5524-1.7506-3.0131QC'd by Selleck
Inactive00043.3730.82350.03162.1071.7002-1.91383.373QC'd by Selleck
Inactive00042.2123-4.94820.01822.4902-0.04663.47292.2123QC'd by Selleck
Inactive0004-6.8722-2.3397-1.6401-4.488-0.7912-2.054-6.8722QC'd by Selleck
Inactive00042.68872.97954.87572.02642.29024.4582.6887QC'd by MedChem Express
Inactive0004-3.8031-1.1794-1.5257-1.59471.0625-2.7807-3.8031QC'd by Selleck
Inactive0004-10.2079-6.2462-2.2383-3.1976-2.6796-7.2482-10.2079QC'd by Selleck
Inactive00043.20441.15581.27971.8267-0.40880.06273.2044QC'd by Analyticon
Inactive0004-8.9309-1.3351-3.9232-1.9433-5.1495-5.1305-8.9309QC'd by Analyticon
Inactive0004-2.583-2.8916-5.1264-4.8462-1.10660.1205-2.583QC'd by Analyticon
Inactive0004-2.75110.2404-3.0231-3.8049-6.48331.0107-2.7511QC'd by Analyticon
Inactive0004-4.5021.02690.00121.26520.39560.7999-4.502QC'd by Analyticon
Inactive00042.29161.59671.72554.12930.66291.2592.2916QC'd by Analyticon
Inactive00043.0438-1.4768-0.49070.27762.287-0.85233.0438QC'd by Analyticon
Inactive0004-4.3119-0.9159-1.5721-0.78780.5085-2.4781-4.3119QC'd by Analyticon
Inactive00041.0585.28035.28657.895410.16324.55741.058QC'd by Analyticon
Inactive00042.9292-2.6967-2.5902-0.50822.84874.3512.9292QC'd by Analyticon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: CPF001
Protocol: HEK 293, NIH 3T3, CRL-7250, HACAT and KB 3-1 cells were seeded into white 1536-well plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 250, 400, 500, 500, 500 cells/well in 5 uL of medium respectively. A pintool (Kalypsys) was used to transfer 23 nL of compound solution to the 1536-well assay plates. After 48 or 72 hr incubation at 37 degree celcius, 5% CO and 95% humidity, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a dispenser (Aspect Automation, St. Paul, MN) with solenoid valves (Lee Valves, Westbrook CT). Plates were left at room temperature for 10 min before imaging the ATP-coupled luminescence using a ViewLux microplate imager (PerkinElmer, Waltham, MA).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.176 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.372 uMActivity at 1.908 uMActivity at 4.964 uMActivity at 9.273 uMActivity at 17.43 uMActivity at 44.77 uMActivity at 91.96 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000073700 uMActivity at 0.0000316373 uMActivity at 0.0000755538 uMActivity at 0.0001736587 uMActivity at 0.0003606937 uMActivity at 0.0007618542 uMActivity at 0.00133 uMActivity at 0.00262 uMActivity at 0.00635 uMActivity at 0.00856 uMActivity at 0.017 uM
Inactive0-6.08624.95490.8467-19.0684-1.540 0 0 0 0 0 12.118100-8.34361.8417-20.8904-17.20922.1181
Inactive00043.093704.02863.4263-3.42834.65930.95863.0937
Inactive0-8.43624.95490.60020-10.442940 0 0 0 0 0 1-5.6741-7.8694.8276000-3.665-5.6741
Inactive0004-1.22691.59440.8268-6.8139003.009-1.2269
Inactive00040000.646
Inactive00042.016104.739100.507404.00372.0161
Inactive00040-58.9387-0.658900.7761-3.050100
Inactive0-5.38623.57220.9641-17.9156140 0 0 0 0 0 10001.05953.84450-17.0130
Inactive0004-1.61750000-31.91564.5285-1.6175
Inactive000403.5826.95880
Inactive00044.1629-0.06810-0.13403.503204.1629
Inactive00040.0775-4.4477004.2892-3.083200.0775
Inactive0004-4.2864-6.2990000-3.464-4.2864
Inhibitor20.230130.466710Partial curve; partial efficacy; poor fit-4.6944.95490.9513-30.9667-0.5-2.40 0 0 0 0 0 0-27.47223.59671.00910-2.7438-3.3305-0.4297-27.4722
Inactive000406.34610
Inactive0004-5.47750-1.336404.40630-3.1548-5.4775
Inactive00042.2138-0.3090-3.3277-5.07761.864902.2138
Inactive0004-6.8569-2.008600000-6.8569
Inhibitor20.2301111.05610Single point of activity-4.6944.95490.9964-109.52221.5338-30 0 0 0 0 0 0-97.61333.530.1744-1.61494.641802.914-97.6133
Inactive0-4.6944.95490.8369-20.4658340 0 0 0 0 0 0-17.88822.63860
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:RecName: Full=Sialate O-acetylesterase; AltName: Full=H-Lse; AltName: Full=Sialic acid-specific 9-O-acetylesterase; Flags: Precursor [Homo sapiens]
External ID: SIAE_INH_FP_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this biochemical assay is to identify compounds that act as inhibitors of sialic acid acetylesterase (SIAE). In this assay, SIAE protein is incubated with test compounds and fluorophosphonate-rhodamine (FP-Rh) activity-based probe. The reaction is excited with linear polarized light and the intensity of the emitted light is measured as the polarization value (mP). As designed, test compounds that act as SIAE inhibitors will prevent SIAE-probe interactions, thereby increasing the proportion of free (unbound) fluorescent probe in the well, leading to low fluorescence polarization. Compounds are tested in singlicate at a nominal test concentration of 9.66 micromolar.

Protocol Summary:

Prior to the start of the assay, 3 microliters of assay buffer (1X DPBS and 0.01% Pluronic F-127) were dispensed into column 1 thru column 3 of 1536 microtiter plates. Next, 3 microliters of assay buffer containing 0.73uM of SIAE protein were dispensed into columns 4 thru 48. Then, 39 nL of test compound in DMSO or DMSO alone (0.97% final concentration) were added to the appropriate wells and incubated for 45 minutes at 25 degrees Celsius.

The assay was started by dispensing 1.0 microliter of 300 nM FP-Rh in assay buffer to all wells. Plates were centrifuged and after 120 minutes of incubation at 25 degrees Celsius, fluorescence polarization was read on a Viewlux microplate reader (PerkinElmer, Turku, Finland) using a BODIPY TMR FP filter set and a BODIPY dichroic mirror (excitation = 525nm, emission = 598nm) for 25 seconds for each polarization plane (parallel and perpendicular).

Prior to further calculations, the following formula was used to calculate fluorescence polarization (FP):

FP = ( Raw1 - Raw2 ) / ( Raw1 + Raw2 )

Where:

Raw1 is defined as the S channel.
Raw2 is defined as the P channel.

The percent inhibition for each compound was calculated as follows:

100 *( ( Test_Compound - Median_Low_Control ) / ( Median_High_Control - Median_Low_Control ) )

Where:

Test_Compound is defined as wells containing SIAE protein in the presence of test compound and FP-Rh.
High_Control is defined as wells containing DMSO, FP-Rh but, no SIAE protein.
Low_Control is defined as the median of the wells containing test compounds.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Four values were calculated: (1) the average percent inhibition of all high controls tested plus three times the standard deviation of the high controls, (2) the average percent inhibition of all low controls tested minus three times the standard deviation of the low controls, (3) the average percent inhibition of all compounds tested between (1) and (2), and (4) three times their standard deviation. The sum of two of these values, (3) and (4), was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition/activity than the cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The activity score range for active compounds is 100-2, for inactive 2-0.

List of Reagents:

SIAE protein (supplied by Assay Provider)
FP-Rh probe (supplied by Assay Provider)
DPBS (Mediatech, part 20-031-CV)
Pluronic F-127 (Invitrogen, part P6866)
1536-well plates (Greiner, part 789176)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 9.66 uM
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
6.91
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Broad Institute 靶标:Caspase 6, apoptosis related cysteine peptidase
External ID: 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2
Protocol: Caspase 6 enzyme was received from collaborator and stored at -80 C. Stock concentration was at 1.2 mg/ml (43.1 uM).

Assay Buffer:
100 mM Hepes pH 7.5, 10% sucrose, 0.1 % CHAPS, 5 mM DTT (final concentration) was added fresh just prior to assay

Reagents:
VEID-R110-VEID: Caspase 6 substrate, was reconstituted to 10 mM from dry powder with DMSO and stored at -20 C.
VEID-CHO: Caspase inhibitor (positive control) was reconstituted to 10 mM from dry powder with DMSO and stored at -20 C.

Assay Ready Plates:
1536 black, solid bottom plates containing 7.5 ul of compound

Protocol:
Add 4 ul 2.2 nM Caspase-6 to 1536 ARPS using BioRaptR
Add 100 nL VEID-CHO to positive control wells using Combi nL
Incubate Room temp 60 min
Add 2 ul of 24 uM VEID-R110-VEID (Caspase 6 substrate) to all wells
Incubate at room temp for 40 min
Read plate on Envision (FITC settings and filters)
Comment: PRESENCE OF CONTROLS: Neutral control wells (NC) and positive control wells (PC) were included on every plate.

EXPECTED OUTCOME: Active compounds result in decreasing readout signal.

NORMALIZATION:
The raw signals of the plate wells were normalized using the 'Neutral Controls' method in Genedata Assay Analyzer (v10.0.2):
The median raw signal of the intraplate neutral controls (NC) is set to a normalized activity value of 0.
A normalized activity value of 100 is defined as (2)(NC).
A normalized activity value of -50 is defined as (0.5)(NC).
Experimental wells values were scaled to this range.
All well activities were then multiplied by -1 to create a positive activity readout value range, to match Pubchem convention.


PATTERN CORRECTION: The plate pattern correction algorithm 'Runwise Pattern (Multiplicative)' in Genedata (v10.0.2) was applied to the normalized plate data.

PUBCHEM_ACTIVITY_SCORE:
This was set as equal to the mean of the normalized and corrected sample replicate activities, rounded to the nearest integer .
The minimum PUBCHEM_ACTIVITY_SCORE required for a compound to be called a hit (the activity threshold, or AT) was set at 35.

PERCENTAGE OF ACTIVE REPLICATES:
For each sample, the percentage of replicates (PCT_ACTIVE_REP) which had activity scores >= AT was determined.
The minimum percentage of replicates required for a compound to be called a hit (PAR_T) was set at 100.

PUBCHEM_ACTIVITY_OUTCOME:
Samples passing BOTH threshold criteria were assigned an outcome of 2 (active):
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP >= PAR_T

Samples passing NEITHER threshold criteria were assigned an outcome of 1 (inactive):
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP < PAR_T

Samples passing AT only were assigned an outcome of 3 (inconclusive) :
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP < PAR_T

Samples passing PAR_T only were assigned an outcome of 3 (inconclusive) :
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP >= PAR_T
REPRODUCIBILITY_COSINE_TRANSFORMPCT_ACTIVE_REPLICATESREPLICATE_A_ACTIVITY_SCORE_12.48uM_(%)
00-6.052
00-6.27
00-6.306
00-6.039
00-6.269
00-6.681
00-6.107
00-6.772
00-6.297
00-6.301
00-6.929
00-6.036
00-6.046
00-6.202
00-6.513
00-6.312
00-6.488
00-6.404
00-6.918
00-6.65
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:E3 ubiquitin-protein ligase UHRF1 isoform 1 [Homo sapiens]
External ID: UHRF1-CPGDNA_INH_TRFRET_1536_1X%INH CSRUN for MBD2-CPGDNA INH
Protocol: Assay Overview:

The purpose of this assay is to determine whether compounds identified as inhibitors of MBD2 are nonselective, as determined by inhibition of methylated DNA-binding activity of the SRA domain polypeptide of ubiquitin-like with PHD and ring finger domains 1 (UHRF1). The UHRF1 gene encodes a member of a subfamily of RING-finger type E3 ubiquitin ligases. It contains a Set-and RING Associated (SRA) domain that binds to partially methylated DNA sequences during DNA synthesis. UHRF1 exhibits a different mode of DNA binding than MBD2, binding so-called hemi-methylated cytosines in order to promote their fully methylation. This assay is performed in a similar manner as the MBD2 screen, except that it employs recombinant UHRF1 SRA domain protein (UHRF1_SRA) and hemi-methylated DNA as its substrate. This assay monitors the ability of compounds to inhibit binding of cloned recombinant UHRF1_SRA to a FAM-labeled 14 bp hairpin oligonucleotide containing a hemimethylated CpG. In this biochemical assay, test compounds are incubated with UHRF1_SRA and a 5-carboxyfluorescene (FAM)-labeled 14bp hairpin DNA oligonucleotide containing one hemimethylated CpG dinucleotide in the presence of Tb-labeled anti-His antibody. An inhibitor of the UHRF1_SRA:FAM hemimethylated CpG interaction will inhibit binding between UHRF1 and FAM hemimethylated oligo, leading to reduced energy transfer and reduced well FRET (fluorescein emission / Tb emission). Compounds are tested in singlicate at a final nominal concentration of 4.4 micromolar.

Protocol Summary:

The assay was started by dispensing 5 microliters of Control Mix in assay buffer (4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 125 mM NaCl, 10 mM Tris-HCl (pH 7.4), and 0.2% Tween-20) containing 125 nanomolar of UHRF1 protein, 5 micromolar of FAM labeled methylated CpG DNA oligo and 5 nanomolar of Terbium labeled anti-his antibody into columns 1 thru columns 2 of 1536 microtiter plates. Next, 5 microliters of Experimental Mix containing 125 nanomolar of UHRF1 protein, 100 nanomolar FAM labeled Hemimethylated CpG DNA oligo and 5 nanomolar Terbium labeled anti-his antibody in assay buffer were dispensed into columns 3 thru 48. Then, the plates were centrifuged and pinned with 22 nL of test compound in DMSO, Mitoxantrone (1.3 micromolar final concentration) in DMSO or DMSO alone (0.44% final concentration). The plates were incubated for 60 minutes at 25 degrees Celsius and TR-FRET was measured on a Viewlux microplate reader (Perkin Elmer, Turku, Finland). After excitation at 340 nm, well fluorescence was monitored at 495 nm (Tb) and 525 nm (FAM). For each well, a fluorescence ratio was calculated according to the following mathematical expression:
Ratio = I525nm / I495nm

Where:

I525nm represents the measured fluorescence emission at 525 nm.
I495nm represents the measured fluorescence emission at 495 nm.

The percent inhibition for each compound was calculated using as follows:

%_Inhibition = 100 * ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) )

Where:

Test_Compound is defined as wells containing the Experimental Mix in the presence of test compound.
High_Control is defined as wells containing the Experimental Mix, Mitoxantrone and DMSO.
Low_Control is defined as the median of the wells containing test compounds.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated: (1) the average percent inhibition of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition than the cutoff parameter was declared active.

The reported Pubchem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-19, and for inactive compounds 19-0.

List of Reagents:

UHRF1_SRA protein (supplied by Assay Provider)
FAM labeled Hemimethylated CpG DNA Oligo (IDT-custom order)
FAM labeled Methylated CpG DNA Oligo (IDT-custom order)
Lanthascreen Tb Anti-His Antibody (Invitrogen, part PV5895)
MgCl2 (Fisher, part BP214)
NaCl (Sigma, part S6546)
DTT (Fisher, part BP172)
EDTA (Sigma, part E7889)
Tris (Amresco, part 0497)
Tween 20 (Sigma, part P9416)
Glycerol (Sigma, part G7893)
1536-well plates (Corning, part 7261)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 4.4 uM
4.21
4.21
4.21
4.21
4.21
4.21
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:N/A
External ID: SBCCG-A1016-RevErbaLBD-Primary-Assay
Protocol: This assay is to identify modulators of Rev-erb alpha protein binding to DNA

A. Materials:
REV-alpha_beta purified protein = Rastinejad lab
FITC-DNA = Rastinejad lab
Tris = Biorad (cat #161-0719)
DTT = Akron Biotechnology (cat #AK2948-0005)
5M NaCl = Sigma-Aldrich (cat #56546-1L)
Glycerol 99.5% = Acros (cat #327255000)
Tween 20 = Sigma-Aldrich (cat #P1379)
Corning high base black plates = Corning (cat #3724)
Molecular grade water = Cellgro (cat #46-000-CM)

B. Plate Map:
Negative (low) control in columns 1 and 2 is 6nM DNA and 35nM Protein, DMSO
Positive (high) control in columns 3 and 4, Protein at 750nM and 6nM DNA, DMSO
Test compound in columns 5 - 48, Protein at 35nM + 6nM DNA + test compound

C. Procedures:
Step#Description
1#Prepare 2X Rev-erb alpha protein stock and 2X DNA stock
2#Using LabCyte Echo, transfer xnL from a 2 mM Echo qualified plate containing test compounds into assay plate Col. 5 - 48. Add same volume of DMSO in col 1-4.
3#Spin plates at 1000 rpm for 1 minute in centrifuge.
4#Using the bioraptr, add 3 uL/well of (35nM protein control) to columns 1 and 2 and test compound wells.
5#Using the bioraptr, add 3 uL/well of Mix 2 (750nM protein) to col. 3-4 for the positive control
6#Using the bioraptr, add 3uL/well of Mix 3 (DNA) to col. 1-48.
7#Spin plates at 1000 rpm for 1 minute in centrifuge.
8#Incubate plates in the dark at room temperature for 90 minutes.
9#Set up Perkin Elmer EnVision as described in section Instrument setting.
10#Read plates on EnVision using FP Dual enhanced mirror, FP 480 excitation filter, FP-P-pol 535 and FP-S-pol 535 emissin filters
Comment: Actives were selected based on, % response = 45% or greater
BatchID%Activity_Corrected at 10 uMValue at 10 uMFRatioMean HighSTD Deviation HighMean LowSTD Deviation Low
MLS-0047618.P030-3.493.68211.044.170.559.390.94
MLS-0047644.P0305.014.11640.924.170.559.390.94
MLS-0047572.P030-2.833.69691.044.170.559.390.94
MLS-0051226.P0300.813.94510.974.170.559.390.94
MLS-0018734.P030-4.413.68651.044.170.559.390.94
MLS-0099666.P0281.273.98090.984.170.559.390.94
MLS-0021904.P031-3.013.78121.014.170.559.390.94
MLS-0003494.P0306.804.21360.884.170.559.390.94
MLS-0041706.P0304.324.15710.934.170.559.390.94
MLS-0051069.P030-3.403.77220.984.170.559.390.94
MLS-0008767.P030-4.323.69821.104.170.559.390.94
MLS-0004317.P030-5.103.65011.054.170.559.390.94
MLS-0024446.P0301.543.9761.004.170.559.390.94
MLS-0043221.P0303.454.13640.944.170.559.390.94
MLS-0093353.P0282.204.08610.934.170.559.390.94
MLS-0039240.P030-3.253.80520.984.170.559.390.94
MLS-0009783.P0250.253.8930.944.170.559.390.94
MLS-0027652.P0311.203.92910.964.170.559.390.94
MLS-0034571.P030-0.403.85850.964.170.559.390.94
MLS-0001714.P0303.944.08250.924.170.559.390.94
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: MTASE-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 2 uL; SMMTase Enzyme (2x) in reaction buffer, columns 1- 48.
2; Reagent; 1 uL; SAM (4x) in reaction buffer, columns 1-48.
3; Controls; 23 nL; DMSO in column 4; sinefungin in DMSO (0 uM - 40 uM) in 7-point 1:2 dilution series (n = 2) in column 2.
4; Compounds; 23 nL; Columns 5-48.
5; Reagent; 1 uL; Substrate (4x) in reaction buffer, columns 2-48.
6; Time; 20-30 min; Incubation.
7; Reagent; 1 uL; MTase-Glo reagent (5X), columns 1-48.
8; Time; 30 min; Incubation.
9; Reagent; 5 uL; MTase-Glo Detection reagent, columns 1-48.
10; Time; 30 min; Incubation, luminescence evolution.
11; Detection; Luminescence; ViewLux uHTS Microplate Imager (PerkinElmer).

NOTES (numbers refer to Sequence numbers above)
1, 2, 5. White Medium Binding Greiner 1536-well plates (Cat #789175-F, Greiner Bio-One, Monroe, NC); Reaction buffer: 50 mM Tris, pH 8.0, 3 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, and 0.1 mg/mL BSA. Evaporation was prevented by covering assay plates with metal lids containing holes to allow gas diffusion.
1. Six SMMTase were profiled: HNMT, GNMT, PNMT, COMT, NNMT, GAMT
2. The corresponding SAM cofactor concentration was used for each SMMTase: HNMT - 9.3 uM SAM; GNMT - 12.1 uM SAM; PNMT - 3.6 uM SAM; COMT - 14.5 uM SAM; NNMT 11.9 uM SAM; GAMT - 5.6 uM SAM.
3, 4. Pintool transfer
5. The corresponding substrate was used for each enzyme: HNMT - 5.3 uM Histamine; GNMT - >500 uM Glycine; PNMT - 16.2 uM Norephinephrine; COMT - 13.7 uM Norephinephrine; NNMT - 3.8 uM Nicotinamide; GAMT - 2.5 uM Guanidinoacetate.6, 8, 10. Room temperature
6. Final reaction conditions: 10 nM COMT, 5 uM SAM, 15 uM norepinephrine, 50 mM Tris, pH 8.0, 3 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, and 0.1 mg/mL BSA; refer to tables 2 and S1 for specific timing.
8. Conversion of SAH to ADP; MTase Glo Kit (Promega, Madison, WI).
10. Conversion of ADP to ATP and detection by UltraGlo luciferase; MTase Glo Kit (Promega, Madison, WI).
11. Settings: 20 s exposure, 1X binning, high gain, medium speed.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are assayed at single point activity (40 uM).
2. Active / Inactive compound calling is based on the results of the enzyme assay panel. ACTIVE compounds have PUBCHEM_ACTIVITY_SCORE = 50 and are compounds that have <= -50% max response in ANY ONE of the six enzymes. INACTIVE compounds have PUBCHEM_ACTIVITY_SCORE = 0 and are those that have >= -30% max response in ALL SIX enzymes. The remaining compounds are INCONCLUSIVE and have PUBCHEM_ACITIVITY_SCORE = 30.
COMT-Max_ResponseGAMT-Max_ResponseGNMT-Max_ResponseHNMT-Max_ResponseNNMT-Max_ResponsePNMT-Max_Response
-14.477-0.906-64.36-7.723-13.221-6.568
-97.283-96.83-99.246-99.097
-11.662-7.108-69.542-15.105-18.57-11.209
9.957-8.37-63.807-27.029-13.633-0.512
-1.3788.081-1.801-70.001-9.255-2.174
-4.184-8.838-45.186-20.976-17.93-50.762
-64.186-17.487-82.517-23.323-14.889-4.424
-28.27-13.82-44.132-13.042-22.645-61.981
-95.9186.395-70.158.26-8.601-15.867
-6.366.696-61.41910.286-22.134-20.539
2.7649.187-5.281.889-50.6463.945
5.467.241-52.1632.748-5.3684.271
18.645-5.1-85.869-4.46517.42
-33.223-8.861-69.978-8.649-22.429-13.542
-22.681-17.904-81.69-53.866-21.453-18.314
3.649-5.536-6.193-64.526-18.858-7.356
-17.938-19.922-61.7-32.188-41.884-42.419
-0.0336.8778.069-87.187-3.6082.522
66.24812.293-50.945-8.947-3.8437.458
-0.7140.817-11.379-86.711-10.789-2.627
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:N/A
External ID: SBCCG-A1014-TWEAK-Fn14-Primary-Assay
Protocol: A. Brief Description of the Assay:
This assay attempts to identify small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay. The assay is run in 1536-well format and is measured via luminescence.

B. Assay Procedures:

Day 1#
1.#Harvest cells. Spin, resuspend in 10% FBS DMEM
2.#Split cell at 1:6
3.#Incubate the flasks for 48hr prior to the experiment day in 37 C 5% CO2 incubator.
#
Day 3#
1.#Harvest cells. Spin, resuspend in Opti-MEM and count.
2.#Dilute cell to 0.25 x106 c/mL.
3.#Prime the Multidrop Combi with 5ml Opti-MEM and add 4microL Assay media to full plate.
a.#>>Plate with Multidrop Combi.
4.#Spin plates at 1000 RPM for 1 min, lid plate.
5.#Incubate plate overnight in 37 C 5% CO2 incubator.
#
Day 4#
1.#Transfer compound (10mM) and DMSO using LabCyte ECHO Dose Response protocol.
2.#Spin plates at 1000 RPM for 1 min.
3.#Incubate plate for 1 hour in 37 C 5% CO2 incubator.
4.#Transfer 2microL of Human TWEAK (120ng/ml) using Multidrop Combi.
5.#Spin plates at 1000 RPM for 1 min and incubate plate for 8 hours in 37 C 5% CO2 incubator.
6.#Add 2.5 microL of Bright Glo reagent and spin the plates at 1000rpm for 1min.
7.#Incubate at RT for 5 min.
8.#Read plate with PerkinElmer ViewLux.

C. Plate Map:

Positive (Low) control in column 1-4, DMSO.
Negative (High) control in columns 45-48, DMSO.
Test wells in columns 5-44.
Comment:
%Activity_Corrected at 10 uMValue at 10 uMMean HighSTD Deviation HighMean LowSTD Deviation Low
-16.417046.1995736.841539.88822.02236.26
-7.996489.9985736.841539.88822.02236.26
2.665170.6725736.841539.88822.02236.26
-7.876645.1655736.841539.88822.02236.26
4.915426.5495736.841539.88822.02236.26
10.765338.8255736.841539.88822.02236.26
-1.385994.515736.841539.88822.02236.26
36.643912.0095736.841539.88822.02236.26
-11.536222.6655736.841539.88822.02236.26
12.295713.4395736.841539.88822.02236.26
28.814508.0765736.841539.88822.02236.26
-15.616523.3125736.841539.88822.02236.26
2.865454.655736.841539.88822.02236.26
-2.966844.0795736.841539.88822.02236.26
31.864672.6955736.841539.88822.02236.26
4.366032.0495736.841539.88822.02236.26
3.046638.0595736.841539.88822.02236.26
-10.946877.2845736.841539.88822.02236.26
16.35502.5165736.841539.88822.02236.26
54.713120.3435736.841539.88822.02236.26
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: OBG420
Protocol: Assay Protocol Summary:

1,000 cells in 4 uL of media were dispensed into white, solid bottom 1536-well plates using a Multidrop Combi (Thermo Scientific). The Assay plates were incubated for 16 hours at 37 C with 5% CO2 in assay plates, followed by the addition of 23 nL of DMSO or drug dissolved in DMSO. Each compound was assayed in five concentrations (0.092, 0.46, 2.3, 11.5, and 57.5 uM), using the automated Wako 1536 Pin Tool workstation and incubated at 37 C with 5% CO2 48 hours. 4 uL of ATPlite, the ATP monitoring reagent, was then added to the each well of the assay plates using the Multidrop Combi reagent dispenser followed by incubation for 15 minutes at room temperature. The resulting luminescence was measured using the ViewLux plate reader.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, cytotoxic compounds are considered active and show up as apparent inhibitors, which are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002299000 uMActivity at 0.0009353959 uMActivity at 0.00184 uMActivity at 0.00468 uMActivity at 0.00919 uMActivity at 0.016 uMActivity at 0.027 uMActivity at 0.051 uMActivity at 0.092 uMActivity at 0.155 uMActivity at 0.256 uMActivity at 0.462 uMActivity at 0.846 uMActivity at 1.283 uMActivity at 2.310 uMActivity at 4.246 uMActivity at 6.551 uMActivity at 11.58 uMActivity at 25.26 uMActivity at 38.52 uMActivity at 57.54 uMActivity at 116.1 uMActivity at 221.6 uMActivity at 288.3 uMPanel IDPanel Name
Inactive0.089120.43770-7.054.95490.524316-4.437740 0 0 0 013.1195-1.614723.02214.923222.436413.11953PA-1
Inactive0.501219.5120-6.34.50450.98372.5-17.01240 0 0 0 04.6148-17.0933-15.1392.02030.96314.61484SKOV3
Inactive0.089110.17840-7.054.95490.4664-7.67842.540 0 0 0 0-7.22470.9983-11.3986-10.48-0.961-7.22475C33A
Inactive000046.8018-1.79437.92887.71697.15576.80186JEG-3
Inactive0.6315.87540-6.24.95490.65335-0.875440 0 0 0 04.99780.7404-1.97958.09512.36074.99787Es-2
Inactive00004-1.56592.9339-4.8958-4.79511.5969-1.56598Hek293T
Inactive0.08919.9950-7.054.95490.3786-7.4952.540 0 0 0 0-5.41281.1477-11.5205-0.3743-12.9125-5.41289Tov112D
Inactive00004-3.29573.83081.4062-4.436-2.7163-3.295710Tov-21-G
Inactive0.707914.66040-6.154.95490.999411.5-3.160440 0 0 0 11.8313-3.0503-3.035511.111111.20241.831311OV90
Inactive2.511911.03920-5.61.62590.99184.5-6.539240 0 0 0 04.3244-5.7563-6.6993-3.04413.02174.324412CASKI
Inactive000044.00029.26091.730716.16898.27064.00021CAOV3
Inactive0.112.42240-71.64360.8881-1.922410.540 0 0 0 0-4.51867.76070.4819-0.6217-0.7957-4.51862HeLa
Inactive000049.02713.25131.741213.527517.68579.0273PA-1
Inactive0.3162180-6.54.44950.963772540 0 0 0 119.687125.203421.51315.01739.427119.68714SKOV3
Inactive000040.33690.4452-0.91255.72924.440.33695C33A
Inactive0.063110.50-7.24.95490.8451212.540 0 0 0 01.087910.83860.19022.46194.63951.08796JEG-3
Inactive0.50129.55980-6.34.95490.95170-9.559840 0 0 0 0-0.0179-8.4158-10.46650.9667-1.2439-0.01797Es-2
Inactive0.063114.81190-7.24.95490.534-5.8119940 0 0 0 10.28146.5861-12.75991.4268-6.08970.28148Hek293T
Inactive8.91258.5410-5.054.0450.6148-0.54140 0 0 0 07.75193.7595-4.2009-0.57340.66357.75199Tov112D
Inactive000041.0625-0.46660.2533-1.2691-7.13331.062510Tov-21-G
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NSD2-synergy-p-2C
Protocol: High-throughput drug screening of isogenic RCH-ACV cell lines was performed at the National Center for Advancing Translational Science (NCATS), National Institutes of Health as previously described (1). Briefly, isogenic RCH-ACV NSD2 p.E1099K mutant (9B) and WT cells (2C) were plated at 500 cells/well in a 1536-well plate with a 72-hour incubation with compounds prior to addition of CellTiter-Glo to assess cell viability. NCATS libraries screened include: NPC, MIPE 5.0, Kinase and NPACT. To determine compound activity in the qHTS assay, the concentration-response data for each sample was plotted and modeled by a four-parameter logistic fit yielding IC50 and efficacy (maximal response) values. The area under the curve (AUC) of the dose-response curve ensures both efficacy (magnitude of cell killing) and potency (concentration that elicits cell killing) are accounted for in the analysis of activity.

Reference:
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062633 uMActivity at 0.0000234000 uMActivity at 0.0000299492 uMActivity at 0.0000680174 uMActivity at 0.0001469594 uMActivity at 0.0003236290 uMActivity at 0.0006759500 uMActivity at 0.00129 uMActivity at 0.00271 uMActivity at 0.00485 uMActivity at 0.00758 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.399 uMActivity at 1.898 uMActivity at 4.965 uMActivity at 9.229 uMActivity at 17.27 uMActivity at 44.90 uMActivity at 91.89 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Inactive00049.3597000002.228909.3597QC'd by Microsource
Inactive0-4.4754.95490.8748-21.4867440 0 0 0 0 0 0 0-17.07226.10422.829307.402506.12865.2151-17.0722QC'd by Vitas
Inactive0-8.2751.17050.66112-6.66740 0 0 0 0 0 0 0-1.0776-6.3892-2.9698-1.73725.8740.35322.4192.3477-1.0776QC'd by Labotest
Inactive0-4.4254.95490.4933-23.5282-340 0 0 0 0 0 0 0-17.94020.3948-8.1012-10.4184-5.55441.8102-4.77655.7051-17.9402QC'd by Vitas
Inactive000407.8331009.349608.39368.85740QC'd by Sequoia
Inactive000402.13462.08732.87872.198101.071700QC'd by SIGMA
Inactive000406.747707.7196.37060000QC'd by Prestwick
Inactive00041.32598.1273007.30856.14859.763401.3259QC'd by Enzo
Inactive0-6.7754.95490.7871-25.4234-14.789241 0 0 0 0 0 0 1-14.8266-40.4001-18.8558-14.3881-11.9076-28.2695-23.675-23.6904-14.8266QC'd by Microsource
Inactive00040003.22385.382307.503400QC'd by Microsource
Inactive0-4.4754.95490.4377-10.0741240 0 0 0 0 0 0 0-7.9784006.8904-2.128300.76149.8865-7.9784QC'd by Labotest
Inactive0004-2.11844.73944.4107-0.61385.167402.3218-1.3941-2.1184QC'd by Microsource
Inactive000400.23422.97255.131802.023500.05890QC'd by Enzo
Inactive0-8.7250.60.79454.5-11.988640 0 0 0 0 0 0 1-9.0185-8.3238-0.45670.90310.07213.33947.72623.0826-9.0185QC'd by Vitas
Inactive0-9.1254.95490.55695-5.355240 0 0 0 0 0 0 1-2.6103-2.7966.99953.42281.61018.09837.01342.0138-2.6103QC'd by Specs
Inactive00040.9896009.6344004.278600.9896QC'd by GVK
Inactive0-5.5254.0950.6337-3.6963340 0 0 0 0 0 0 0-3.46713.29266.721104.917102.2046-3.4969-3.4671QC'd by Prestwick
Inactive00043.12693.073206.53832.82740-3.41288.31143.1269QC'd by Labotest
Inactive0004002.5786.65920003.36630QC'd by Prestwick
Inactive00042.6761008.9375000.40802.6761QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:Protein DAF-12, isoform a [Caenorhabditis elegans]
External ID: HGDAF12_AG_LUMI_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as agonists of the nuclear receptor daf-12. In this assay, CV-1cells are co-transfected with a GAL4-responsive reporter plasmid (UAS-tk-luc) and expression vector encoding GAL4-hgDAF12. The ability of compounds to increase transcriptional activity is assessed by measuring luciferase expression from the reporter gene plasmid. Compounds were tested in singlicate at a final nominal concentration of 6.8 micromolar.

Protocol Summary:

HEK293 cells were routinely cultured in T-175 flasks containing 25 mL of DMEM media supplemented with 10% v/v fetal bovine serum and 1% v/v antibiotic-antimycotic mix at 37 C, 5% CO2 and 95% relative humidity (RH). The day prior to run the assay, the HEK293 cells were harvested using 5 mL of TrypLE reagents and seeded in fresh media at a density of 10 million cells per T175 flask. The following day, cells were transfected with 1 mL of serum-free OptiMEM containing 8 ug of the hgDAF12-expressing vector, 20 ug of the MH1000-tk-luc reporter plasmid and 80 uL of transfection reagent. Twenty four hours post transfection, cells were harvested using 5 mL of preheated TrypLE and resuspended at a concentration of 1 million cells per mL in phenol-red free DMEM supplemented as above. Sodium butyrate, a compound shown to increase the luminscent signal in this assay, was used as a positive control.

The assay was started by dispensing 5 uL of cell suspension into each well of white, solid-bottom 1536-well plates using a flying reagent dispenser (Aurora) and placed in the incubator for 3 hours. Cells were then treated with 34 nL/well of either test compounds, DMSO (Low Control, final concentration 0.68%) or 2 mM of Sodium Butyrate (High Control). Plates were incubated for 24 hours at 37 C, 5% CO2 and 95%RH and then removed from the incubator and equilibrated to room temperature for 10 minutes. Luciferase activity was detected by addition of 5 uL of One-Glo reagent to each well. After a 15 minute incubation time, light emission was measured with the ViewLux reader (PerkinElmer).

The percent activation of each test compound was calculated as follows:

%_Activation = 100 * ( ( Test_Compound - Median_Low_Control ) / ( Median_High_Control - Median__Low_Control ) )

Where:

High_Control is defined as wells treated with 2 mM Sodium Butyrate
Low_Control is defined as wells treated with DMSO only.
Test_Compound is defined as wells treated with test compound.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated: (1) the average percent inhibition of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition than the cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-12, and for inactive compounds 12-0.

List of Reagents:

MH1000-tk-luc luciferase reporter plasmid (Assay Provider)
hgDAF12 expressing plasmid (Assay Provider)

List of Consumables:

Sodium Butyrate (Sigma, part B5887)
HEK293 cells (ATCC, part CRL-1573)
DMEM (Invitrogen, part 11965)
FBS (Hyclone, part SH30088.03)
Antibiotic-Antimycotic 100X Liquid Solution (Gibco, part 15240)
TransIT 293 (Mirus Corporation, part MIR-2700)
OptiMEM (Invitrogen, part 31985)
TrypLE Trypsin Replacement Enzyme (Invitrogen, part 12604)
One-Glo (Promega, part E6130)
1536-well plates (Greiner part 789173)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate luciferase activity and hence well luminescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.

In absence of a Protein Entry for the DAF-12 protein from H. glycines in NCBI's database, links to the target sequence and origin refer to the closest known orthologue from the prototypic parasitic helminth C.elegans.
Activation at 6.8 uM
62.09
60.25
59.18
53.21
50.22
48.95
47.43
45.92
42.05
38.56
36.82
34.13
32.75
32.06
31.73
31.3
28.81
28.09
28
27.93
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NSD2-synergy-p-9B
Protocol: High-throughput drug screening of isogenic RCH-ACV cell lines was performed at the National Center for Advancing Translational Science (NCATS), National Institutes of Health as previously described (1). Briefly, isogenic RCH-ACV NSD2 p.E1099K mutant (9B) and WT cells (2C) were plated at 500 cells/well in a 1536-well plate with a 72-hour incubation with compounds prior to addition of CellTiter-Glo to assess cell viability. NCATS libraries screened include: NPC, MIPE 5.0, Kinase and NPACT. To determine compound activity in the qHTS assay, the concentration-response data for each sample was plotted and modeled by a four-parameter logistic fit yielding IC50 and efficacy (maximal response) values. The area under the curve (AUC) of the dose-response curve ensures both efficacy (magnitude of cell killing) and potency (concentration that elicits cell killing) are accounted for in the analysis of activity.

Reference:
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062633 uMActivity at 0.0000234000 uMActivity at 0.0000299492 uMActivity at 0.0000680174 uMActivity at 0.0001469594 uMActivity at 0.0003236290 uMActivity at 0.0006759500 uMActivity at 0.00129 uMActivity at 0.00271 uMActivity at 0.00485 uMActivity at 0.00758 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.399 uMActivity at 1.898 uMActivity at 4.965 uMActivity at 9.229 uMActivity at 17.27 uMActivity at 44.90 uMActivity at 91.89 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Inhibitor0.001595.0131100Complete curve; high efficacy-8.82954.95490.995-92.98592.0272-1.10 0 0 0 0 0 0 0 0 0 0-96.2587-1.6791-84.9271-90.9202-90.8631-90.7375-92.2911-92.6732-94.1019-94.0673-96.0913-96.2587QC'd by SIGMA
Inhibitor0.001796.0144100Complete curve; high efficacy-8.76833.24750.9987-95.37860.6358-1.10 0 0 0 0 0 0 0 0 0 0-96.92941.7123-0.1391-34.4453-93.3159-93.9442-94.1795-94.3745-94.7424-94.9325-95.6129-96.9294QC'd by MedChem Express
Inhibitor0.0017101.1335100Complete curve; high efficacy-8.76834.50450.9988-96.45574.6778-1.10 0 0 0 0 0 0 0 0 0 0-98.62542.93835.3252-23.8352-93.6078-94.3407-94.7755-96.5382-96.9802-98.093-97.488-98.6254QC'd by MedChem Express
Inhibitor0.001495.7664100Complete curve; high efficacy-8.86833.06540.9932-91.73124.0352-1.10 0 0 0 0 0 0 0 0 0 0-94.373606.5073-50.3576-85.2142-89.4583-90.3553-90.6328-93.2878-91.6178-92.6738-94.3736QC'd by MedChem Express
Inhibitor0.002792.056799Complete curve; high efficacy-8.5753.990.9971-93.082-1.0254-1.10 0 0 0 0 0 0 0-97.5703-1.153-56.5542-91.9507-92.331-93.0234-92.9105-92.2466-97.5703QC'd by Alfa Aesar
Inhibitor0.002786.152899Complete curve; high efficacy-8.5754.95490.9984-92.0573-5.9045-1.10 0 0 0 0 0 0 0-92.9872-5.0961-62.3948-91.5014-91.2009-92.0539-90.8793-91.9519-92.9872QC'd by Microsource
Inhibitor0.002198.487899Complete curve; high efficacy-8.6754.50450.9983-91.97956.5083-1.10 0 0 0 0 0 0 0-94.04855.8681-73.3835-89.9758-90.798-91.9458-91.2065-93.7497-94.0485QC'd by Bosche
Inhibitor7.0E-482.733499Complete curve; high efficacy-9.1750.60.8847-82.65670.0767-1.10 0 0 0 0 0 0 0-94.3569-37.5208-62.7186-72.7916-74.3825-79.8918-76.6331-78.5528-94.3569QC'd by Selleck
Inhibitor0.003795.081999Complete curve; high efficacy-8.43621.22210.9994-94.52050.5614-1.10 0 0 0 0 0 0-93.7704-1.16310.6157-11.9264-47.6173-82.383-92.7843-93.7704QC'd by Adooq
Inhibitor0.003394.047999Complete curve; high efficacy-8.47953.51170.9958-93.96230.0856-1.10 0 0 0 0 0 0 0 0 0 0-97.87741.2665-23.1756-88.8678-90.2585-91.8229-92.3997-94.1271-95.2991-93.6757-95.8566-97.8774QC'd by MedChem Express
Inhibitor0.0047102.007598Complete curve; high efficacy-8.32952.24810.997-94.17637.8312-1.10 0 0 0 0 0 0 0 0 0 0-98.71735.6987-9.7434-65.3554-90.638-91.2058-92.371-92.7427-94.2549-94.3053-96.979-98.7173QC'd by GVK
Inhibitor0.0047100.42998Complete curve; high efficacy-8.3253.67720.9994-93.22767.2013-1.10 0 0 0 0 0 0 0-94.74358.1328-8.6557-90.5176-92.1158-93.5383-93.4255-92.4974-94.7435QC'd by Prestwick
Inhibitor0.003896.763498Complete curve; high efficacy-8.4253.990.9994-92.02054.743-1.10 0 0 0 0 0 0 0-93.51674.0536-21.1619-91.8053-91.1174-91.9789-90.7784-91.2901-93.5167QC'd by Selleck
Inhibitor0.004590.539798Complete curve; high efficacy-8.34664.50450.9995-92.4565-1.9167-1.10 0 0 0 0 0 0-93.156-4.128-89.5728-91.2217-93.3904-92.524-93.0057-93.156QC'd by Selleck
Inhibitor0.005298.298798Complete curve; high efficacy-8.2884.95490.9993-92.65815.6406-1.10 0 0 0 0 0 0-93.59410-91.9394-91.381-91.3804-93.5391-93.3571-93.5941QC'd by ChemieTek
Inhibitor0.005298.854698Complete curve; high efficacy-8.2880.60.9861-94.11974.7349-1.10 0 0 0 0 0 0-93.9318-33.6729-64.3585-76.1096-84.2151-92.4038-93.1111-93.9318QC'd by MedChem Express
Inhibitor0.00486.042698Complete curve; high efficacy-8.39924.50450.9996-92.288-6.2454-1.10 0 0 0 0 0 0-91.795-7.0299-86.4668-91.4418-93.2202-92.6549-92.4417-91.795QC'd by Selleck
Inhibitor0.004698.020398Complete curve; high efficacy-8.3383.51170.9996-93.16844.8519-1.10 0 0 0 0 0 0-93.7644-11.8828-91.4502-92.2553-94.1095-92.9439-93.2642-93.7644QC'd by SIGMA
Inhibitor0.0042104.449798Complete curve; high efficacy-8.37954.95490.9968-93.920410.5293-1.10 0 0 0 0 0 0 0 0 0 0-96.62598.66757.5142-90.2575-91.0844-91.1114-92.6871-93.2743-95.4523-94.079-95.5345-96.6259QC'd by BioAustralis
Inhibitor0.004294.942198Complete curve; high efficacy-8.37952.84730.9968-94.75910.183-1.10 0 0 0 0 0 0 0 0 0 0-96.93990.6808-16.1375-78.234-91.1234-91.9081-92.3507-95.4781-97.4887-95.7111-95.4747-96.9399QC'd by ActiveBioChem
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: s-sky_synergy-MV-411_DR-CTG72-MIPE_NPC_NPACT_Kinase-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Media; 2uL; white, solid-bottom Corning assay plate.
2; Compounds; 23nL; Echo acoustic dispenser.
3; Cell; 5uL; 500 cells per well.
4: Incubation; 72hr; 37 C, 5% CO2, 95% humidity.
5; Reagent; 3uL; CellTiter-Glo reagent (Promega).
6; Incubation; 10min; room temperature.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to Sequence numbers above
1. Quantitative high-throughput screening (qHTS) of small molecule compounds was conducted on drug resistant SYKi MV4-11 cell line. Briefly, 2uL growth media (RPMI 1640 + 1% penicillin/streptomycin + 10% FBS) were added into an assay plate using a Multidrop Combi dispenser (Thermo Fisher Scientific).
2. Twenty-three nanoliter of small molecule compounds were added to each assay plates using the Echo acoustic dispenser (Beckman Coulter).
3. Cells were seeded into the assay plates at a final density of 500 cells in 5uL of media per well using the Multidrop Combi dispenser.
4. Plates were covered with stainless steel gasketed lids and incubated for 72 hours at standard cell culture conditions.
5. Viability was assessed by adding 3uL of CellTiter-Glo detection reagent (Promega).
6. Plates were covered with gasket lids and incubated for 10 minutes at room temperature.
7. Luminescence was measured on a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062652 uMActivity at 0.0000234000 uMActivity at 0.0000299754 uMActivity at 0.0000680318 uMActivity at 0.0001469781 uMActivity at 0.0003237363 uMActivity at 0.0006761082 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00486 uMActivity at 0.00759 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.356 uMActivity at 0.588 uMActivity at 1.402 uMActivity at 1.903 uMActivity at 4.972 uMActivity at 9.253 uMActivity at 17.29 uMActivity at 44.98 uMActivity at 91.90 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Cytotoxic0.00882.203484Complete curve; high efficacy-8.09921.010.966921.0427103.2462-1.10 0 0 0 0 0 013.188495.474859.067235.842331.665221.923822.070613.1884QC'd by Analyticon
Cytotoxic0.025981.057283Complete curve; high efficacy-7.58624.95490.92316.497297.5544-1.10 0 0 0 0 0 02.512597.003593.26858.94736.670723.420912.53742.5125QC'd by MedChem Express
Cytotoxic0.819985.290183Complete curve; high efficacy-6.08621.75290.99432.3577117.6478-1.10 0 0 0 0 0 034.7953115.2038115.6711122.1398.373449.123231.010634.7953QC'd by Glixx
Cytotoxic0.0190.438383Complete curve; high efficacy-7.99921.06410.985619.9781110.4164-1.10 0 0 0 0 0 013.8267101.704171.224135.805628.627925.082819.478713.8267QC'd by Analyticon
Cytotoxic0.0092105.836183Complete curve; high efficacy-8.03624.0950.998416.204122.0401-1.10 0 0 0 0 0 013.8473120.968928.848618.13117.368317.353714.687813.8473QC'd by SIGMA
Cytotoxic0.468384.095583Complete curve; high efficacy-6.32954.44950.96929.5128113.6083-1.10 0 0 0 0 0 0 0 0 0 021.2667108.9911100.6389111.6185114.5273123.8697121.846750.484436.16335.491326.950121.2667QC'd by MedChem Express
Cytotoxic0.104882.764282Complete curve; high efficacy-6.97951.41630.983812.632295.3964-1.10 0 0 0 0 0 0 0 0 0 010.575588.311793.092698.209696.743461.009638.863620.85115.78315.70359.904810.5755QC'd by BIOMOL
Cytotoxic0.177891.15582Complete curve; high efficacy-6.750.60.967113.9433105.0983-1.10 0 0 0 0 0 09.94996.781688.005652.483744.630729.767723.42539.949QC'd by Waterstone
Cytotoxic0.0106101.825682Complete curve; high efficacy-7.9752.72020.992711.1635112.9891-1.10 0 0 0 0 0 0 010.2995105.5432116.579542.386110.210110.828611.463311.646810.2995QC'd by Prestwick
Cytotoxic0.668497.583882Complete curve; high efficacy-6.1752.33320.990218.8259116.4097-1.10 0 0 0 0 0 0 015.8771121.1891108.6953122.087113.851596.846325.162623.985315.8771QC'd by Enzo
Cytotoxic0.042299.181282Complete curve; high efficacy-7.3751.34430.993310.554109.7352-1.10 0 0 0 0 0 0 010.7613114.3989100.783890.706544.474211.202813.845711.361610.7613QC'd by Tocris
Cytotoxic0.007584.106682Complete curve; high efficacy-8.1254.95490.99839.434493.541-1.10 0 0 0 0 0 0 06.535491.798594.110412.665511.09298.63279.997110.07546.5354QC'd by Bosche
Cytotoxic0.421785.920382Complete curve; high efficacy-6.3750.80.962221.4982107.4185-1.10 0 0 0 0 0 0 016.639100.4185107.3168112.829384.599367.881738.354237.879716.639QC'd by Vitas
Cytotoxic0.145895.744482Complete curve; high efficacy-6.83621.55790.976614.7016110.446-1.10 0 0 0 0 0 04.7392104.3625115.347884.378731.790525.599818.03364.7392QC'd by Microsource
Cytotoxic0.0036107.247382Complete curve; high efficacy-8.4444.95490.99898.6172115.8646-1.10 0 0 0 0 0 07.4398110.64829.223610.03329.4928.91416.32217.4398QC'd by Selleck
Cytotoxic0.163680.294782Complete curve; high efficacy-6.78622.04790.976317.79598.0898-1.10 0 0 0 0 0 06.7352100.462595.567485.02829.253227.68320.08926.7352QC'd by Selleck
Cytotoxic0.023197.640682Complete curve; high efficacy-7.63624.95490.999510.3864108.027-1.10 0 0 0 0 0 010.177107.94198.68449.835111.696111.67178.800110.177QC'd by Selleck
Cytotoxic1.587786.327482Complete curve; high efficacy-5.79921.3310.964223.21109.5374-1.10 0 0 0 0 0 029.2744118.455699.7114104.7412100.992385.097633.922129.2744QC'd by MedChem Express
Cytotoxic0.014689.488582Complete curve; high efficacy-7.83621.28760.99529.344198.8326-1.10 0 0 0 0 0 07.000590.702951.556722.53611.87749.85658.1887.0005QC'd by SynKinase
Cytotoxic0.006596.843182Complete curve; high efficacy-8.18624.0950.99488.9496105.7927-1.10 0 0 0 0 0 03.839102.120912.445311.444810.88219.89667.70273.839QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: sca2-steadyglo_p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 4 uL; white, solid bottom, 1536-well Greiner assay plate.
2; Incubation; 2 hr; 37 degree C in 5% humidified CO2.
3; Compounds; 23 nL; Kalypsis pintool (Wako USA) equipped with a 1536-well pin head.
4; Incubation; 24 hr; 37 degree C in 5% humidified CO2.
5; Reagent; 1 uL; Gly-Phe-7-Amino-4-trifluoromethylcoumarin.
6; Incubation; 30 min; 37 degree C in 5% humidified CO2.
7; Detection; Fluorescence; ViewLux plate reader (PerkinElmer).
8; Reagent; 3 uL; SteadyGlo luciferase solution (Promega).
9; Incubation; 5 min; room temperature.
10; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to Sequence numbers above)
1. S2 cells expressing ATXN2-luciferase reporter were suspended in phenol-red free DMEM and dispensed in assay plates using a Multidrop Combi dispenser (Thermo Fisher Scientific). Wells containing medium only were plated on each plate, and values were used to normalize (100% inhibition) in the luciferase and CellTiter-Fluor assays.
2. Assay plates were incubated. Evaporation was prevented by covering assay plates with metal lids containing holes to allow gas diffusion.
3. Compounds were added in a dose response manner with the final concentrations of 57, 11.4, 2.28, 0.46, 0.091, 0.018, 0.0037 uM. Vehicle-only plates, with DMSO being pin-transferred to columns 5-48, were inserted uniformly at the beginning and the end of each library to monitor and record any shifts in assay performance.
5. 125 uM Gly-Phe-7-Amino-4-trifluoromethylcoumarin (MP Biomedicals) working concentration was used at a final concentration of 25 uM.
7. To assess cell viability; the assay plates were read using the ViewLux high-throughput CCD imager (PerkinElmer), wherein single end-point fluorescence measurement was acquired (excitation 405/10; emission 540/25 nm).
8. Detection reagent SteadyGlo Luciferase (Promega) was added to the assay plate.
10. Luminescence is then measured on the ViewLux imager equipped with a clear emission filter using a 2 sec exposure. All screening operations were performed on a fully integrated robotic system (Kalypsys) containing one RX-130 and two RX-90 anthropomorphic robotic arms (Staubli).

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000389080 uMActivity at 0.0001066275 uMActivity at 0.0001907270 uMActivity at 0.0004540328 uMActivity at 0.0007572215 uMActivity at 0.0009786446 uMActivity at 0.00290 uMActivity at 0.00451 uMActivity at 0.00876 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.081 uMActivity at 0.235 uMActivity at 0.460 uMActivity at 0.709 uMActivity at 1.038 uMActivity at 2.223 uMActivity at 5.554 uMActivity at 11.31 uMActivity at 18.91 uMActivity at 25.62 uMActivity at 56.99 uMActivity at 115.7 uMActivity at 221.8 uMActivity at 288.0 uMCompound QC
Inactive042.3627-1.83840.97362.7692-6.811610.608-9.3295-56.763-12.31270.57957.23242.3627QC'd by SigmaAldrich
Inactive0-4.51414.95490.572322.51.112340 0 0 0 0 0 0 0 0 0 021.6963-1.39272.4941-5.3231-2.3094-0.47615.2087-4.14282.25061.63622.818121.6963QC'd by BIOMOL
Inactive0-8.11410.60.606519-241 0 0 0 0 0 0 0 0 0 015.9551-25.09624.955110.442211.132413.606820.895214.523414.555527.098317.643215.9551QC'd by Tocris
Inactive0-4.61413.06540.7875-17.83926.540 0 0 0 0 0 0 0 0 0 0-16.53276.581215.210810.12572.1473.35956.79093.25014.35496.2493-0.5643-16.5327QC'd by Tocris
Inactive04-1.74531.93162.40851.62774.63811.55222.50752.35313.96978.48790.0327-1.7453QC'd by BIOMOL
Inactive0-4.31414.95490.6935-23.7101040 0 0 0 0 0 0 0 0 0 0-16.4251-5.59111.1441-6.5191-1.217-0.63721.57633.9012.48061.97740.2599-16.4251QC'd by BIOMOL
Inactive0-4.66413.92950.6373-16.64882.540 0 0 0 0 0 0 0 0 0 0-16.3745.65591.7906-4.5705-6.89536.10464.24993.31416.92735.3525-4.468-16.374QC'd by BIOMOL
Inactive0-4.31414.95490.4902-23.783-0.540 0 0 0 0 0 0 0 0 0 0-16.9025-2.06667.138-6.965-0.12665.83090.3157-2.3556-10.36541.10380.6509-16.9025QC'd by Tocris
Inactive0-4.56414.50450.410521340 0 0 0 0 0 0 0 0 0 02.335415.497814.042710.14959.895217.7354.626113.566217.997811.978611.19012.3354QC'd by Tocris
Activator0.004327.66120Complete curve; partial efficacy-8.36413.29750.65794-23.66121.21 0 0 0 0 0 0 0 0 0 0-4.3551-32.7811-17.63431.62983.17989.471412.78253.18725.21822.0742-1.3727-4.3551QC'd by SigmaAldrich
Inactive0-6.41414.95490.5517-7.16964.540 0 0 0 0 0 0 0 0 0 0-8.4812-6.30037.01386.60416.34737.26234.356-8.6256-9.64313.1993-13.058-8.4812QC'd by BIOMOL
Inactive0-4.61411.44870.7435-15.26876.540 0 0 0 0 0 0 0 0 0 0-11.057310.06734.63033.32295.36510.24964.116112.74941.25174.4953-2.3092-11.0573QC'd by BIOMOL
Inactive0-5.96412.33320.8302-3.462714.540 0 0 0 0 0 0 0 0 0 0-3.192519.249920.31819.81299.965211.608916.89619.9355-1.98791.0088-7.4689-3.1925QC'd by SIGMA
Activator27.282436.61280Single point of activity-4.56414.0950.825235.3387-1.274130 0 0 0 0 0 0 0 0 0 033.70989.34823.35390.6827-9.8386-2.9593-1.1813-1.6759-5.2524-3.31295.710333.7098QC'd by Tocris
Inactive0-5.71412.40640.504911-5.238840 0 0 0 0 0 0 0 0 0 05.41976.54525.2021-11.8205-13.5849-15.199-2.6782-4.01734.12419.433117.7195.4197QC'd by Tocris
Inactive04-5.6859-10.3996-3.2778-8.7479-13.5578-10.8099-16.1474-15.1368-3.1261-6.8761-13.1475-5.6859QC'd by Tocris
Inactive0-7.21410.70.426482240 0 0 0 0 0 0 0 0 0 012.32510.960825.245522.15817.64210.480212.545913.84024.75094.977311.888612.325QC'd by BIOMOL
Activator21.671228.99230Partial curve; partial efficacy; poor fit-4.66413.92950.6883323.00772.40 0 0 0 0 0 0 0 0 0 031.11329.470114.68163.9423-1.89740.4850.50218.04698.282-2.493615.388831.1132QC'd by Tocris
Inactive0-5.71412.72020.8351-5.12911140 0 0 0 0 0 0 0 0 0 0-5.94097.61158.10845.746213.178516.781815.47339.59151.4277-3.8135-4.7653-5.9409QC'd by SIGMA
Activator27.282426.22240Partial curve; partial efficacy; poor fit-4.56411.96730.7623281.77762.40 0 0 0 0 0 0 0 0 0 024.0356.81375.82-5.6020.74664.30282.1745-3.07565.3482.78559.367524.035QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: s-sky_synergy-MV-411_N-CTG72-MIPE_NPC_NPACT_Kinase-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Media; 2uL; white, solid-bottom Corning assay plate.
2; Compounds; 23nL; Echo acoustic dispenser.
3; Cell; 5uL; 500 cells per well.
4: Incubation; 72hr; 37 C, 5% CO2, 95% humidity.
5; Reagent; 3uL; CellTiter-Glo reagent (Promega).
6; Incubation; 10min; room temperature.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to Sequence numbers above
1. Quantitative high-throughput screening (qHTS) of small molecule compounds was conducted on naive SYKi MV4-11 cell line. Briefly, 2uL growth media (RPMI 1640 + 1% penicillin/streptomycin + 10% FBS) were added into an assay plate using a Multidrop Combi dispenser (Thermo Fisher Scientific).
2. Twenty-three nanoliter of small molecule compounds were added to each assay plates using the Echo acoustic dispenser (Beckman Coulter).
3. Cells were seeded into the assay plates at a final density of 500 cells in 5uL of media per well using the Multi-drop Combi dispenser.
4. Plates were covered with stainless steel gasketed lids and incubated for 72 hours at standard cell culture conditions.
5. Viability was assessed by adding 3uL of CellTiter-Glo detection reagent (Promega).
6. Plates were covered with gasket lids and incubated for 10 minutes at room temperature.
7. Luminescence was measured on a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062652 uMActivity at 0.0000234000 uMActivity at 0.0000299754 uMActivity at 0.0000680318 uMActivity at 0.0001469781 uMActivity at 0.0003237363 uMActivity at 0.0006761082 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00486 uMActivity at 0.00759 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.356 uMActivity at 0.588 uMActivity at 1.402 uMActivity at 1.903 uMActivity at 4.972 uMActivity at 9.253 uMActivity at 17.29 uMActivity at 44.98 uMActivity at 91.90 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Cytotoxic0.016689.527684Complete curve; high efficacy-7.77952.09370.944225.8586115.3863-1.10 0 0 0 0 0 0 0 0 0 05.6755108.6505117.9375108.116652.745348.993823.989228.850825.686529.035727.31935.6755QC'd by MedChem Express
Cytotoxic0.0281.223183Complete curve; high efficacy-7.69920.80.972316.819798.0429-1.10 0 0 0 0 0 08.45590.219374.545244.291328.140927.05921.55068.455QC'd by Analyticon
Cytotoxic0.032686.593783Complete curve; high efficacy-7.48620.70.95318.8792105.4729-1.10 0 0 0 0 0 08.453296.808473.066745.439734.552529.766627.43068.4532QC'd by MedChem Express
Cytotoxic0.01683.312682Complete curve; high efficacy-7.79644.95490.99689.607592.9201-1.10 0 0 0 0 0 0 09.777389.297696.418711.99539.71678.86779.754210.35039.7773QC'd by LightBiologicals
Cytotoxic0.010694.295182Complete curve; high efficacy-7.9753.1320.995511.6947105.9898-1.10 0 0 0 0 0 0 011.6947100.9198109.394435.824211.756910.793412.383613.314511.6947QC'd by Prestwick
Cytotoxic0.002788.975382Complete curve; high efficacy-8.5754.95490.99928.907497.8826-1.10 0 0 0 0 0 0 06.903497.991442.29369.96869.10388.22179.30529.09336.9034QC'd by Alfa Aesar
Cytotoxic0.008480.513982Complete curve; high efficacy-8.0754.95490.99738.893889.4076-1.10 0 0 0 0 0 0 06.357787.157291.349912.957111.042110.34028.91169.86186.3577QC'd by Bosche
Cytotoxic0.005197.54282Complete curve; high efficacy-8.2944.50450.99928.7153106.2574-1.10 0 0 0 0 0 07.9842105.047213.76299.49049.84647.65467.1497.9842QC'd by Selleck
Cytotoxic0.020694.499882Complete curve; high efficacy-7.68624.0950.998411.2634105.7632-1.10 0 0 0 0 0 010.8677105.387387.541714.414211.97659.14619.209710.8677QC'd by Selleck
Cytotoxic0.461193.529282Complete curve; high efficacy-6.33621.46410.963718.0367111.5659-1.10 0 0 0 0 0 06.0375113.1729110.6758104.027672.57924.333235.37316.0375QC'd by ChemieTek
Cytotoxic0.025983.407982Complete curve; high efficacy-7.58621.17050.994210.379993.7878-1.10 0 0 0 0 0 05.519287.484466.342228.540116.433812.144911.87075.5192QC'd by MedChem Express
Cytotoxic0.020680.277982Complete curve; high efficacy-7.68623.67720.970514.587194.865-1.10 0 0 0 0 0 07.291596.26274.959527.541914.606313.184910.65757.2915QC'd by MedChem Express
Cytotoxic0.025999.996582Complete curve; high efficacy-7.58621.11050.962710.993110.9895-1.10 0 0 0 0 0 03.5224101.819278.672730.344220.104225.11194.47963.5224QC'd by APExBIO
Cytotoxic0.014690.789582Complete curve; high efficacy-7.83621.34370.9969.109499.8989-1.10 0 0 0 0 0 06.212391.419653.831819.277613.66628.56187.43726.2123QC'd by APExBIO
Cytotoxic0.651381.720382Complete curve; high efficacy-6.18621.47870.989621.402103.1224-1.10 0 0 0 0 0 021.0506108.908195.7413101.202878.035734.663424.989321.0506QC'd by Glixx
Cytotoxic0.01384.007482Complete curve; high efficacy-7.88621.41630.994410.069994.0773-1.10 0 0 0 0 0 05.978686.088247.355717.899613.582410.519910.4225.9786QC'd by MedChem Express
Cytotoxic0.08285.068682Complete curve; high efficacy-7.08620.910.991514.09999.1676-1.10 0 0 0 0 0 010.217194.606584.923959.808127.552123.690516.789310.2171QC'd by Glixx
Cytotoxic0.006584.635382Complete curve; high efficacy-8.18624.0950.99828.850193.4854-1.10 0 0 0 0 0 06.501790.372511.997510.293910.1119.52798.25216.5017QC'd by APExBIO
Cytotoxic0.00982.724382Complete curve; high efficacy-8.0441.28760.991710.51293.2363-1.10 0 0 0 0 0 07.734485.514346.479122.47513.19099.748711.73337.7344QC'd by MedChem Express
Cytotoxic4.0E-494.19682Complete curve; high efficacy-9.3752.40640.99887.7324101.9284-1.10 0 0 0 0 0 07.3587100.769474.71979.88399.60588.64768.49037.3587QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:HNF4 Alpha
External ID: BHood-p-21Jun2013-01
Protocol: This assay is to identify inhibitors of HNF4 alpha protein binding to DNA
##

A. Materials:##
Description#Company#Cat #
1M TRIS #BioRad#161-0719
DTT#RPI#D11000
Glycerol#Amersco #0854-1L
NaCL#Fisher Bioreagents#BP358-212
Tween 20#Sigma#P1379
HNF4 Protein #Assay Provider#
FITC-DNA#Assay Provider#
1536 well black high base plate#Aurora#00019120BX
##
B. Plate Map:##
Positive control in columns 1 and 2 is DNA and 70nM Protein##
Negative control in columns 3 and 4, Protein at 650nM and DNA, DMSO##
Test compound in columns 5 - 48, Protein at 70nM + DNA + test compound

C. Procedures:##########
Step#Description#########
1#Transfer test compounds to columns 5-48, DMSO to columns 1-4 using ECHO 555.#########
2#Set up Envision as as described in G. Instrument setting.#########
3#Prepare assay buffer.#########
4#Dispense undiluted HNF4 protein solution at into col 3-4 and 140nM HNF4 protein into columns 1,2, and 5-48. #########
5#Dispense 3uL/well of FITC-DNA (FAC = 5nM) using BioRAPTR#########
6#Spin down plates on Eppendorf centrifuge 5810 at 1000 rpm for 1 minute.#########
7#Incubate plates at RT for 1 hour.#########
8#Read using FP protocol on Envision#########
##########
D. Assay Conditions:##########
Reagent##Final Conc.#Unit#######
1#Tris pH7.4#0.02#M#######
2#NaCl#0.05#M#######
3#DTT#0.01#M#######
4#Glycerol#10#%#######
5#Protein#650 for EC100 and 70nM for EC20#uM#######
6#DNA#5#nM#######
*#6uL reaction volume#########
*#60 min reaction at room temp#########
*#10uM test compound#########
*#0.5% DMSO
Comment:
%Activity_Corrected at 10 uMValue at 10 uMMean HighSTD Deviation HighMean LowSTD Deviation Low
-6.39105.0999985116.057.38199.696.53
-0.54109.8000031116.057.38199.696.53
-0.14111.9000015116.057.38199.696.53
3.17114.4000015116.057.38199.696.53
0.67110.0999985116.057.38199.696.53
-1.92108.3000031116.057.38199.696.53
-1.35108.0999985116.057.38199.696.53
1.56110.5999985116.057.38199.696.53
1.88112.1999969116.057.38199.696.53
1.69111.5999985116.057.38199.696.53
-0.73109.9000015116.057.38199.696.53
-0.36111.1999969116.057.38199.696.53
9.41119.5999985116.057.38199.696.53
-0.85109.3000031116.057.38199.696.53
-0.03110.0999985116.057.38199.696.53
2.36112116.057.38199.696.53
3.01113.1999969116.057.38199.696.53
-0.42109.0999985116.057.38199.696.53
-1.98107.5999985116.057.38199.696.53
0.83108.9000015116.057.38199.696.53
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:tyrosyl-DNA phosphodiesterase 2 [Homo sapiens]
External ID: TPD2_INH_EPIABS_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as inhibitors of the activity of tyrosyl DNA phosphodiesterase 2 (TDP2). TDP2 is a divalent cation-dependent enzyme that repairs TopII-associated DNA strand breaks. It is hypothesized that inhibitors of TDP2 may serve as useful adjuvants in combination with cancer drugs such as etoposide.

In this biochemical assay, recombinant human TDP2 protein is incubated at 37 degrees Celsius with the T5PNP substrate in the presence of Mg2+-containing assay buffer.T5PNP is a substrate for snake venom phosphodiesterase, as well as a substrate for TDP2. As a substrate for TDP2, T5PNP is used to mimic the TopII-DNA complex. TDP2 cleaves the phosphodiester bond in T5PNP, and the chromogenic p-nitrophenol group is released. As time increases the TDP2 enzyme will increasingly catalyze hydrolysis of the T5PNP substrate, resulting in increased release of p-nitrophenol and detection at 415nM wavelength. Compounds are tested in singlicate at a final nominal concentration of 12.8microM.

Protocol Summary:

Prior to the start of the assay, 2 ul of a solution containing T5PNP subtrate (final concentration 5mM) in assay buffer (50mM Tris-HCl pH7.5, 1mM DTT, 1mM MgCl2, 50mM KCl and 100ug/ml BSA) was dispended into a all wells of a 1536 well plate. Next, 39nL of test compound in DMSO or DMSO alone (1% final concentration) was added to the appropriate wells. The assay was started by dispensing 1 ul of a solution contanting TDP2 enzyme (120nM final concentration) in assay buffer to wells in columns 4-48 and 1ul of assay buffer alone to wells in columnes 1-3. Plates were centrifuged and incubated for 2hrs at 37 degrees Celsius at which time fluorescence intensity was measured (Ex. 405nm and Em. 405nm) using a EnVision microplate reader (Perkin Elmer).

Prior to further calculations, the following formula was used to calculate Epi Absorbance (EPIABS)

EPIABS = -log10( sample / background)

Where:

Sample is defined as the fluorescent intensity of wells containing test compounds or DMSO.
Background is defined as the fluorescent intensity of wells containing buffer and T5PNP only.

The % inhibition for each well was then calculated as follows:

%_Inhibition = ( EPIABS_Test_Compound - MedianEPIABS_Low_Control ) / ( MedianEPIABS_High_Control - MedianEPIABS_Low_Control ) * 100

Where:

Test_Compound is defined as wells containing test compound, TDP2 and T5PNP.
High_Control is defined as wells containing only Buffer and T5PNP.
Low_Control is defined as wells containing DMSO, TDP2 and T5PNP.

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated: (1) the average percent inhibition of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition than the cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-22, and for inactive compounds 22-0.

List of Reagents:

TDP2 (supplied by Assay Provider)
Tris Base(Sigma, 93349)
DTT (Sigma, 43815)
BSA (Sigma, A2153)
MgCl2 (Sigma,M2670)
KCl (Sigma, P9333)
T5PNP (Sigma, T4510)
1536 well plates (Corning 7254)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. In this case the results of each separate campaign were assigned "Active/Inactive" status based upon that campaign's specific compound activity cutoff value. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 12.8 uM
9.44
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
9.43
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:Phospholipase C, gamma 1 [Homo sapiens]
External ID: PLCG1_INH_QFRET_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this biochemical assay is to identify compounds that act as inhibitors of the activity of phospholipase C isozymes, PLC-G1. In this assay, PLC-G1 isozyme is incubated with test compounds and fluorogenic reporter WH-15. As designed, test compounds that act as PLC-G1 inhibitors will prevent the hydrolysis of WH-15 fluorogenic reporter, thus preventing the release of IP3, a quinomethide derivative, and 6-aminoquinoline, which is highly fluorescent, leading to decreasing well fluorescence. Compounds are tested in singlicate at a nominal test concentration of 12.2 micromolar.

Protocol Summary:

Prior to the start of the assay, 2 microliters of PLC-G1 at a final concentration of 5pg/ul (in 50 mM HEPES pH 7.2, 70 mM KCl, 3mM CaCL2, 3mM EGTA, 2mM DTT, 0.04mg/mL acid-free BSA, with Cholate 0.5%) are dispensed into 1536 microtiter plates, 1 microliter of assay buffer is dispensed into columns 4-48 and 1 microliter of 0.2M EGTA is added to columns 1-3. Compounds are added to plate (final concentration 12.2uM) and incubated for 10 minutes at 25 degrees Celsius. The assay start by the addition of 2 microliter of WH-15 fluorogenic reporter at a final concentration 10uM in Assay Buffer to all wells. Plates were centrifuged and after 90 min of incubation at 25 degrees Celsius fluorescence is measured at 355nm excitation and 535nm emmision.

The percent inhibition for each compound was calculated as follows:

100 *( ( Test_Compound - Median_Low_Control ) / ( Median_High_Control - Median_Low_Control ) )

Where:

Test_Compound is defined as wells containing PLCG1 in the presence of test compound and WH15 fluoreogenic reporter.
High_Control is defined as wells containing PLCG1, WH15 fluoreogenic reporter and EGTA.
Low_Control is defined as the median of the wells containing test compounds.

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Four values were calculated: (1) the average percent inhibition of all high controls tested plus three times the standard deviation of the high controls, (2) the average percent inhibition of all low controls tested minus three times the standard deviation of the low controls, (3) the average percent inhibition of all compounds tested between (1) and (2), and (4) three times their standard deviation. The sum of two of these values, (3) and (4), was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition/activity than the cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The activity score range for active compounds is 100-11, for inactive 11-0.

List of Reagents:

PLCG1 isozyme (Supplied by Assay Provider)
WH-15 fluorogenic reporter (Supplied by KXTBio)
HEPES (Fisher, BP310)
Sodium cholate hydrate (Sigma, C6445)
CaCl2 (Sigma, 06991)
EGTA (Fisher, O2783)
DTT (Fisher, BP172)
KCl (Sigma, P9541)
1536-well plates (Corning, part 7261)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 12.2 uM
4.43
4.43
4.43
4.43
4.43
4.43
4.43
4.43
4.43
4.43
4.43
4.43
4.43
4.43
4.43
4.42
4.42
4.42
4.42
4.42
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NTMT1-p-MTaseGlo
Protocol: Materials: NTMT1 enzyme, substrate SPKRIA, control peptide RCC1-6 is provided by the Huang laboratory.

MTaseGlo Assay:
PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION
1; Enzyme; 3 uL; Dispense enzyme mixture (final concentrations of 125 nM NTMT1 and 100 uM SAM) into Greiner 1536-well white / solid bottom assay plate (Greiner Bio One, Monroe, NC).
2; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array (Wako Automation, Richmond, VA)
3; Incubation; 15 min; Incubate at room temperature
4; Substrate; 1 uL; Dispense 1 uL of substrate at final concentration of 1 uM. Buffer solution was dispensed in control wells. The assay plate was covered with metal lids.
5; Incubation; 30 min; Incubate at room temperature, protected from lights.
6; Reagent; 1 uL; Dispensed 5x MTase-Glo detection reagent (R) into the assay plate. The plate was covered with metal lids.
7; Incubation; 30 min; Incubate the assay plates at room temperature in the dark to allow for SAH to be converted to ADP.
8; Reagent; 5 uL; Dispense 5 uL of 1x MTase-Glo Detection Solution (R) to allow for ADP to be converted to ATP which was then detected with a luciferase reaction.
9; Centrifuge; 15 sec; Centrifuge the assay plate for 15 seconds at 1000 RPM.
10; Incubation; 30 min; Assay plates were incubation at room temperature in the dark.
11; Detection; Luminescence; Plates were read on ViewLux detector (PerkinElmer). Data were normalized to no-enzyme (0% activity) and no-inhibitor (DMSO; 100%) controls, and the resulting percent inhibition data were fitted to a 4-parameter Hill equation using GraphPad Prism.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000420468 uMActivity at 0.0001060182 uMActivity at 0.0001893301 uMActivity at 0.0004489405 uMActivity at 0.0009664426 uMActivity at 0.00171 uMActivity at 0.00292 uMActivity at 0.00536 uMActivity at 0.00931 uMActivity at 0.020 uMActivity at 0.041 uMActivity at 0.085 uMActivity at 0.146 uMActivity at 0.251 uMActivity at 0.501 uMActivity at 1.073 uMActivity at 2.225 uMActivity at 4.221 uMActivity at 6.452 uMActivity at 12.64 uMActivity at 29.84 uMActivity at 57.50 uMActivity at 114.0 uMActivity at 227.6 uMActivity at 379.2 uMActivity at 573.0 uMCompound QC
Inactive0004-8.3336-1.4117-0.6141-1.80790.0446-8.3336QC'd by Sytravon
Inactive0-5.754.95490.364-29.48243.380540 0 0 0 1-1.39543.25350.7839-59.13736.0E-4-1.3954QC'd by Sytravon
Inactive0-6.753.1320.78430.870212.540 0 0 0 04.496310.2975-0.4426-1.35820.16264.4963QC'd by Sytravon
Inactive00042.0548-1.7066-2.8833-2.0050.36932.0548QC'd by Sytravon
Inactive0004-5.64220.4339-3.0268-4.4255-2.8516-5.6422QC'd by Sytravon
Inactive00040.2315-0.9193-0.962513.7196-1.97040.2315QC'd by Sytravon
Inactive0-5.054.95490.5023-0.05257.540 0 0 0 15.3132.711112.72021.5451-0.04385.313QC'd by Sytravon
Inactive00044.3883-3.3207-0.3808-0.1461-2.9714.3883QC'd by Sytravon
Inactive00045.7635-0.6995-1.72946.10241.83175.7635QC'd by Sytravon
Inactive0-4.31.06930.8616-4.25739.540 0 0 0 0-1.881111.14848.55025.98854.608-1.8811QC'd by Sytravon
Inactive0004-1.7273-3.4115-0.1881-2.6331-1.6916-1.7273QC'd by Sytravon
Inactive00044.3895-3.0627-1.10014.78020.86424.3895QC'd by Sytravon
Inactive0-54.95490.664910.50.702140 0 0 0 013.78374.4863-3.58167.22047.367813.7837QC'd by Sytravon
Inactive00046.01793.3436.89312.29364.52246.0179QC'd by Sytravon
Inactive000411.32073.08785.1642.55725.361511.3207QC'd by Sytravon
Inactive00048.73833.26642.73073.24051.84638.7383QC'd by Sytravon
Inactive0-4.052.72020.9497-18.9142-2.292240 0 0 0 0-14.0952-1.0768-4.0059-2.4795-5.6228-14.0952QC'd by Sytravon
Inactive0004-7.7765-2.2569-3.9959-1.34510.1566-7.7765QC'd by Sytravon
Inactive0-44.95490.7054-25.0658-0.540 0 0 0 0-17.5549-2.6051-3.8192-2.69936.0774-17.5549QC'd by Sytravon
Inactive0-5.84.95490.4109-5.3905440 0 0 0 0-2.49043.8042.4492-14.07540.8551-2.4904QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MDR001
Protocol: The HeLa derivative cell line, KB-3-1, and its colchicine-selected, P-gp-overexpressing subline, KB-8-5-11 were maintained in DMEM with 10% FCS and Pen/Strep with glutamine at 37 degree C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/mL. HEK-293 cells transfected with empty vector (pcDNA) or vector containing human ABCB1 (MDR-19) or ABCG2 (R-5) have been described previously (Robey, Lin, Qiu, Chan & Bates, 2011) and were maintained in EMEM supplemented with 10% FCS, Pen/Strep and glutamine with 2 mg/ml G418 to select for the expression of the transporter. Cultures were confirmed to be free of mycoplasma infection using the MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD). For the screen, assay medium was identical to culture medium except for KB-8-5-11 where colchicine was excluded from the medium.

All cell lines were plated into 1536-well plates at 500 cells/well in 5 uL media. Compounds were then pinned in dose-response using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37 degree C in 5% CO2 for an additional 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer). Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. Cherry-picked hits from screening analysis were tested with both the KB pair of cell lines, and the pcDNA (empty vector control) and MDR-19 (P-gp overexpressing) pair were tested, in the absence and presence of tariquidar.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073700 uMActivity at 0.0000311978 uMActivity at 0.0000755538 uMActivity at 0.0001700784 uMActivity at 0.0003537877 uMActivity at 0.0007609388 uMActivity at 0.00133 uMActivity at 0.00267 uMActivity at 0.00634 uMActivity at 0.00855 uMActivity at 0.017 uMActivity at 0.041 uMActivity at 0.071 uMActivity at 0.179 uMActivity at 0.354 uMActivity at 0.663 uMActivity at 1.576 uMActivity at 1.933 uMActivity at 5.110 uMActivity at 9.286 uMActivity at 17.35 uMActivity at 44.46 uMActivity at 93.38 uMActivity at 162.7 uMCompound QC
Inactive000406.942202.372800.458305.80229.8216000QC'd by BIOMOL
Inactive00040000.78791.0771004.091704.998300QC'd by BIOMOL
Inactive0-7.37924.95490.41460.86115.540 0 0 0 0 0 0 0 0 0 01.837309.11175.53448.2389002.305104.4881-0.94911.8373QC'd by BIOMOL
Inactive0-5.17922.72020.8215-20.66392.540 0 0 0 0 0 0 0 0 0 1-6.09160-2.79660.22858.08152.5833.73547.32021.7166-5.5554-18.8865-6.0916QC'd by BIOMOL
Inactive00043.74957.22936.37145.613507.482901.69948.4113003.7495QC'd by BIOMOL
Inactive00046.36577.19537.3079001.87945.979907.4799006.3657QC'd by BIOMOL
Inhibitor14.81835.514921Partial curve; partial efficacy-4.82923.06540.9214-31.01494.5-2.20 0 0 0 0 0 0 0 0 0 0-30.42915.77728.87813.66834.2274.72228.01864.5719-4.21873.6532-13.8256-30.4291QC'd by BIOMOL
Inactive000405.78175.8939008.5995006.074406.5850QC'd by BIOMOL
Inactive0004-2.104508.25230-2.17247.221607.3601-2.8223-6.14464.4899-2.1045QC'd by BIOMOL
Inactive0-4.42924.95490.4721-18.4451.540 0 0 0 0 0 0 0 0 0 0-13.287507.01614.53755.0482005.2422-2.8732-8.90186.1541-13.2875QC'd by BIOMOL
Inactive00049.43850000.93210.52520009.489409.4385QC'd by BIOMOL
Inactive0004-1.189406.558504.48600.538104.86393.46642.4738-1.1894QC'd by BIOMOL
Inactive0-6.07924.95490.40475.50.155340 0 0 0 0 0 0 0 0 0 101.4724.5108000-2.787208.386408.06150QC'd by BIOMOL
Inactive0004000.71730.66792.56178.0704009.810508.97310QC'd by BIOMOL
Inactive00041.1339-2.329408.3935009.78267.57146.4163001.1339QC'd by BIOMOL
Inactive0-9.02924.95490.38982-12.787140 0 0 0 0 0 0 0 0 0 1-4.0609-8.98923.4212-1.75787.17160.61375.21776.7693.1957-7.1191-0.2144-4.0609QC'd by BIOMOL
Inhibitor20.931101.63441Partial curve; high efficacy-4.67924.0950.99-99.56492.069-2.10 0 0 0 0 0 0 0 0 0 0-91.68045.251107.629403.87461.2696000-20.7764-91.6804QC'd by BIOMOL
Inactive000402.320402.28163.4121.25641.61620000.22870QC'd by BIOMOL
Inactive0-4.57924.50450.7778-24.88853.540 0 0 0 0 0 0 0 0 0 0-22.82385.74268.64626.02173.77214.16569.06293.0606-1.1003-6.03351.2279-22.8238QC'd by BIOMOL
Inhibitor33.1734109.831210Single point of activity-4.47924.95490.9783-109.32610.505-30 0 0 0 0 0 0 0 0 0 0-91.5629-0.0109-1.05751.09492.26989.4465-3.45940-7.435400-91.5629QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MDR002
Protocol: The HeLa derivative cell line, KB-3-1, and its colchicine-selected, P-gp-overexpressing subline, KB-8-5-11 were maintained in DMEM with 10% FCS and Pen/Strep with glutamine at 37 degree C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/mL. HEK-293 cells transfected with empty vector (pcDNA) or vector containing human ABCB1 (MDR-19) or ABCG2 (R-5) have been described previously (Robey, Lin, Qiu, Chan & Bates, 2011) and were maintained in EMEM supplemented with 10% FCS, Pen/Strep and glutamine with 2 mg/ml G418 to select for the expression of the transporter. Cultures were confirmed to be free of mycoplasma infection using the MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD). For the screen, assay medium was identical to culture medium except for KB-8-5-11 where colchicine was excluded from the medium.

All cell lines were plated into 1536-well plates at 500 cells/well in 5 uL media. Compounds were then pinned in dose-response using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37 degree C in 5% CO2 for an additional 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer). Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. Cherry-picked hits from screening analysis were tested with both the KB pair of cell lines, and the pcDNA (empty vector control) and MDR-19 (P-gp overexpressing) pair were tested, in the absence and presence of tariquidar.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073700 uMActivity at 0.0000311978 uMActivity at 0.0000755538 uMActivity at 0.0001700784 uMActivity at 0.0003537877 uMActivity at 0.0007609388 uMActivity at 0.00133 uMActivity at 0.00267 uMActivity at 0.00634 uMActivity at 0.00855 uMActivity at 0.017 uMActivity at 0.041 uMActivity at 0.071 uMActivity at 0.179 uMActivity at 0.354 uMActivity at 0.663 uMActivity at 1.576 uMActivity at 1.933 uMActivity at 5.110 uMActivity at 9.286 uMActivity at 17.35 uMActivity at 44.46 uMActivity at 93.38 uMActivity at 162.7 uMCompound QC
Inhibitor4.109535.955421Complete curve; partial efficacy-5.38621.47870.9847-33.45542.5-1.20 0 0 0 0 0 0-32.46282.18335.970600-5.6126-25.295-32.4628QC'd by Axon Medchem
Inhibitor14.58134.657110Partial curve; partial efficacy; poor fit-4.83622.33320.9403-32.15712.5-2.40 0 0 0 0 0 0-29.71430007.41155.8195-6.9018-29.7143QC'd by Tocris
Inactive0-4.83621.86170.9256-16.65942.540 0 0 0 0 0 0-14.71612.62120.581.02516.28291.7864-3.3449-14.7161QC'd by Glixx
Inhibitor1.63666.161564Complete curve; partial efficacy-5.78622.72020.9997-65.81160.3499-1.20 0 0 0 0 0 0-66.50140000-37.9408-64.7373-66.5014QC'd by Glixx
Inactive0-4.63621.96730.7584-23.667-2.467140 0 0 0 0 0 0-19.3058-0.694-0.3893-3.2758-10.1148-2.3842-5.3061-19.3058QC'd by SIGMA
Inactive0-4.78623.06541-20.0675040 0 0 0 0 0 0-19.222900000-2.9492-19.2229QC'd by Axon Medchem
Inhibitor10.322547.836221Partial curve; partial efficacy-4.98621.88510.9724-41.83626-2.20 0 0 0 0 0 0-38.7819.20936.095507.71415.1385-14.8631-38.781QC'd by MedChem Express
Inactive00046.01782.42486.41361.896906.213206.0178QC'd by Tocris
Inhibitor29.092960.09310Single point of activity-4.53624.95491-60.03460.0584-30 0 0 0 0 0 0-54.4164000000-54.4164QC'd by Tocris
Inactive0004-6.543200000-1.4393-6.5432QC'd by Tocris
Inhibitor16.360136.851110Partial curve; partial efficacy; poor fit-4.78621.010.8986-32.35114.5-2.40 0 0 0 0 0 0-23.62598.789708.696100-7.2303-23.6259QC'd by Tocris
Inactive00049.2406001.75143.496707.9269.2406QC'd by Glixx
Inhibitor9.233.715210Partial curve; partial efficacy; poor fit-5.03621.41630.9706-30.21523.5-2.40 0 0 0 0 0 0-27.26265.31472.675106.30420-12.9935-27.2626QC'd by Tocris
Inhibitor16.360152.695221Partial curve; partial efficacy-4.78621.28760.9602-49.04213.653-2.20 0 0 0 0 0 0-37.79029.1493005.18520-13.7877-37.7902QC'd by Tocris
Inactive0-4.78624.44950.9565-27.1196340 1 0 0 0 0 0-26.76640-80.85495.97525.378600.9575-26.7664QC'd by Tocris
Inhibitor0.580574.818526Complete curve; partial efficacy-6.23623.67720.9839-72.75452.064-1.20 0 0 0 0 0 0-64.73751.50932.14072.7381-9.5317-70.5587-81.6221-64.7375QC'd by MedChem Express
Inhibitor18.356499.324110Single point of activity-4.73623.62720.9917-97.78141.5427-30 0 0 0 0 0 0-94.201708.64420-1.04460-6.3447-94.2017QC'd by Tocris
Inhibitor29.092985.830210Single point of activity-4.53624.95490.9979-84.3311.4991-30 0 0 0 0 0 0-76.60620.5645002.14332.14953.4024-76.6062QC'd by MedChem Express
Inhibitor12.995349.172121Partial curve; partial efficacy-4.88622.25260.9678-45.67253.4996-2.20 0 0 0 0 0 0-42.17617.83150.28501.26966.3138-12.2728-42.1761QC'd by Tocris
Inactive0-4.68621.88510.8683-38.0965-12.016740 0 0 0 0 0 0-33.4065-7.5139-13.5025-14.684-16.035-8.8732-16.7676-33.4065QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Broad Institute 靶标:N/A
External ID: 7056-01_Inhibitor_SinglePoint_HTS_Activity
Protocol: Bac rRNA Automation Protocol
Day 1:
1. Grow each E. coli strain (one wild type (GFP) and six humanized mutants (RFP) including the control G2058) individually. Pick each strain into a separate 50 mL conical tube with 10 mL of LB medium supplemented with 100 ug/mL amplicillin and 50 ug/mL spectinomycin.
2. Incubate strains overnight at 37 degrees with shaking at 190 RPM.
Day 2:
1. In the morning, check OD600 of the cultures.
2. Dilute the cultures to OD 600 = 0.05 in LB medium supplanted with 100 ug/mL ampicillin.
3. Return strains to 37 degrees with shaking at 190 RPM for about 3. 5 hours. Grow strains to reach OD 600 about 0.5 (exponential growth phase).
4. Mix strains (final OD600= 0.02) in the proportion 50% wild-type, 8.33% each of the six mutants in LB medium supplemented with 100 ug/mL ampicillin and 1 mM IPTG (which is used to induce expression of fluorescent proteins).
5. Dispense 30 uL/well of bacteria mixture to 384 well Assay Ready Plates (ARPs) containing positive controls (Erythromycin 15 mg/mL, 50 nL in column 1 and Choramphenicol 15 mg/mL, 50 nL in column 23).
6. Place breathable film on plate using Plate Loc.
7. Incubate plates in Steristore at 37 degrees, 0% CO2 for 24 hours, 95% humidity.
Day 3:
1. Remove assay plate from Steristore.
2. Remove breathable film with X-Peel.
3. Read GFP signal using EnVision plate reader (mirror: FITC #403, Ex: FITC 485 #102, Em: FITC 535 #206).
4. Read RFP signal using EnVision plate reader (mirror: BODIPY TMR #405, Ex: photometric 550 #312, Em: Cy3 595 #229).
5. Read OD600 signal using EnVision plate reader (Ex: Photometric 600 #319).
6. Store plate in Steristore incubator.
Equipment Required
Combi
Plate Loc
Steristore (37 C, 95% humiodity, 0% CO2,)
X-Peel
2 EnVisions
Comment: PRESENCE OF CONTROLS: Neutral control wells (NC) and positive control
wells (PC) were included on every plate. One positive control,
Chloramphenicol, was used to determine the baseline fluorescence and OD
as it was expected to non-selectively kill all 6 strains, GFP wild-type
and RFP mutant. The other positive control, Erythromycin, was expected
to selectively spare one RFP control strain (G2058) and was therefore
used as a guideline for calculating the performance of a selective GFP
inhibitor.

NORMALIZATION:
Each of three layers was independently normalized using the 'Neutral
Controls' method in Genedata Assay Analyzer (v7.0.3):
The median raw signal of the intraplate neutral control wells was set to
a normalized activity value of 0.
The a raw signal of 0 was set to a normalized activity value of -100.
Experimental wells values were scaled to this range.

PATTERN CORRECTION: The plate pattern correction algorithm 'Assay
Pattern (multiplicative)' in Genedata (v7.0.3) was applied to the
normalized plate data for each layer.

AGGREGATE COMPOUND LAYER SCORING: In addition to the reported normalized
percent activities above, each replicate compound measurement was
converted to a z-score relative to the corresponding DMSO-control
distribution, as described for ChemBank (Seiler et al., 2008). ChemBank
composite Z scores were computed to combine replicates for each channel
(RFP, GFP, and OD). We sought compounds that affected the GFP-expressing
wild-type strain while not affecting at least one of the mutant RFP
strains and not affecting overall viability as measured by OD; i.e.,
they score with negative composite Z in the GFP channel with little or
no effect in the RFP or OD channels. To combine the results of the three
channels quantitatively, we defined a trigonometric scaling function to
express our preferences that (1) GFP composite Z scores be negative, and
(2) RFP and OD composite Z score amplitudes exceed GFP composite Z score
amplitudes; such compounds should fall left of the DMSO-control
distribution, but above the main diagonal in a plot of GFP composite Z
versus either OD or RFP composite Z. Using the two ratios of ChemBank
composite Z scores (GFP/RFP and GFP/OD), we defined q1 = arctan(GFP/RFP)
and q2 = arctan(GFP/OD) and expressed our scale factor as F =
cos(-q1)cos(2q1)cos(-q2)cos(2q2), with the four factors respectively
expressing our preferences. As a three-assay composite score, we take
-(ZGFP) x F, which clearly discriminates the compounds of interest when
plotted against RFP or OD.

PUBCHEM_ACTIVITY_SCORE: The above three-assay composite score was
normalized on a scale of 1-100, with 1 being those with the least
desirable observed score representing compounds increasing in GFP signal
and decreasing in RFP or OD, and 100 being the most ideal observed score
representing a loss in GFP with no change in RFP or OD.

PUBCHEM_ACTIVITY_OUTCOME: The above three-assay composite scores were
fit to a standard distribution and a corresponding Holm-Bonferroni
corrected p value significance was calculated. Compounds with a FDR
corrected p value less than 0.05, normalized OD percent score > -30,
negative GFP composite Z score, and the expression Abs(Cos(-q)Cos(2q)) >
(sqrt2)/2 for both q1 and q2 were assigned a score of 2 (active).
Compounds failing any of these criteria were assigned a score of 1
(inactive.)
R_RepAG_RepAOD_RepARz_RepAGz_RepAODz_RepAR_RepBG_RepBOD_RepBRz_RepBGz_RepBODz_RepBRczGczODczpval
0.797-18-19.40.20651914-3.850383751-2.7038922-16.1-11.55.704232366-3.446093458-1.6013736134.1795-5.1594-3.04431.42E-11
0.49328.26.50.1277229486.0258505710.9082834639.6124.613.72.4924902615.2621911271.910189991.85287.98191.9931.43E-11
0.82524.32.320.2140124275.2001571670.323907856-3.723.613.5-0.9603853045.0375854081.885037525-0.52787.23921.5621.43E-11
3.9928.518.81.0345403256.0857454292.6242405272.3226.922.30.6023150815.74776733.1147135971.15748.36764.05811.44E-11
4.49-26.8-321.165219102-5.739210892-4.4743440733.34-20.2-22.10.866784036-4.327403516-3.0881637731.4368-7.1182-5.34751.45E-11
-9.66-18-37.5-2.503898725-3.846105547-5.2400969-7.74-17.8-47.9-2.006334093-3.803323506-6.696145159-3.1892-5.409-8.44021.46E-11
-3.57-19.4-39.3-0.92538206-4.139162533-5.497210988-1.85-19.6-43.5-0.479674085-4.186222779-6.077115045-0.9935-5.8869-8.18431.49E-11
7.341.842.81.9033986270.3938086940.39154004-15.8-54.5-74.4-4.107047303-11.65382815-10.39774961-1.5582-7.962-7.07551.50E-11
-3.2523.322.6-0.842670694.9862469583.162223809-12.616.319-3.2669694463.4845972952.654982429-2.9065.98984.11341.51E-11
16.3-0.1815.44.236688948-0.03852.15053576822-3.945.95.712010864-0.841736670.8238829697.0348-0.62242.10321.51E-11
32.93.39-3.018.5252345540.725155607-0.4208845838.16-0.892-2.182.115233075-0.190743733-0.303925627.52390.3779-0.51251.53E-11
-10.6-22.3-6.7-2.743217201-4.774475852-0.93678959-13.9-29.2-15.4-3.606630555-6.246178086-2.153330486-4.49-7.7928-2.1851.54E-11
-0.51220.3-16.7-0.1326752594.340238129-2.3335898194.9723.412.51.2876008155.0076379791.7439042480.81676.6099-0.4171.54E-11
-2.86-28.6-27.1-0.740772358-6.111414654-3.782651282-5.34-28-23-1.384313482-5.980929427-3.206939303-1.5027-8.5506-4.94241.54E-11
1.5620.7-12.60.4031855154.43435862-1.7606725584.3230.228.91.1203630936.4536709884.0327785741.07737.6991.60661.55E-11
-1.229.85.14-0.3106213816.3745242110.7188015590.10119.212.50.02614.1027977971.742506889-0.20127.40861.74041.55E-11
-6.47-29.3-8.74-1.677562882-6.256873596-1.221850861-7.99-28.4-39.8-2.071154915-6.075049919-5.565681587-2.6507-8.72-4.79951.57E-11
-11.813.1-3.48-3.0569499812.800084628-0.486001526.1933.118.31.6057414117.0847061032.55157785-1.02626.98961.46061.59E-11
-5.62-23.8-42.6-1.456134953-5.084645654-5.955544797-4.37-18.4-40.8-1.132808691-3.940226039-5.704020145-1.8307-6.3815-8.24461.60E-11
-2.1417.9-2.05-0.5540883893.835410037-0.286179159-4.7919.6-8.8-1.2417076734.184083677-1.229815808-1.26985.6706-1.0721.62E-11
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:67.9K protein [Vaccinia virus]
External ID: Vaccinia-p2mCherry
Protocol: A549 cells were plated at a concentration of approximately 6,000 cells per well in clear-bottom black-walled plates. Compounds were added to the assay plate followed by addition of virus (LREV) that expresses the Venus fluorescent protein early in viral ininfection. During the late viral infection, mCherry was also added to the plate at an MOI of 10 (~ 60,000 plaque forming units (PFU) of virus). Following virus addition, plates were incubated in a tissue-culture incubator for 12-18 hours. At increasing times postinfection, fluorescence from both Venus and mCherrry was determined using a plate-reader and standard conditions for observing Venus fluorescence (EX515/EM530) and mCherry fluorescence (EX587/EM610). In each plate, positive controls (virus infection in the presence of 1% DMSO only) and an inhibitory drug control (AraC at 500 nM) was included and used to normalize the data.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00111 uMActivity at 0.00284 uMActivity at 0.00446 uMActivity at 0.00891 uMActivity at 0.015 uMActivity at 0.029 uMActivity at 0.036 uMActivity at 0.073 uMActivity at 0.113 uMActivity at 0.149 uMActivity at 0.293 uMActivity at 0.487 uMActivity at 0.726 uMActivity at 1.458 uMActivity at 2.011 uMActivity at 3.331 uMActivity at 5.199 uMActivity at 7.343 uMActivity at 13.78 uMActivity at 20.90 uMActivity at 36.53 uMActivity at 60.71 uMActivity at 87.88 uMActivity at 127.3 uMActivity at 194.0 uMCompound QC
Inactive01.39870.9996-13.0836-0.585340 0 0 1-0.8016-2.9877-9.467-12.5697-0.8016QC'd by "Asinex Ltd."
Inhibitor12.589340.511110Single point of activity-4.94.50450.9991-45.3562-4.8451-30 0 0 0-45.0493-5.3378-3.9936-8.2693-45.0493QC'd by "Asinex Ltd."
Inactive040-2.0352000QC'd by "Asinex Ltd."
Inactive04000-0.99410QC'd by "Asinex Ltd."
Inactive04.954910-13.633540 0 0 00-12.1946000QC'd by "Asinex Ltd."
Inactive0400000QC'd by "Asinex Ltd."
Inactive04-13.3369-12.1444-5.0835-13.8274-13.3369QC'd by "Asinex Ltd."
Inactive040-4.5112-3.956800QC'd by "Asinex Ltd."
Inactive0400000QC'd by "Asinex Ltd."
Inactive01.80790.9998-19.4131.540 0 0 1-2.29920-11.3763-18.6775-2.2992QC'd by "Asinex Ltd."
Inactive04.95490.77214-15.639840 0 0 00-10.469-15.9421-20.94990QC'd by "Asinex Ltd."
Inactive04.95490.9987-20.1455-0.540 0 0 0-19.28790-0.8113-0.6866-19.2879QC'd by "Asinex Ltd."
Inactive04.95490.9999-7.3207040 0 0 0-6.934000-6.934QC'd by "Asinex Ltd."
Inactive04-10.13410-23.8022-3.1543-10.1341QC'd by "Asinex Ltd."
Inactive01.82650.9999-31.5926140 0 0 1-8.44790-12.323-29.2439-8.4479QC'd by "Asinex Ltd."
Inactive00.70.95422-18.098140 0 0 00-15.9151-9.0083-6.24390QC'd by "Asinex Ltd."
Inactive04.95490.79940.5884-8.240 0 0 0-1.1763-9.1365-5.7126-9.75-1.1763QC'd by "Asinex Ltd."
Inactive00.60.9653-16.23140.75640 0 0 0-14.3595-3.5367-8.6422-10.5182-14.3595QC'd by "Asinex Ltd."
Inactive04-3.3063-1.5829-0.45720-3.3063QC'd by "Asinex Ltd."
Inactive04.95490.7973-6.6878-1.540 0 0 10-2.54350-5.57310QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:RecName: Full=Rap guanine nucleotide exchange factor 3; AltName: Full=Exchange factor directly activated by cAMP 1; AltName: Full=Exchange protein directly activated by cAMP 1; Short=EPAC 1; AltName: Full=Rap1 guanine-nucleotide-exchange factor directly activated by cAMP; AltName: Full=cAMP-regulated guanine nucleotide exchange factor I; Short=cAMP-GEFI
External ID: EPAC1-agonist-p1
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00130 uMActivity at 0.00261 uMActivity at 0.00391 uMActivity at 0.00782 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.035 uMActivity at 0.070 uMActivity at 0.106 uMActivity at 0.211 uMActivity at 0.317 uMActivity at 0.633 uMActivity at 0.950 uMActivity at 1.720 uMActivity at 3.040 uMActivity at 5.698 uMActivity at 8.547 uMActivity at 15.63 uMActivity at 25.64 uMActivity at 51.28 uMActivity at 76.90 uMActivity at 153.8 uMActivity at 154.0 uMCompound QC
Inactive04.95490.8886-12.20651.540 0 0 0-9.33880.17090.81343.1053-9.3388QC'd by "Key Organics Ltd."
Inactive04.44950.99461940 0 0 01.30188.99088.95780.71981.3018QC'd by "DPISMR"
Inactive04.95490.661219240 0 0 016.39737.63723.8451016.3973QC'd by "Key Organics Ltd."
Inactive00.60.954618-240 0 0 013.90711.78046.93869.739313.9071QC'd by "DPISMR"
Inactive04.95490.8159-2.83374.540 0 0 0-0.69476.00333.00433.9613-0.6947QC'd by "DPISMR"
Inactive04.95490.88871-15.061240 0 0 0-2.3986-15.051-0.01394.4512-2.3986QC'd by "DPISMR"
Inactive02.09370.99947-0.920440 0 0 1-0.3283-0.7670.30915.6555-0.3283QC'd by "DPISMR"
Inactive04.95490.9917113.540 0 0 12.81833.82893.25269.00052.8183QC'd by "DPISMR"
Inactive04.50450.98715.5840 0 0 014.54397.86288.57199.602214.5439QC'd by "DPISMR"
Inactive04.95490.4155-0.5-9.143440 0 0 1-4.6031-6.36953.3511-4.639-4.6031QC'd by "DPISMR"
Inactive04.50450.999-0.7475-8.249540 0 0 1-5.4106-6.4579-0.6229-0.8099-5.4106QC'd by "InterBioScreen"
Inactive041.593-1.49392.1662.2221.593QC'd by "InterBioScreen"
Inactive04.95490.6286110.058640 0 0 08.60613.9411-0.2733-2.45128.6061QC'd by "InterBioScreen"
Inactive01.62590.991615440 0 0 013.30013.67535.21910.002313.3001QC'd by "InterBioScreen"
Inactive04.50450.9816-6.5515440 0 0 0-5.04293.34484.76451.5692-5.0429QC'd by "DPISMR"
Inactive046.45952.87153.56864.16176.4595QC'd by "DPISMR"
Inactive03.67720.999512.5-2.175740 0 0 09.9965-2.2298-2.03362.05799.9965QC'd by "DPISMR"
Inactive04.50450.9996-0.8312740 0 0 13.51266.87466.6766-0.69273.5126QC'd by "DPISMR"
Inactive01.86170.9999-6.2131240 0 0 1-1.39661.7089-1.1576-5.5943-1.3966QC'd by "DPISMR"
Inactive04-5.9044-3.6854-6.4554-5.89-5.9044QC'd by "DPISMR"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:Phospholipase C, beta 3 (phosphatidylinositol-specific) [Homo sapiens]
External ID: PLCB3_INH_QFRET_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this biochemical assay is to identify compounds that act as inhibitors of the activity of phospholipase C isozymes, PLC-B3. In this assay, PLC-B3 isozyme is incubated with test compounds and fluorogenic reporter WH-15. As designed, test compounds that act as PLC-B3 inhibitors will prevent the hydrolysis of WH-15 fluorogenic reporter, thus preventing the release of IP3, a quinomethide derivative, and 6-aminoquinoline, which is highly fluorescent, leading to decreasing well fluorescence. Compounds are tested in singlicate at a nominal test concentration of 12.2 micromolar.

Protocol Summary:

Prior to the start of the assay, 2 microliters of PLC-B3 at a final concentration of 0.4ng/ul (in 50 mM HEPES pH 7.2, 70 mM KCl, 3mM CaCL2, 3mM EGTA, 2mM DTT, 0.04mg/mL acid-free BSA, with Cholate 0.5%) are dispensed into 1536 microtiter plates, 1 microliter of assay buffer is dispensed into columns 4-48 and 1 microliter of 0.2M EGTA is added to columns 1-3. Compounds are added to plate (final concentration 12.2uM) and incubated for 10 minutes at 25 degrees Celsius. The assay start by the addition of 2 microliter of WH-15 fluorogenic reporter at a final concentration 10uM in Assay Buffer to all wells. Plates were centrifuged and after 90 min of incubation at 25 degrees Celsius fluorescence is measured at 355nm excitation and 535nm emmision.

The percent inhibition for each compound was calculated as follows:

100 *( ( Test_Compound - Median_Low_Control) / ( Median_High_Control - Median_Low_Control) )

Where:

Test_Compound is defined as wells containing PLCB3 in the presence of test compound and WH15 fluoreogenic reporter.
High_Control is defined as wells containing PLCB3, WH15 fluoreogenic reporter and EGTA.
Low_Control is defined as the median of the wells containing test compounds.

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Four values were calculated: (1) the average percent inhibition of all high controls tested plus three times the standard deviation of the high controls, (2) the average percent inhibition of all low controls tested minus three times the standard deviation of the low controls, (3) the average percent inhibition of all compounds tested between (1) and (2), and (4) three times their standard deviation. The sum of two of these values, (3) and (4), was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition/activity than the cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The activity score range for active compounds is 100-13, for inactive 13-0.

List of Reagents:

PLCB3 isozyme (Supplied by Assay Provider)
WH-15 fluorogenic reporter (Supplied by KXTBio)
HEPES (Fisher, BP310)
Sodium cholate hydrate (Sigma, C6445)
CaCl2 (Sigma, 06991)
EGTA (Fisher, O2783)
DTT (Fisher, BP172)
KCl (Sigma, P9541)
1536-well plates (Corning, part 7261)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 12.2 uM
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
2.58
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:ADAM10 [Homo sapiens]
External ID: ADAM10_INH_QFRET_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that inhibit ADAM10. This assay employs a fluorophore and quencher pair. F =EDANS fluorophore, Q = DABCYL quencher. When intact, EDANS emission at 460nm is quenched by DABCYL via fluorescence resonance energy transfer. Upon cleavage of the scissile bond (A~V) by ADAM protease, the distance between fluorophore and quencher increases resulting in fluorescence increase at 460nm. Compounds are tested in singlicate at a nominal final nominal concentration of 6.95 micromolar.

Protocol Summary:

Prior to the start of the assay, 2.5 microliters 2X ADAM10 enzyme (20 nM in Assay Buffer: 50 mM HEPES, 0.01% Brij, pH 7.5) are dispensed into 1536 microtiter plates. Compounds are added to plate (final concentration TBD) and incubated for 30 minutes at 25 degrees Celsius. The assay is started by dispensing 2.5 microliter of2X DM2 substrate (20 uM in Assay Buffer) to all wells. Plates are centrifuged and after 3 hours of incubation at 25 degrees Celsius, fluorescence is measured (excitation = 359nm, emission = 460nm).

The % inhibition for each well was then calculated as follows:

%_Inhibition = ( RFU_Test_Compound - MedianRFU_Low_Control ) / ( MedianRFU_High_Control - MedianRFU_Low_Control ) * 100

Where:

Test_Compound is defined as wells containing test compound.
High_Control is defined as wells treated with 1 micromolar Marimastat
Low_Control is defined as wells containing DMSO.

Interval Cutoff:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Four values were calculated: (1) the average percent inhibition of all high controls tested plus three times the standard deviation of the high controls, (2) the average percent inhibition of all low controls tested minus three times the standard deviation of the low controls, (3) the average percent inhibition of all compounds tested between (1) and (2), and (4) three times their standard deviation. The sum of two of these values, (3) and (4), was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition/activity than the cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The activity score range for active compounds is 100-19, for inactive 19-0.

List of Reagents:

ADAM10 enzyme (R&D Systems, part # 936-AD)
EDANS-DABCYL DM2 peptide substrate (Supplied by Assay Provider)
0.5M HEPES solution, pH7.5 (Teknova, part #101319-900)
Brij-35 (Sigma-Aldrich, part # P1254)
1536 well plate (Corning, part # 7261)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. In this case the results of each separate campaign were assigned "Active/Inactive" status based upon that campaign's specific compound activity cutoff value. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 7.0 uM
20.14
20.12
20.11
20.1
20.09
20.09
20.05
20.03
19.99
19.97
19.96
19.95
19.95
19.92
19.91
19.91
19.88
19.87
19.85
19.84
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:RecName: Full=Rap guanine nucleotide exchange factor 4; AltName: Full=Exchange factor directly activated by cAMP 2; AltName: Full=Exchange protein directly activated by cAMP 2; Short=EPAC 2; AltName: Full=cAMP-regulated guanine nucleotide exchange factor II; Short=cAMP-GEFII
External ID: EPAC2-agonist-p1
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00130 uMActivity at 0.00261 uMActivity at 0.00392 uMActivity at 0.00782 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.035 uMActivity at 0.070 uMActivity at 0.106 uMActivity at 0.211 uMActivity at 0.317 uMActivity at 0.633 uMActivity at 0.950 uMActivity at 1.729 uMActivity at 3.041 uMActivity at 5.698 uMActivity at 8.547 uMActivity at 15.64 uMActivity at 25.64 uMActivity at 51.28 uMActivity at 76.90 uMActivity at 153.8 uMActivity at 154.0 uMCompound QC
Inactive0410.46087.01089.882411.595410.4608QC'd by "Evotec San Francisco"
Inactive04.50450.9524-9.9879840 0 0 0-6.656610.12716.26495.2249-6.6566QC'd by "Evotec San Francisco"
Inactive044.722310.03612.59097.8644.7223QC'd by "Evotec San Francisco"
Inactive04.95490.38031.5-1.286940 0 0 00.83241.0824-3.57241.70550.8324QC'd by "Evotec San Francisco"
Inactive04.95490.3571-6.4443-0.540 0 0 1-1.9614-4.06123.1043-4.9536-1.9614QC'd by "Evotec San Francisco"
Inactive04.95490.46653-4.296640 0 0 05.2342-2.74724.515-1.445.2342QC'd by "Evotec San Francisco"
Inactive02.58840.9303-11140 0 0 02.663712.26479.55827.80592.6637QC'd by "Asinex Ltd."
Inactive04.95490.8697010.540 0 0 02.03178.707211.290511.46862.0317QC'd by "Life Chemicals"
Inactive04.95490.7766-26.540 0 0 16.14354.61988.6590.18516.1435QC'd by "Enamine"
Inactive04.95490.8-0.5640 0 0 01.11867.46084.49025.521.1186QC'd by "Evotec San Francisco"
Inactive04.95490.9854-11.2591.540 0 0 0-8.54921.44571.68761.2165-8.5492QC'd by "Asinex Ltd."
Inactive044.29823.23160.34932.09954.2982QC'd by "Evotec San Francisco"
Inactive049.83148.4417-0.68257.6649.8314QC'd by "Evotec San Francisco"
Inactive046.10068.7077.99436.10346.1006QC'd by "Evotec San Francisco"
Inactive047.45910.3601-0.40669.01617.459QC'd by "Asinex Ltd."
Inactive03.1320.988413.55.540 0 0 011.87225.60614.94697.845711.8722QC'd by "Evotec San Francisco"
Inactive043.00731.20530.663-0.22553.0073QC'd by "Evotec San Francisco"
Inactive04.95490.7345-10.68792.540 0 0 0-8.07333.9779-1.48584.3192-8.0733QC'd by "Evotec San Francisco"
Inactive04.95490.99637.513.540 0 0 113.045713.23513.47828.148213.0457QC'd by "Evotec San Francisco"
Inactive03.92950.9988814.540 0 0 08.146514.638614.37438.26318.1465QC'd by "Evotec San Francisco"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:RecName: Full=Rap guanine nucleotide exchange factor 4; AltName: Full=Exchange factor directly activated by cAMP 2; AltName: Full=Exchange protein directly activated by cAMP 2; Short=EPAC 2; AltName: Full=cAMP-regulated guanine nucleotide exchange factor II; Short=cAMP-GEFII
External ID: EPAC2-antagonist-p1
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009677143 uMActivity at 0.00194 uMActivity at 0.00291 uMActivity at 0.00581 uMActivity at 0.00871 uMActivity at 0.017 uMActivity at 0.026 uMActivity at 0.052 uMActivity at 0.078 uMActivity at 0.157 uMActivity at 0.235 uMActivity at 0.470 uMActivity at 0.705 uMActivity at 1.284 uMActivity at 2.260 uMActivity at 4.233 uMActivity at 6.349 uMActivity at 11.58 uMActivity at 19.05 uMActivity at 38.10 uMActivity at 57.11 uMActivity at 114.0 uMActivity at 114.3 uMCompound QC
Inactive04.95490.7048-8.7522-0.540 0 0 0-6.04351.4635-2.8274-0.4375-6.0435QC'd by "Asinex Ltd."
Inactive03.06540.9989-6.4516840 0 0 0-5.7937.7628.0053-2.8812-5.793QC'd by "Asinex Ltd."
Inactive041.016-3.92610.2472-1.70041.016QC'd by "Asinex Ltd."
Inactive04.95490.5913-9.0878-140 0 0 10.0518-4.02521.9451-7.15650.0518QC'd by "Asinex Ltd."
Inactive04-0.6802-0.9131-3.5111-1.817-0.6802QC'd by "Asinex Ltd."
Inactive04-2.8241-1.2916-5.7377-2.6734-2.8241QC'd by "Asinex Ltd."
Inactive04-0.279-1.1632-1.8636-3.7981-0.279QC'd by "Asinex Ltd."
Inactive045.09824.17992.81583.77495.0982QC'd by "Asinex Ltd."
Inactive04.44950.7563-2.1926-9.270140 0 0 0-3.8115-6.4751-1.1615-0.9938-3.8115QC'd by "Asinex Ltd."
Inactive04-0.4451-4.4456-3.9827-3.3669-0.4451QC'd by "Asinex Ltd."
Inactive04.95490.8792132340 0 0 011.827520.422312.792415.013311.8275QC'd by "DPISMR"
Inactive01.0310.9968-2.3165940 0 0 0-1.93046.34641.7861-0.9296-1.9304QC'd by "DPISMR"
Inactive03.06540.9459-4.5957440 0 0 0-3.25013.9276-0.5201-5.4964-3.2501QC'd by "DPISMR"
Inactive04.95490.8912310.540 0 0 017.684511.476311.22759.361417.6845QC'd by "DPISMR"
Inactive046.90916.15046.82164.78296.9091QC'd by "DPISMR"
Inactive04.95490.4105-4.0565240 0 0 0-2.18240.391-7.9638-2.0627-2.1824QC'd by "DPISMR"
Inactive03.92950.8357114.540 0 0 010.61246.44723.007310.084410.6124QC'd by "DPISMR"
Inactive01.46410.7074-1.3623840 0 0 0-3.63535.0536-0.21161.2591-3.6353QC'd by "Asinex Ltd."
Inactive0414.665715.451216.053313.535414.6657QC'd by "Asinex Ltd."
Inactive04.95490.9571-12.8142340 0 0 0-11.34271.11344.3515-14.0118-11.3427QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:67.9K protein [Vaccinia virus]
External ID: Vaccinia-p2Venus
Protocol: A549 cells were plated at a concentration of approximately 6,000 cells per well in clear-bottom black-walled plates. Compounds were added to the assay plate followed by addition of virus (LREV) that expresses the Venus fluorescent protein early in viral infection. During the late viral infection, mCherry was also added to the plate at an MOI of 10 (~ 60,000 plaque forming units (PFU) of virus). Following virus addition, plates were incubated in a tissue-culture incubator for 12-18 hours. At increasing times post-infection, fluorescence from both Venus and mCherrry was determined using a plate-reader and standard conditions for observing Venus fluorescence (EX515/EM530) and mCherry fluorescence (EX587/EM610). In each plate, positive controls (virus infection in the presence of 1% DMSO only) and an inhibitory drug control (AraC at 500 nM) was included and used to normalize the data.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00111 uMActivity at 0.00284 uMActivity at 0.00446 uMActivity at 0.00891 uMActivity at 0.015 uMActivity at 0.029 uMActivity at 0.036 uMActivity at 0.073 uMActivity at 0.113 uMActivity at 0.149 uMActivity at 0.293 uMActivity at 0.487 uMActivity at 0.726 uMActivity at 1.458 uMActivity at 2.011 uMActivity at 3.331 uMActivity at 5.199 uMActivity at 7.343 uMActivity at 13.78 uMActivity at 20.90 uMActivity at 36.52 uMActivity at 60.71 uMActivity at 87.88 uMActivity at 127.3 uMActivity at 194.0 uMCompound QC
Inactive01.46410.71-12.454-240 0 0 0-11.2117-5.20930.6206-7.2594-11.2117QC'd by "Chem Div"
Inactive04-11.3429-16.0267-12.2608-14.6132-11.3429QC'd by "Chem Div"
Inactive01.62590.9272-14.3148-0.87740 0 0 0-15.2623-7.8142-13.6096-13.0621-15.2623QC'd by "Chem Div"
Inactive04-12.3142-9.814-12.586-8.4662-12.3142QC'd by "Chem Div"
Inactive04-8.2677-9.1999-12.2836-11.2753-8.2677QC'd by "Chem Div"
Inactive04.50450.9238-23.3577-9.005740 0 0 0-23.2147-6.6714-11.5717-9.7492-23.2147QC'd by "Chem Div"
Inhibitor11.220218.895721Partial curve; partial efficacy-4.953.51170.9065-31.7758-12.8801-2.20 0 0 0-31.4798-16.0985-9.0667-16.5103-31.4798QC'd by "Chem Div"
Inactive04.95490.8003-13.5254-8.878340 0 0 0-13.3545-10.4528-7.3986-12.9731-13.3545QC'd by "Chem Div"
Inactive02.33320.9015-5.5393840 0 0 0-5.44945.481810.30710-5.4494QC'd by "Chem Div"
Inactive01.96730.9741-21.6735-12.493740 0 0 0-21.3946-13.4008-12.078-16.6303-21.3946QC'd by "Chem Div"
Inactive04-5.6419-17.3934-2.7552-14.5706-5.6419QC'd by "Chem Div"
Inactive04.95490.8944-16.0102-8.684840 0 0 0-15.0085-7.2373-9.9603-8.6791-15.0085QC'd by "Chem Div"
Inactive01.55790.9997-19.5854-2.051340 0 0 1-5.8527-2.9594-9.4187-17.9878-5.8527QC'd by "Chem Div"
Inactive00.90.997418-20.238340 0 0 012.7737-17.6986-10.21151.105512.7737QC'd by "Chem Div"
Inactive01.88510.9998-14.291-6.778340 0 0 1-6.726-6.8986-8.4505-13.1591-6.726QC'd by "Chem Div"
Inactive00.90.9901-24.8053-6.556940 0 0 0-19.0044-6.7141-9.2211-12.2131-19.0044QC'd by "Chem Div"
Inhibitor1025.752521Partial curve; partial efficacy-54.95490.9958-34.5683-8.8157-2.20 0 0 0-34.709-9.7184-7.7631-13.3604-34.709QC'd by "Chem Div"
Inactive00.50.7446-13.2445-2.110940 0 0 0-9.3704-2.5924-6.2168-4.8236-9.3704QC'd by "Chem Div"
Inactive04.95490.8017-7.4285-18.016840 0 0 0-7.4434-13.764-5.7738-9.5578-7.4434QC'd by "Chem Div"
Activator31.6228490Partial curve; high efficacy-4.50.80.9998651142.10 0 0 1118.3965112.9568110.0983102.4909118.3965QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:RecName: Full=Rap guanine nucleotide exchange factor 3; AltName: Full=Exchange factor directly activated by cAMP 1; AltName: Full=Exchange protein directly activated by cAMP 1; Short=EPAC 1; AltName: Full=Rap1 guanine-nucleotide-exchange factor directly activated by cAMP; AltName: Full=cAMP-regulated guanine nucleotide exchange factor I; Short=cAMP-GEFI
External ID: EPAC1-antagonist-p1
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009732759 uMActivity at 0.00195 uMActivity at 0.00292 uMActivity at 0.00584 uMActivity at 0.00876 uMActivity at 0.018 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.158 uMActivity at 0.237 uMActivity at 0.473 uMActivity at 0.710 uMActivity at 1.285 uMActivity at 2.271 uMActivity at 4.257 uMActivity at 6.386 uMActivity at 11.67 uMActivity at 19.16 uMActivity at 38.31 uMActivity at 57.50 uMActivity at 114.9 uMActivity at 115.0 uMCompound QC
Inactive04.95490.6357-13.3671340 0 0 0-9.4726-0.7791.69888.5143-9.4726QC'd by "DPISMR"
Inactive02.12110.9998-8.2164440 0 0 13.17623.7215-0.7009-7.68033.1762QC'd by "DPISMR"
Inactive03.1321-13.7219440 0 0 13.60913.89811.3033-13.10163.6091QC'd by "DPISMR"
Inactive04.95490.9741-18.5982-9.043440 0 0 0-17.3903-9.206-8.7862-19.2485-17.3903QC'd by "ChemBridge"
Inactive04.95490.43781.51040 0 0 05.18718.35327.998613.2895.1871QC'd by "ChemBridge"
Inactive04.95490.7771-4.07025.540 0 0 0-0.85475.30783.8385-7.5585-0.8547QC'd by "ChemBridge"
Inactive04.50450.766711-5.579640 0 0 09.2214-0.7359-10.0664-0.82029.2214QC'd by "DPISMR"
Inactive04.95490.71191-9.40740 0 0 0-0.2155-6.58914.6092-0.9755-0.2155QC'd by "DPISMR"
Inactive042.882-1.40172.3838-0.11252.882QC'd by "DPISMR"
Inactive03.51170.9038180.783740 0 0 013.35392.939-1.84693.966813.3539QC'd by "DPISMR"
Inactive04-3.7029-2.43560-1.0469-3.7029QC'd by "DPISMR"
Inactive04.95490.4378-22.7322-17.799140 0 0 0-22.4575-21.8075-13.9993-23.1102-22.4575QC'd by "DPISMR"
Inactive04.95490.4933013.540 0 0 05.196111.327210.398618.61635.1961QC'd by "DPISMR"
Inactive04.0950.8348-5.068610.540 0 0 0-9.223810.3777-3.0185-1.0598-9.2238QC'd by "DPISMR"
Inactive04.95490.83-39.0048-1.540 0 0 0-29.1707-3.3466-6.66414.5818-29.1707QC'd by "DPISMR"
Inactive04.0950.93212-7.546140 0 0 09.0346-7.53846.667815.169.0346QC'd by "ChemBridge"
Inactive04.95490.6648-3.10581040 0 0 00.96037.7379-8.4215-2.21280.9603QC'd by "DPISMR"
Inactive01.10.7701-26.1833-2.290340 0 0 0-22.6528-2.7419-8.6812-9.3542-22.6528QC'd by "DPISMR"
Inactive04.0950.927-1.329713.540 0 0 0-3.608113.40583.051.1045-3.6081QC'd by "DPISMR"
Inactive01.10.943721240 0 0 01.39988.80644.33443.49391.3998QC'd by "DPISMR"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A7681
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Compounds dissolved in DMSO, and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073560 uMActivity at 0.0000367800 uMActivity at 0.0000735600 uMActivity at 0.0001677464 uMActivity at 0.0003678000 uMActivity at 0.0007363003 uMActivity at 0.00153 uMActivity at 0.00368 uMActivity at 0.00723 uMActivity at 0.00914 uMActivity at 0.018 uMActivity at 0.039 uMActivity at 0.092 uMActivity at 0.191 uMActivity at 0.460 uMActivity at 0.910 uMActivity at 1.182 uMActivity at 2.302 uMActivity at 4.834 uMActivity at 11.49 uMActivity at 23.94 uMActivity at 57.45 uMActivity at 115.4 uMActivity at 193.5 uMActivity at 288.3 uMCompound QC
Inhibitor1.0964121.524587Complete curve; high efficacy-5.960.60.996-99.00122.5235-1.10 0 0 0 0 0 0 0-91.416421.20118.089711.55633.2362-23.6097-54.3722-70.1237-91.4164QC'd by GVK
Inactive00041.30296.4095.7452-8.127411.434512.7995.91137.13891.3029QC'd by Vitas
Inhibitor0.05596.749490Complete curve; high efficacy-7.260.60.9836-74.157422.592-1.10 0 0 0 0 0 0 0-78.849512.345912.9899-11.4013-37.5586-53.042-61.5426-65.313-78.8495QC'd by Bosche
Inactive0004-9.339-4.094-2.86744.5071-4.4459-5.3433-2.46713.5091-9.339QC'd by BIOMOL
Inactive0-6.614.95490.77852.5-6.094140 0 0 0 0 0 0 1-8.7946-5.07-2.6335-5.97-10.49513.49112.05881.9174-8.7946QC'd by SIGMA
Inhibitor34.671339.82710Single point of activity-4.462.30310.825-41.327-1.5-30 0 0 0 0 0 0 0-31.93923.6009-5.26172.22954.1407-8.6455-6.9529-4.2362-31.9392QC'd by Microsource
Inactive040 0 0 0 0 0 0 0-13.898620.649216.42211.68939.501116.6467-2.6177-2.1673-13.8986QC'd by Vitas
Inhibitor15.487178.566741Partial curve; partial efficacy-4.810.80.995-76.6721.8947-2.20 0 0 0 0 0 0 0-58.08492.73420.67454.0214-0.609-3.975-12.9528-31.6593-58.0849QC'd by Sequoia
Inactive000426.644512.4429-0.644219.37847.33520.35134.22857.434426.6445QC'd by Microsource
Inactive0-5.92134.95490.79423.5-5.645240 0 0 0 0 0 1-9.4213-2.1113-8.4544-4.6822-8.22654.16062.7472-9.4213QC'd by Tocris
Inactive0004-2.8012-11.1342-2.1920-10.8176-0.6934-3.3166-1.4979-2.8012QC'd by SIGMA
Inactive0-5.764.95490.510428.8996-2.44840 1 0 0 0 0 0 1-2.30523.7377-36.8683-4.4543-19.5675-9.380122.243229.0984-2.305QC'd by Vitas
Inhibitor12.301887.401142Partial curve; high efficacy-4.910.60.9549-73.550113.8509-2.10 0 0 0 0 0 0 0-54.873522.14538.368412.13289.0141-1.3852-8.6537-22.9862-54.8735QC'd by Microsource
Inhibitor27.540450.239310Single point of activity-4.561.75290.9401-50.16480.0744-30 0 0 0 0 0 0 0-39.142.8036-3.03351.3596-6.01625.1159-1.7887-9.2175-39.14QC'd by Microsource
Inactive0-5.310.60.8041-16.01361740 0 0 0 0 0 0 0-11.67817.682513.435821.75976.519717.4375-0.6278-0.9036-11.678QC'd by Enzo
Inhibitor15.487177.547110Partial curve; partial efficacy; poor fit-4.811.1110.829-67.10610.4411-2.40 0 0 0 0 0 0 0-53.05410.743524.16552.70531.738225.7669-4.8999-19.2859-53.0541QC'd by Bosche
Inactive0-6.361.46410.8922-22.47584.540 0 0 0 0 0 0 0-25.49972.54256.30397.767-1.9911-6.3102-26.2299-15.2464-25.4997QC'd by Microsource
Inactive0-4.511.96730.4991426.540 0 0 0 0 0 0 016.846225.531732.670220.285228.569325.635926.981725.029716.8462QC'd by GVK
Inhibitor0.870947.278824Complete curve; partial efficacy-6.064.95490.9676-45.67661.6021-1.20 0 0 0 0 0 0 1-20.51278.27430.9756-1.5573-1.30970.8922-49.683-41.1152-20.5127QC'd by Enzo
Inactive0-6.064.95490.4399-0.676240 0 0 0 0 0 0 1-0.0131.95381.5464-4.31350.312-2.768216.93540.8252-0.013QC'd by Sequoia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:COUP transcription factor 2 isoform a [Homo sapiens]
External ID: COUPTFII_INH_LUMI_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this cell-based assay is to identify compounds that can inhibit COUP-TFII transcriptional activity. The expression vectors for COUP-TFII (pcDNA6.2-COUP-TFII) and the luciferase reporter NGFIA-Luc (pXP2-168) are transiently cotransfected into HEK-293T cells.

COUP-TFII has been shown to efficiently activate NGFI-A-Luc expression (17) and the readout can be measured by a luminometer. Small molecules that inhibit COUP-TFII transcriptional activity will decrease the promoter activity that can be detected by luciferase assay. As designed, compounds that inhibit COUP-TFII activity will decrease luciferase activity, resulting in decreased well luminescence.

Protocol Summary:

HEK293 cells were routinely cultured in T-175 flasks containing 25 mL of DMEM media supplemented with 10% v/v fetal bovine serum and 1% v/v antibiotic-antimycotic mix at 37 C, 5% CO2 and 95% relative humidity (RH). The day prior to run the assay, the HEK293 cells were harvested using 5 mL of TrypLE reagents and seeded in fresh media at a density of 10 million cells per T175 flask. The following day, cells were transfected with 1 mL of serum-free OptiMEM containing 12 ug of the plasmid encoding for COUP-TF2, 8 ug of the pX2-168 luciferase reporter plasmid, and 60 uL of X-tremeGene 9 transfection reagent. Twenty four hours post transfection, cells were harvested using 5 mL of preheated TrypLE and resuspended at a concentration of 800,000 cells per mL in phenol-red free DMEM supplemented as above. In the absence of a pharmacological positive control, COUP-TF2 inhibition was mimicked by transfecting cells in absence of the COUP-TF2 expressing vector (i.e. reporter plasmid only).

The assay was started by dispensing 5 uL of cell suspension into each well of white, sterile, solid-bottom 1536-well plates. The first three columns received control cells (no COUP-TF2 expressed) whereas the rest of the plate was dispensed with COUP-TF2-transfected cells. After addition of cells the plates were spun down. The plates were incubated for 4 hours and then treated with 43 nL/well of test compounds or DMSO (final concentration 0.65%) on COUP-TF2 cells and Control cells. Plates were incubated for eighteen hours at 37 C, 5% CO2 and 95% RH. Plates were then removed from the incubator and equilibrated to room temperature for 10 minutes. Luciferase activity was detected by addition of 5 uL of One-Glo reagent to each well. After a 10 minute incubation time, light emission was measured with the ViewLux reader (PerkinElmer).

The percent inhibition for each compound was calculated as follows:

%_Inhibition = ( ( Test_Compound - Median_Sample_Field ) / ( Median_High_Control - Median_Sample_Field ) ) * 100

Where:

High_Control is defined as wells containing cells transfected with reporter plamid only (pX2-168)
Test_Compound is defined as well containing cells cotransfected with pcDNA6.2-COUP-TFII and pX2-168 in the presence of test compounds
Sample_Field is defined as wells containing cells cotransfected with pcDNA6.2-COUP-TFII and pX2-168 in the presence of test compounds

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent inhibition of test compound wells that are within the High and Low Controls (i.e. higher than the average plues three standard deveiations of the Low Control wells and lower than the average minus three stardard deviation of the High Control wells) and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for each plate, i.e. any compound that exhibited greater % inhibition than that particular plate's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-34, and for inactive compounds 34-0.

List of Reagents:

pX2-168 luciferase reporter plasmid (Assay Provider)
pcDNA6.2-COUP-TFII plasmid (Assay Provider)
HEK293 cells (ATCC, part CRL-1573)
DMEM (Invitrogen, part 21063)
FBS (Hyclone, part SH30088.03)
Antibiotic-Antimycotic 100X Liquid Solution (Gibco, part 15240)
X-tremeGENE 9 DNA Transfection Reagent (Roche, part 06365809001)
OptiMEM (Invitrogen, part 31985)
TrypLE Trypsin Replacement Enzyme (Invitrogen, part 12604)
OneGlo (Promega, part E6130)
1536-well plates (Corning, part 7298)
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 8.6 uM
106.95
105.22
102.54
102.3
102.07
101.4
100.96
100.14
100.1
99.97
99.03
98.78
98.41
98.12
97.86
97.71
96.99
96.63
96.21
95.86
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NMMLSC 靶标:botulinum neurotoxin type F, BoNT/F [Clostridium botulinum Bf]
External ID: UNMCMD_Botulinum_LightChainF_Protease_HTS_MLPCN
Protocol: This assay will be used to identify small molecule inhibitors of Botulinum toxin type A and F light chain proteases (BoNTALC and BoNTFLC) and inhibitors of Bacillus anthracis Lethal Factor protease (LF) in a multiplex format. Proteases that are not inhibited will cleave their substrates and produce a loss of signal effect. If the proteases are inhibited by a small molecule cleavage will not occur, thus the signal should stay the same. Full length protease substrates are used in order to detect inhibitors that act at either the protease catalytic site or at sites of protease interaction with substrate distal to the cleavage site.

Protease inhibition assays were performed as previously described (5), but with modifications. Biotinylated GFP protease substrates for LF, BoNTALC, BoNTFLC, and a protease-resistant substrate (pinpointGFP) were prepared and loaded on color-coded streptavidin microspheres (Spherotech Blue Array Particle kit, 5.1 microm diameter) as previously described (5-7). Additions to wells were in sequence as follows: 1st, 4 microL protease buffer (50 mM HEPES, 100 mM NaCl, 1 mg/ml bovine serum albumin, 0.025% Tween-20, pH 7.4); 2nd, 2 microL of a mixture of 1.5 microM LF, 5 nM BoNTALC and 375 nM BoNTFLC in protease buffer; 3rd, 100 nL of test compounds (1 mM in DMSO); and 4th, 4 microL containing 2x10;5/ml of each set of microspheres. Plates were sealed and incubated at 24 degreesC overnight (16-18 h), rotating continuously from inverted to upright position until analyzed in 1536 well plate format with the HyperCyt Cluster Cytometer platform the following day.

The assay response range was defined by replicate control wells containing protease buffer alone (PCntrl, positive control) or the protease mixture alone (NCntrl, negative control). Additional positive controls included Ebselen, VAMP peptide and IN-2-LF (selective inhibitors of BoNTALC, BoNTFLC and LF, respectively), which were added separately and together as a mixture to validate protease inhibition. In each well the median fluorescence intensity (MFI) was determined for each set of substrate-bearing microspheres. A fifth streptavidin microsphere set included in each well had no GFP moiety attached and was used to quantify the contribution of innate test compound fluorescence to the assay readout. All MFI values for substrate-bearing microspheres were corrected by subtraction of the MFI value for the substrate-free microspheres in the same well.

Test compound inhibition of substrate cleavage by protease was then calculated as 100 x (MFI:Test - Mean MFI:NCntrl)/(Mean MFI:PCntrl - Mean MFI:NCntrl) in which MFI:Test represents corrected MFI in the
presence of test compound, and Mean MFI:PCntrl and MFI:NCntrl represent means for replicate MFI determinations in control wells.

PubChem Score equals percent inhibition.
Comment: Development of the HyperCyt Cluster Cytometer Platform for processing of 1536 well plates by high throughput flow cytometry was supported by NIH/NIMH Grant 1R01HG005066 to Bruce Edwards.
PERCENT_INHIBITION
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
5.2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NMMLSC 靶标:botulinum neurotoxin type A [Clostridium botulinum A str. ATCC 3502]
External ID: UNMCMD_Botulinum_LightChainA_Protease_HTS_MLPCN
Protocol:
This assay will be used to identify small molecule inhibitors of Botulinum toxin type A and F light chain proteases (BoNTALC and BoNTFLC) and inhibitors of Bacillus anthracis Lethal Factor protease (LF) in a multiplex format. Proteases that are not inhibited will cleave their substrates and produce a loss of signal effect. If the proteases are inhibited by a small molecule cleavage will not occur, thus the signal should stay the same. Full length protease substrates are used in order to detect inhibitors that act at either the protease catalytic site or at sites of protease interaction with substrate distal to the cleavage site.

Protease inhibition assays were performed as previously described (5), but with modifications. Biotinylated GFP protease substrates for LF, BoNTALC, BoNTFLC, and a protease-resistant substrate (pinpointGFP) were prepared and loaded on color-coded streptavidin microspheres (Spherotech Blue Array Particle kit, 5.1 microm diameter) as previously described (5-7). Additions to wells were in sequence as follows: 1st, 4 microL protease buffer (50 mM HEPES, 100 mM NaCl, 1 mg/ml bovine serum albumin, 0.025% Tween-20, pH 7.4); 2nd, 2 microL of a mixture of 1.5 microM LF, 5 nM BoNTALC and 375 nM BoNTFLC in protease buffer; 3rd, 100 nanoL of test compounds (1 mM in DMSO); and 4th, 4 microL containing 2x10;5/ml of each set of microspheres. Plates were sealed and incubated at 24 degreesC overnight (16-18 h), rotating continuously from inverted to upright position until analyzed in 1536 well plate format with the HyperCyt Cluster Cytometer platform the following day.

The assay response range was defined by replicate control wells containing protease buffer alone (PCntrl, positive control) or the protease mixture alone (NCntrl, negative control). Additional positive controls included Ebselen, VAMP peptide and IN-2-LF (selective inhibitors of BoNTALC, BoNTFLC and LF, respectively), which were added separately and together as a mixture to validate protease inhibition. In each well the median fluorescence intensity (MFI) was determined for each set of substrate-bearing microspheres. A fifth streptavidin microsphere set included in each well had no GFP moiety attached and was used to quantify the contribution of innate test compound fluorescence to the assay readout. All MFI values for substrate-bearing microspheres were corrected by subtraction of the MFI value for the substrate-free microspheres in the same well.

Test compound inhibition of substrate cleavage by protease was then calculated as 100 x (MFI:Test - Mean MFI:NCntrl)/(Mean MFI:PCntrl - Mean MFI:NCntrl) in which MFI:Test represents corrected MFI in the
presence of test compound, and Mean MFI:PCntrl and MFI:NCntrl represent means for replicate MFI determinations in control wells.

PubChem Score equals the percent inhibition.
Comment: Development of the HyperCyt Cluster Cytometer Platform for processing of 1536 well plates by high throughput flow cytometry was supported by NIH/NIMH Grant 1R01HG005066 to Bruce Edwards.
PERCENT_INHIBITION
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: GPx1-biochemical-p4-p7
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent 1; 3 uL; GPx1 enzyme or no enzyme control in 1536-well, black, solid Greiner assay plate.
2; Compound; 25 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head.
3; Incubation; 30 min; room temperature.
4; Reagent 2; 1 uL; 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA substrate
5; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.
6; Incubation; 15 min; room temperature.
7; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.

NOTES (numbers refer to Sequence numbers above)
1. 3 uL of 16.66 nM GPX1 and 0.016% BSA in assay buffer (50 mM Tris-HCl, 2 mM EDTA (pH 7.5), 150 mM NaCl) was added to columns 3-48 of 1536-well assay plates using a BioRAPTR Flying Reagent Dispenser (Let's Go Robotics (LGR), Carlsbad, CA). A no-enzyme control (0.01% BSA in TES assay buffer) was added to columns 1-2.
2. 25 nL of test compounds and DMSO controls were added to each well with a pin tool (Kalypsys).
3. The assay plates were incubated for 30 minutes at room temperature.
4. 1 uL of master mix (500 nM glutathione reductase (GR), 5 mM reduced glutathione (GSH), 2.5 mM NADPH in assay buffer) was added. 1 uL of cumene hydroperoxide (CHP) ([2.5 mM] in 50% EtOH) was then added within 5 minutes to initiate the reaction. Final concentrations were: 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA.
5. Initial fluorescence readout (t=0) at 340/450 nm was measured using a ViewLux multimodal detector (PerkinElmer, Waltham, MA).
7. Endpoint fluorescence readout (t=15) at 340/450 nm was measured 15 min after room temperature incubation.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000080000 uMActivity at 0.0000294000 uMActivity at 0.0000322389 uMActivity at 0.0000640000 uMActivity at 0.0001602685 uMActivity at 0.0003305803 uMActivity at 0.0007029698 uMActivity at 0.00145 uMActivity at 0.00305 uMActivity at 0.00484 uMActivity at 0.00883 uMActivity at 0.016 uMActivity at 0.036 uMActivity at 0.076 uMActivity at 0.127 uMActivity at 0.227 uMActivity at 0.400 uMActivity at 1.089 uMActivity at 1.958 uMActivity at 4.491 uMActivity at 9.517 uMActivity at 15.29 uMActivity at 27.66 uMActivity at 48.83 uMActivity at 98.28 uMActivity at 150.0 uMCompound QC
Inhibitor1.153584.01186Complete curve; high efficacy-5.9382.95230.9935-85.511-1.5-1.10 0 0 0 0 0 1000.55170-10.1942-66.3862-86.37470QC'd by MedChem Express
Inhibitor4.0381107.130985Complete curve; high efficacy-5.39381.10.9833-107.6309-0.5-1.10 0 0 0 0 0 0-99.10763.0643-3.35612.7295-17.6643-28.702-81.8703-99.1076QC'd by Prestwick
Inhibitor4.5309100.661985Complete curve; high efficacy-5.34381.46410.9928-111.2365-10.5746-1.10 0 0 0 0 0 0-102.4277-6.7289-14.1368-11.7774-11.5064-34.358-88.9997-102.4277QC'd by Glixx
Inhibitor3.207694.995685Complete curve; high efficacy-5.49381.69240.997-110.0264-15.0308-1.10 0 0 0 0 0 0-108.5073-10.859-15.7072-17.8113-19.7979-44.1871-99.3353-108.5073QC'd by MedChem Express
Inhibitor3.207694.333585Complete curve; high efficacy-5.49381.55790.9917-98.6297-4.2962-1.10 0 0 0 0 0 0-97.268-10.9671-0.2469-8.8219-8.6028-35.074-85.0291-97.268QC'd by Vitas
Inhibitor4.0381101.224485Complete curve; high efficacy-5.39382.24810.9999-101.22440-1.10 0 0 0 0 0 0-101.0224000.6663-1.57-17.0563-89.6716-101.0224QC'd by DC Chemicals
Inhibitor4.5309102.529384Complete curve; high efficacy-5.34381.88510.9958-104.0293-1.5-1.10 0 0 0 0 0 0-100.803500-6.96670.0183-19.6985-87.3271-100.8035QC'd by MedChem Express
Inhibitor5.152590.153784Complete curve; high efficacy-5.2881.96730.9895-98.5024-8.3487-1.10 0 0 0 0 0 0-96.571-12.4368-8.9031-14.8602-3.6239-19.2852-77.5914-96.571QC'd by EMD Chemicals
Inhibitor6.496.476183Complete curve; high efficacy-5.19383.92950.9988-94.97611.5-1.10 0 0 0 0 0 0-95.357503.3535002.0026-79.8012-95.3575QC'd by Microsource
Inhibitor6.489.09983Complete curve; high efficacy-5.19384.44950.9997-88.5990.5-1.10 0 0 0 0 0 0-88.422200.5042.224300-77.8921-88.4222QC'd by SigmaAldrich
Inhibitor4.0928572.588765Partial curve; high efficacy-5.3882.90231-572.58870-2.10 0 0 0 0 0 100000-52.3008-521.48330QC'd by Microsource
Inhibitor2.547977.642365Complete curve; partial efficacy-5.59384.50450.9919-92.3162-14.6738-1.20 0 0 0 0 0 0-90.5524-12.7147-12.5699-11.8115-21.2763-34.6101-93.8172-90.5524QC'd by SIGMA
Inhibitor2.023979.203365Complete curve; partial efficacy-5.69381.1110.9975-92.0986-12.8952-1.20 0 0 0 0 0 0-89.2428-13.3008-14.4831-11.996-25.7417-51.5286-82.1843-89.2428QC'd by SIGMA
Inhibitor2.547939.753164Complete curve; partial efficacy-5.59384.50450.9617-72.8813-33.1282-1.20 0 0 0 0 0 0-68.5285-37.2443-35.4912-31.4131-28.8568-43.7703-77.3346-68.5285QC'd by Microsource
Inhibitor5.7812259.6350Partial curve; high efficacy-5.2381.69240.9999-259.630-2.10 0 0 0 0 0 0-250.1252000-1.0316-34.0768-179.1962-250.1252QC'd by Adooq
Inhibitor4.0928222.462650Partial curve; high efficacy-5.3882.58840.9995-221.46261-2.10 0 0 0 0 0 100003.8047-24.8352-196.33210QC'd by Glixx
Inhibitor18.0377742.537649Partial curve; high efficacy-4.74382.72021-741.53761-2.10 0 0 0 0 0 0-698.2464003.833500-124.2034-698.2464QC'd by Vitas
Inhibitor16.0761622.503649Partial curve; high efficacy-4.79382.25261-622.50360-2.10 0 0 0 0 0 0-576.39220000-5.8017-157.3588-576.3922QC'd by Glixx
Inhibitor16.0761415.830746Partial curve; high efficacy-4.79382.25260.9995-418.3307-2.5-2.10 0 0 0 0 0 0-387.3433-6.004500-3.7575-3.0222-113.565-387.3433QC'd by SIGMA
Inhibitor16.2936426.190146Partial curve; high efficacy-4.7882.72020.9998-425.69010.5-2.10 0 0 0 0 0 0-400.838100003.5739-74.4409-400.8381QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NMMLSC 靶标:lethal factor [Bacillus anthracis str. A2012]
External ID: UNMCMD_Anthrax_LethalFactor_Protease_HTS_MLPCN
Protocol: This assay will be used to identify small molecule inhibitors of Botulinum toxin type A and F light chain proteases (BoNTALC and BoNTFLC) and inhibitors of Bacillus anthracis Lethal Factor protease (LF) in a multiplex format. Proteases that are not inhibited will cleave their substrates and produce a loss of signal effect. If the proteases are inhibited by a small molecule cleavage will not occur, thus the signal should stay the same. Full length protease substrates are used in order to detect inhibitors that act at either the protease catalytic site or at sites of protease interaction with substrate distal to the cleavage site.

Protease inhibition assays were performed as previously described (5), but with modifications. Biotinylated GFP protease substrates for LF, BoNTALC, BoNTFLC, and a protease-resistant substrate (pinpointGFP) were prepared and loaded on color-coded streptavidin microspheres (Spherotech Blue Array Particle kit, 5.1 microm diameter) as previously described (5-7). Additions to wells were in sequence as follows: 1st, 4 microL protease buffer (50 mM HEPES, 100 mM NaCl, 1 mg/ml bovine serum albumin, 0.025% Tween-20, pH 7.4); 2nd, 2 microL of a mixture of 1.5 microM LF, 5 nM BoNTALC and 375 nM BoNTFLC in protease buffer; 3rd, 100 nL of test compounds (1 mM in DMSO); and 4th, 4 microL containing 2x10;5/ml of each set of microspheres. Plates were sealed and incubated at 24 degreesC overnight (16-18 h), rotating continuously from inverted to upright position until analyzed in 1536 well plate format with the HyperCyt Cluster Cytometer platform the following day.

The assay response range was defined by replicate control wells containing protease buffer alone (PCntrl, positive control) or the protease mixture alone (NCntrl, negative control). Additional positive controls included Ebselen, VAMP peptide and IN-2-LF (selective inhibitors of BoNTALC, BoNTFLC and LF, respectively), which were added separately and together as a mixture to validate protease inhibition. In each well the median fluorescence intensity (MFI) was determined for each set of substrate-bearing microspheres. A fifth streptavidin microsphere set included in each well had no GFP moiety attached and was used to quantify the contribution of innate test compound fluorescence to the assay readout. All MFI values for substrate-bearing microspheres were corrected by subtraction of the MFI value for the substrate-free microspheres in the same well.

Test compound inhibition of substrate cleavage by protease was then calculated as 100 x (MFI:Test - Mean MFI:NCntrl)/(Mean MFI:PCntrl - Mean MFI:NCntrl) in which MFI:Test represents corrected MFI in the
presence of test compound, and Mean MFI:PCntrl and MFI:NCntrl represent means for replicate MFI determinations in control wells.

Pubchem Activity Score equals the percent compound inhibition.
Comment: Development of the HyperCyt Cluster Cytometer Platform for processing of 1536 well plates by high throughput flow cytometry was supported by NIH/NIMH Grant 1R01HG005066 to Bruce Edwards.
PERCENT_INHIBITION
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: PI4K2A
Protocol: For the robotic screening, the ADP-Glo assay using the ADP-Glotrade mark Kinase Assay kit from Promega was miniaturized and optimized on 1536-well white solid bottom plates (Greiner Bio-one). The substrate, 1.2 mM PI, prepared in the assay buffer (40mM Tris pH7.5, 20mM MgCl2, 1mM EGTA, 0.4% Triton X-100, 0.5mM DTT, 0.5mg/ml BSA) and PI4K2A enzyme, diluted also in the assay buffer to 4ug/mL, were dispensed onto the plates in equal volumes (1microl/well), pinned with 23 nL/well tested compounds or control followed by dispensation of 1microl/well 300microM ATP. The plates were incubated for one hour. Then, 2 muL/well of ADP-Glo reagent was added and incubated for 40 minutes. Next, 4microL/well of Kinase Detection Buffer was added to the plates and incubated for additional 40 minutes. All incubation steps were performed at ambient temperature. The resulting luminescence signal was measured on Viewlux plate reader (PerkinElmer). Adenosine, a partial non-specific inhibitor, was used as a positive control at 100microM final concentration to assess the assay's quality and plate-to-plate reproducibility. We also used "no enzyme" control to gauge the assay's maximal potential inhibition (IC100).
Comment: PubChem score indicates % inhibition activity at 76.9 uM of the compound (Max_response). Active compounds with Max_response greater than 90%, PUBCHEM_ACTIVITY_SCORE is 100. Active compounds with Max_response greater than 80%, PUBCHEM_ACTIVITY_SCORE is 80. Active compounds with Max_response between 50% and 80%, PUBCHEM_ACTIVITY_SCORE is 60. Inconclusive Compounds with Max_response between 30% and 50% have PUBCHEM_ACTIVITY_SCORE 30. For all inactive compounds with Max_response less than 30%, PUBCHEM_ACTIVITY_SCORE is 0
Max_responseActivity at 15.40 uMActivity at 76.90 uMCompound QC
-4.7811-3.1736-4.7811QC'd by ChemBridge
-4.7807-1.5118-4.7807QC'd by Life Chemicals
-4.7807-3.1454-4.7807QC'd by InterBioScreen
-4.78063.611-4.7806QC'd by ChemBridge
-4.7805-1.6207-4.7805QC'd by Life Chemicals
-4.7804-6.8292-4.7804QC'd by Asinex Ltd.
-4.7801-0.8209-4.7801QC'd by Chem Div
-4.7798-1.211-4.7798QC'd by Enamine
-4.7794-4.64-4.7794QC'd by DPISMR
-4.77933.4727-4.7793QC'd by Enamine
-4.7789-4.0331-4.7789QC'd by Chem Div
-4.77874.2825-4.7787QC'd by Asinex Ltd.
-4.7786-5.1813-4.7786QC'd by Florida Center for Heterocyclic Compounds
-4.7778-3.0892-4.7778QC'd by ChemBridge
-4.7773-1.3982-4.7773QC'd by Key Organics Ltd.
-4.7772-4.2776-4.7772QC'd by Sergey Kozmin - Univ. of Chicago - MLI CMLD
-4.777-7.6001-4.777QC'd by Wei Zhang - Fluorous Technologies; Inc. - MLI PSL
-4.7768-2.3177-4.7768QC'd by Specs
-4.7766-3.7761-4.7766QC'd by InterBioScreen
-4.7766-0.1513-4.7766QC'd by InterBioScreen